View Filing Data

Print Document View Excel Document

Cover Page - USD ($) $ in Millions	12 Months Ended
Cover Page - USD ($) $ in Millions	Dec. 31, 2019	Feb. 15, 2020	Jun. 28, 2019
Cover page.
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	001-36042
Entity Registrant Name	PRECIGEN, INC.
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	26-0084895
Entity Address, Address Line One	20374 Seneca Meadows Parkway
Entity Address, City or Town	Germantown,
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20876
City Area Code	301
Local Phone Number	556-9900
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	PGEN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Public Float			$ 659.7
Entity Common Stock, Shares Outstanding (in shares)		169,669,195
Documents Incorporated by Reference	Portions of the registrant's Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders are incorporated by reference in Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2019.
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Central Index Key	0001356090
Current Fiscal Year End Date	--12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 65,793	$ 96,876
Restricted cash	0	6,987
Short-term investments	9,260	119,614
Equity securities	0	384
Receivables
Trade, net	20,650	21,179
Related parties, net	600	4,129
Other	4,978	1,257
Inventory	16,097	20,575
Prepaid expenses and other	6,444	5,327
Current assets held for sale	110,821	9,155
Total current assets	234,643	285,483
Equity securities, noncurrent	0	640
Property, plant and equipment, net	60,969	86,896
Intangible assets, net	68,346	88,962
Goodwill	63,754	93,627
Investments in affiliates	1,461	2,139
Right-of-use assets	25,228
Other assets	1,362	2,069
Noncurrent assets held for sale	0	156,361
Total assets	455,763	716,177
Current liabilities
Accounts payable	5,917	11,973
Accrued compensation and benefits	14,091	9,955
Other accrued liabilities	12,049	19,005
Deferred revenue, including $877 and $6,502 from related parties as of December 31, 2019 and 2018, respectively	5,697	11,088
Lines of credit	1,922	466
Current portion of long-term debt, including $31,211 and $0 to related parties as of December 31, 2019 and 2018, respectively	31,670	479
Current portion of lease liabilities	4,182
Related party payables	51	256
Current liabilities held for sale	47,333	8,340
Total current liabilities	122,912	61,562
Long-term debt, net of current portion, including $25,000 and $55,290 to related parties as of December 31, 2019 and 2018, respectively	186,321	211,216
Deferred revenue, net of current portion, including $30,182 and $44,772 from related parties as of December 31, 2019 and 2018, respectively	48,136	46,728
Lease liabilities, net of current portion	23,849
Deferred tax liabilities	2,834	3,856
Other long-term liabilities	0	3,135
Long-term liabilities held for sale	0	10,958
Total liabilities	384,052	337,455
Commitments and contingencies (Note 17)
Total equity
Common stock, no par value, 400,000,000 shares and 200,000,000 shares authorized as of December 31, 2019 and 2018, respectively; and 163,274,880 shares and 160,020,466 shares issued and outstanding as of December 31, 2019 and 2018, respectively	0	0
Additional paid-in capital	1,752,048	1,722,012
Accumulated deficit	(1,652,869)	(1,330,545)
Accumulated other comprehensive loss	(27,468)	(28,612)
Total Precigen shareholders' equity	71,711	362,855
Noncontrolling interests	0	15,867
Total equity	71,711	378,722
Total liabilities and total equity	$ 455,763	$ 716,177

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Current portion of deferred revenue	$ 5,697	$ 11,088
Current portion of long-term debt, including $31,211 and $0 to related parties as of December 31, 2019 and 2018, respectively	31,670	479
Long-term debt, less current portion	186,321	211,216
Long-term portion of deferred revenue	$ 48,136	$ 46,728
Common stock, shares authorized (in shares)	400,000,000	200,000,000
Common stock, shares issued (in shares)	163,274,880	160,020,466
Common stock, shares outstanding (in shares)	163,274,880	160,020,466
Related Parties, Aggregated
Related Party Transaction [Line Items]
Current portion of deferred revenue	$ 877	$ 6,502
Current portion of long-term debt, including $31,211 and $0 to related parties as of December 31, 2019 and 2018, respectively	31,211	0
Long-term debt, less current portion	25,000	55,290
Long-term portion of deferred revenue	$ 30,182	$ 44,772

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues
Revenues	$ 90,722	$ 151,178	$ 219,463
Operating Expenses
Impairment loss	120,489	60,504	16,773
Other Income (Expense), Net
Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net	7,833	(30,200)	2,586
Equity in net loss of affiliates	(6,730)	(11,608)	(14,283)
Loss from continuing operations before income taxes	(208,687)	(429,742)	(78,367)
Income tax benefit (expense)	930	15,425	(2,072)
Net loss from discontinued operations attributable to Precigen	(116,159)	(100,389)	(46,381)
Net loss	(323,916)	(514,706)	(126,820)
Net loss attributable to the noncontrolling interests	1,592	5,370	9,802
Net loss attributable to Precigen	(322,324)	(509,336)	(117,018)
Amounts Attributable to Precigen
Net loss from continuing operations attributable to Precigen	(206,165)	(408,947)	(70,637)
Net loss from discontinued operations attributable to Precigen	(116,159)	(100,389)	(46,381)
Net loss attributable to Precigen	$ (322,324)	$ (509,336)	$ (117,018)
Net Loss per Share
Net loss from continuing operations attributable to Precigen per share, basic and diluted (in usd per share)	$ (1.34)	$ (3.16)	$ (0.59)
Net loss from discontinued operations attributable to Precigen per share, basic and diluted (in usd per share)	(0.75)	(0.77)	(0.39)
Net loss attributable to Precigen per share, basic and diluted (in usd per share)	$ (2.09)	$ (3.93)	$ (0.98)
Weighted average shares outstanding, basic and diluted (in shares)	154,138,774	129,521,731	119,998,826
Collaboration and licensing agreements
Revenues
Revenues	$ 14,059	$ 69,540	$ 134,624
Continuing Operations
Revenues
Revenues	90,722	151,178	219,463
Operating Expenses
Research and development	101,879	366,248	109,176
Selling, general and administrative	100,844	125,751	130,682
Impairment loss	30,810	0	13,823
Total operating expenses	294,934	554,675	315,373
Operating loss	(204,212)	(403,497)	(95,910)
Other Income (Expense), Net
Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net	8,291	(28,273)	10,130
Interest expense	(17,666)	(8,473)	(584)
Interest and dividend income	3,871	19,017	19,431
Other income, net	3,445	470	1,002
Total other income (expense), net	(2,059)	(17,259)	29,979
Equity in net loss of affiliates	(2,416)	(8,986)	(12,436)
Loss from continuing operations before income taxes	(208,687)	(429,742)	(78,367)
Income tax benefit (expense)	930	15,425	(2,072)
Loss from continuing operations	(207,757)	(414,317)	(80,439)
Continuing Operations \| Collaboration and licensing agreements
Revenues
Revenues	14,059	69,540	134,624
Continuing Operations \| Product
Revenues
Revenues	23,780	28,486	33,585
Operating Expenses
Cost of product and services	31,930	35,087	33,236
Continuing Operations \| Service
Revenues
Revenues	51,803	52,419	50,611
Operating Expenses
Cost of product and services	29,471	27,589	28,456
Continuing Operations \| Other
Revenues
Revenues	$ 1,080	$ 733	$ 643

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Revenues	$ 90,722	$ 151,178	$ 219,463
Collaboration and licensing agreements
Related Party Transaction [Line Items]
Revenues	14,059	69,540	134,624
Continuing Operations
Related Party Transaction [Line Items]
Revenues	90,722	151,178	219,463
Continuing Operations \| Collaboration and licensing agreements
Related Party Transaction [Line Items]
Revenues	14,059	69,540	134,624
Continuing Operations \| Collaboration and licensing agreements \| Related Parties, Aggregated
Related Party Transaction [Line Items]
Revenues	$ 11,832	$ 55,573	$ 122,485

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Net loss	$ (323,916)	$ (514,706)	$ (126,820)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	68	(59)	87
Gain (loss) on foreign currency translation adjustments	1,087	(13,073)	20,599
Comprehensive loss	(322,761)	(527,838)	(106,134)
Comprehensive loss attributable to the noncontrolling interests	1,581	5,548	9,764
Comprehensive loss attributable to Precigen	$ (321,180)	$ (522,290)	$ (96,370)

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

+ Details

Consolidated Statements of Shareholders' and Total Equity - USD ($) $ in Thousands	Total	Total Precigen Shareholders' Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Noncontrolling Interests
Beginning balance at Dec. 31, 2016	$ 569,248	$ 560,237	$ 0	$ 1,325,780	$ (36,202)	$ (729,341)	$ 9,011
Beginning balance, shares at Dec. 31, 2016			118,688,770
Changes in Stockholders' Equity
Stock-based compensation expense	41,576	41,525		41,525			51
Exercises of stock options and warrants	980	952		952			28
Exercises of stock options and warrants, shares			149,429
Shares issued as payment for services	11,118	11,118		11,118			0
Shares issued as payment for services, shares			654,456
Shares and warrants issued in public or private offerings, net of issuance costs	13,686	13,686		13,686			0
Shares and warrants issued in public or private offerings, net of issuance costs, shares			1,207,980
Shares and warrants issued in business combination	16,997	16,997		16,997			0
Shares and warrants issued in business combinations, shares			684,240
Acquisition of noncontrolling interest	(913)	5,082		5,082			(5,995)
Acquisitions of noncontrolling interest, shares			221,743
Shares issued as payment of deferred consideration	0	0		0			0
Shares issued as payment of deferred consideration, shares			480,422
Adjustments for noncontrolling interests	(13)	2,789		2,789			(2,802)
Noncash dividend	0	(22,385)		(22,385)			22,385
Net loss	(126,820)	(117,018)				(117,018)	(9,802)
Other comprehensive income (loss)	20,686	20,648			20,648		38
Ending balance at Dec. 31, 2017	546,545	533,631	$ 0	1,397,005	(15,554)	(847,820)	12,914
Ending balance, shares at Dec. 31, 2017			122,087,040
Changes in Stockholders' Equity
Stock-based compensation expense	36,296	36,174		36,174			122
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants	2,336	297		297			2,039
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants, shares			70,159
Shares issued as payment for services	10,695	10,695		10,695			0
Shares issued as payment for services, shares			909,980
Shares and warrants issued in public or private offerings, net of issuance costs	87,990	82,374		82,374			5,616
Shares and warrants issued in public or private offerings, net of issuance costs, shares			6,900,000
Equity component of convertible debt, net of issuance costs and deferred taxes	36,868	36,868		36,868			0
Shares issued pursuant to share lending agreement	0	0		0			0
Shares issued pursuant to share lending agreement, shares			7,479,431
Shares and warrants issued in business combination	0
Shares issued for reacquired in-process research and development	159,323	159,323		159,323			0
Shares issued for reacquired in-process research and development, shares			22,573,856
Adjustments for noncontrolling interests	0	(724)		(724)			724
Net loss	(514,706)	(509,336)				(509,336)	(5,370)
Other comprehensive income (loss)	(13,132)	(12,954)			(12,954)		(178)
Ending balance at Dec. 31, 2018	$ 378,722	362,855	$ 0	1,722,012	(28,612)	(1,330,545)	15,867
Ending balance, shares at Dec. 31, 2018	160,020,466		160,020,466
Changes in Stockholders' Equity
Stock-based compensation expense	$ 18,950	18,881		18,881			69
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants	313	63		63			250
Shares issued upon vesting of restricted stock units and for exercises of stock options and warrants, shares			1,028,144
Shares issued for accrued compensation	1,102	1,102		1,102
Shares issued for accrued compensation, shares			150,908
Shares issued as payment for services	10,446	10,446		10,446			0
Shares issued as payment for services, shares			2,075,362
Shares and warrants issued in public or private offerings, net of issuance costs	6,611	0		0			6,611
Shares and warrants issued in public or private offerings, net of issuance costs, shares			0
Shares and warrants issued in business combination	0
Adjustments for noncontrolling interests	0	(456)		(456)			456
Deconsolidation of subsidiary	(21,672)						(21,672)
Net loss	(323,916)	(322,324)				(322,324)	(1,592)
Other comprehensive income (loss)	1,155	1,144			1,144		11
Ending balance at Dec. 31, 2019	$ 71,711	$ 71,711	$ 0	$ 1,752,048	$ (27,468)	$ (1,652,869)	$ 0
Ending balance, shares at Dec. 31, 2019	163,274,880		163,274,880

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities
Net loss	$ (323,916)	$ (514,706)	$ (126,820)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	24,896	33,112	31,145
Loss on abandonment and disposals of assets, net	3,071	20,928	3,124
Impairment loss	120,489	60,504	16,773
Reacquisition of in-process research and development	0	236,748	0
Unrealized and realized (appreciation) depreciation on equity securities and preferred stock, net	(7,833)	30,200	(2,586)
Noncash dividend income	(48)	(14,841)	(16,756)
Amortization of premiums (discounts) on investments, net	(1,005)	(771)	411
Equity in net loss of affiliates	6,730	11,608	14,283
Stock-based compensation expense	18,950	36,296	41,576
Shares issued as payment for services	10,446	10,695	11,118
Provision for bad debts	3,242	1,779	1,217
Accretion of debt discount and amortization of deferred financing costs	9,459	4,378	0
Deferred income taxes	(3,674)	(21,278)	(2,528)
Other noncash items	837	1,093	(517)
Receivables:
Trade	(262)	(2,698)	740
Related parties	967	11,003	631
Other	(656)	(542)	661
Inventory	4,100	(478)	663
Prepaid expenses and other	(2,262)	1,006	492
Other assets	333	652	(1,017)
Accounts payable	(5,349)	4,680	(3,402)
Accrued compensation and benefits	5,186	4,385	(1,466)
Other accrued liabilities	(5,516)	356	3,007
Deferred revenue	7,423	(38,578)	(75,337)
Deferred consideration	0	0	(313)
Lease liabilities	(995)
Related party payables	45	(52)	(147)
Other long-term liabilities	(585)	281	1,328
Net cash used in operating activities	(135,927)	(124,240)	(103,720)
Cash flows from investing activities
Purchases of investments	(55,073)	(178,681)	0
Sales and maturities of investments	166,495	65,975	174,542
Purchases of preferred stock and warrants	0	0	(1,161)
Proceeds from sales of equity securities	23,456	217	235
Acquisitions of businesses, net of cash received	0	(920)	2,054
Investments in affiliates	(3,713)	(16,582)	(11,189)
Decrease in cash from deconsolidation of subsidiary	(7,244)	0	0
Return of investment in affiliate	125	2,598	0
Cash received (paid) in asset acquisitions	0	15,500	(14,219)
Purchases of property, plant and equipment	(37,883)	(41,587)	(46,666)
Proceeds from sale of assets	688	2,267	1,636
Issuances of notes receivable	0	0	(2,400)
Proceeds from repayment of notes receivable	0	0	1,500
Net cash provided by (used in) investing activities	86,851	(151,213)	104,332
Cash flows from financing activities
Proceeds from issuance of shares in a private placement	0	0	13,686
Proceeds from issuance of shares and warrants in public offerings, net of issuance costs	6,611	87,990	0
Acquisitions of noncontrolling interests	0	0	(913)
Advances from lines of credit	11,757	4,561	5,906
Repayments of advances from lines of credit	(10,301)	(4,328)	(6,493)
Proceeds from long-term debt, net of issuance costs	376	219,859	325
Payments of long-term debt	(618)	(623)	(519)
Payments of deferred consideration for acquisitions	0	0	(8,678)
Proceeds from stock option and warrant exercises	313	2,336	980
Payment of stock issuance costs	0	0	(10)
Net cash provided by financing activities	8,138	309,795	4,284
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(810)	295	1,055
Net increase (decrease) in cash, cash equivalents, and restricted cash	(41,748)	34,637	5,951
Cash, cash equivalents, and restricted cash
Beginning of year	110,182	75,545	69,594
End of year	68,434	110,182	75,545
Supplemental disclosure of cash flow information
Cash paid during the period for interest	3,751	3,868	617
Cash paid during the period for income taxes	50	216	566
Significant noncash activities
Stock received as consideration for collaboration agreements	4,530	0	0
Receivables converted to preferred stock	0	0	3,385
Stock and warrants issued in business combinations	0	0	16,997
Stock issued to acquire noncontrolling interests	0	0	5,082
Stock issued for reacquired in-process research and development	0	159,323	0
Long-term debt issued to a related party in an asset acquisition	0	30,000	0
Noncash dividend to shareholders	0	0	22,385
Purchases of property and equipment included in accounts payable and other accrued liabilities	694	2,267	2,257
Purchases of equipment financed through debt	0	234	0
Receivable recorded in anticipation of dissolution of affiliate	$ 0	$ 0	$ 2,598

Consolidated Statements of Cash Flows (Reconciliation of Cash) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Statement of Cash Flows [Abstract]
Cash and cash equivalents	$ 65,793	$ 96,876
Restricted cash	0	6,987
Cash and cash equivalents included in current assets held for sale	2,223	5,892
Restricted cash included in other assets	418	427
Cash, cash equivalents, and restricted cash	$ 68,434	$ 110,182

Organization and Basis of Presentation	12 Months Ended
Organization and Basis of Presentation	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Precigen, Inc. ("Precigen"), formerly known as Intrexon Corporation, a Virginia corporation, is a synthetic biology company with an increasing focus on its discovery and clinical stage activities to advance the next generation of gene and cellular therapies to target the most urgent and intractable challenges in immuno-oncology, autoimmune disorders, and infectious diseases. Precigen also continues to advance its methane bioconversion business and its established bovine genetics company. There have been no commercialized products derived either directly by Precigen or through its collaborations or joint ventures ("JVs") to date. PGEN Therapeutics, Inc. ("PGEN Therapeutics"), formerly known as Precigen, Inc., a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cellular therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases, is a wholly owned subsidiary of Precigen with primary operations in Maryland. Precigen ActoBio, Inc. ("ActoBio"), formerly known as ActoBio Therapeutics, Inc., is pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics and is a wholly owned subsidiary of Precigen with primary operations in Belgium. Exemplar Genetics, LLC ("Exemplar") is committed to enabling the study of life-threatening human diseases through the development of miniswine research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications and is a wholly owned subsidiary of Precigen with primary operations in Iowa. Effective October 1, 2019, Precigen transferred substantially all of its proprietary methane bioconversion platform assets to a new wholly owned subsidiary, MBP Titan LLC ("MBP Titan"), with primary operations in California. MBP Titan's proprietary methane bioconversion platform is designed to turn natural gas into more valuable and usable energy and chemical products through novel, highly engineered bacteria that utilize specific energy feedstocks. Prior to October 1, 2019, MBP Titan was an operating division within Precigen. There was no impact to the accompanying consolidated financial statements resulting from the transfer of these assets. Trans Ova Genetics, L.C. ("Trans Ova"), Progentus, L.C. ("Progentus"), and ViaGen, L.C. ("ViaGen"), providers of advanced reproductive technologies, including services and products sold to cattle breeders and other producers, are wholly owned subsidiaries with primary operations in California, Iowa, Maryland, Missouri, New York, Oklahoma, Texas, and Washington. Through April 8, 2019, Precigen consolidated AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture and whose common stock is listed on the Nasdaq Stock Market. On April 9, 2019, AquaBounty completed an underwritten public offering that resulted in Precigen no longer having the contractual right to control AquaBounty's board of directors, and accordingly, Precigen deconsolidated AquaBounty. After remeasuring its retained interest in AquaBounty, Precigen recorded a loss on deconsolidation of $2,648, which is included in other income, net, on the accompanying consolidated statement of operations for the year ended December 31, 2019. The deconsolidation resulted in the derecognition of the carrying amount of $38,682 in net assets that are no longer reported in the accompanying consolidated balance sheet during the year ended December 31, 2019. See Notes 10, 11, and 12 for additional discussion of material impacts to the accompanying consolidated balance sheet as of December 31, 2019. After deconsolidating the entity in April 2019, Precigen accounted for these equity securities using the fair value option. In October 2019, the independent members of the Company's board of directors, with the recommendation of the audit committee and an independent special committee of the Board, unanimously approved the sale of the Company's common shares held in AquaBounty to an affiliate of Third Security, LLC ("Third Security"), a related party, for $21,587, resulting in the recognition of a realized gain of $7,348 which is included in unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net, on the accompanying consolidated statement of operations for the year ended December 31, 2019. On January 31, 2020, Precigen completed the sale of the majority of its bioengineering assets and operations, which are presented as discontinued operations for all periods presented. See Notes 3 and 23 for further discussion. Precigen and its consolidated subsidiaries are hereinafter referred to as the "Company." Liquidity and Going Concern Management believes that existing liquid assets as of December 31, 2019, as well as amounts secured subsequent to December 31, 2019 and before the issuance of these consolidated financial statements, will allow the Company to continue its operations for at least a year from the issuance date of these consolidated financial statements. These consolidated financial statements are presented in United States dollars and are prepared under accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and clinical manufacturing of its and its collaborators' product candidates. Additionally, the accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the year ended December 31, 2019, the Company incurred a net loss attributable to Precigen of $322,324 and, as of December 31, 2019, has an accumulated deficit of $1,652,869. Management expects operating losses and negative cash flows to continue for the foreseeable future and, as a result, the Company will require additional capital to fund its operations and execute its business plan. In the absence of a significant source of recurring revenue, the Company's long-term success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, reduce uses of cash for operating and investing activities for nonhealthcare businesses, obtain regulatory approval of its products, successfully commercialize its products, generate revenue, meet its obligations and, ultimately, attain profitable operations. Upon the original issuance of the Company's financial statements as of and for the year ended December 31, 2018, the Company's resources of cash, cash equivalents, and short-term investments were not sufficient to fund the Company's planned operations through one year after the date the 2018 consolidated financial statements were originally issued and accordingly, there was substantial doubt about the Company's ability to continue as a going concern. The analysis used to determine the Company's ability to continue as a going concern did not include cash sources outside of the Company's direct control that management expected to be available within the twelve months following the original issuance of the 2018 consolidated financial statements. At the time of the original issuance of the 2018 consolidated financial statements, the Company could not ensure that it would be able to obtain sufficient additional funding through monetizing certain of its existing assets, entering into new license and collaboration agreements, issuing additional equity or debt instruments or any other means, and if it was able to do so, they may not be on satisfactory terms. The Company's ability to raise additional capital in the equity and debt markets, should the Company choose to do so, was dependent on a number of factors, including, but not limited to, the market demand for the Company's common stock, which itself is subject to a number of business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that were favorable to the Company. Should the Company not be able to secure additional funding though these means, the Company could have had to engage in any or all of the following activities: (i) shift internal investments from subsidiaries and platforms whose potential for value creation was longer-term to near-term opportunities; (ii) sell certain of its operating subsidiaries to third parties; (iii) reduce operating expenditures for third-party contractors, including consultants, professional advisors and other vendors; and (iv) reduce or delay capital expenditures, including non-essential facility expansions, lab equipment, and information technology projects. The 2018 consolidated financial statements were prepared on a going concern basis and did not include any adjustments to the amounts and classification of assets and liabilities that may have been necessary in the event the Company could no longer continue as a going concern.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.

Revenue Recognition (For the Years Ended December 31, 2019 and 2018)

Effective January 1, 2018, the Company applies Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"). Under ASC 606, the Company recognizes revenue when its customer obtains control of the promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the promises and distinct performance obligations in the contract, (iii) determine the

transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.

Collaboration and licensing revenues

The Company has historically generated collaboration and licensing revenues through agreements with collaborators (known as exclusive channel collaborations or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement; (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii) milestone payments upon the achievement of specified development, regulatory, and commercial activities; and (iv) royalties on sales of products arising from the collaboration or licensing agreement. The agreement typically continues in perpetuity unless terminated and each of the Company's collaborators retain a right to terminate the agreement upon providing the Company written notice a certain period of time prior to such termination, generally 90 days.

The Company's collaboration and licensing agreements typically contain multiple promises, including technology licenses, research and development services and, in certain cases, manufacturing services. The Company determines whether each of the promises is a distinct performance obligation. As the nature of the promises in the Company's collaboration and licensing agreements are highly integrated and interrelated, the Company typically combines most of its promises into a single performance obligation. Because the Company is performing research and development services during early-stage development, the services are integral to the utilization of the technology license. Therefore, the Company has determined that the technology license and research and development services are typically inseparable from each other during the performance period of its collaboration and licensing agreements. Options to acquire additional services are considered to determine if they constitute material rights. Contingent manufacturing services that may be provided under certain of the Company's agreements are considered to be a separate future contract and not part of the current collaboration or licensing agreement.

At contract inception, the Company determines the transaction price, including fixed consideration and any estimated amounts of variable consideration. The upfront payment received upon consummation of the agreement is fixed and nonrefundable. Variable consideration is subject to a constraint and amounts are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include reimbursements for costs incurred by the Company for research and development efforts; milestone payments upon the achievement of certain development, regulatory, and commercial activities; and royalties on sales of products arising from the collaboration or licensing agreement. The Company determines the initial transaction price and excludes variable consideration that is otherwise constrained pursuant to the guidance in ASC 606.

The transaction price is allocated to the performance obligations in the agreement based on the standalone selling price of each performance obligation. The Company typically groups the promises in its collaboration and licensing agreements into one performance obligation so the entire transaction price relates to this single performance obligation. The technology license included in the single performance obligation is considered a functional license. However, it is typically combined into a single performance obligation as the Company provides interrelated research and development services along with other obligations over an estimated period of performance. The Company utilizes judgment to determine the most appropriate method to measure its progress of performance under the agreement, primarily based on inputs necessary to fulfill the performance obligation. The Company evaluates its measure of progress to recognize revenue each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The Company's measure of performance and revenue recognition involves significant judgment and assumptions, including, but not limited to, estimated costs and timelines to complete its performance obligations. The Company evaluates modifications and amendments to its contracts to determine whether any changes should be accounted for prospectively or on a cumulative catch-up basis.

Payments received for cost reimbursements for research and development efforts are recognized as revenue as the services are performed, in connection with the single performance obligation discussed above. The reimbursements relate specifically to the Company's efforts to provide services and the reimbursements are consistent with what the Company would typically charge other collaborators for similar services.

The Company assesses the uncertainty of when and if the milestone will be achieved to determine whether the milestone is included in the transaction price. The Company then assesses whether the revenue is constrained based on whether it is probable that a significant reversal of revenue would not occur when the uncertainty is resolved.

Royalties, including sales-based milestones, received under the agreements will be recognized as revenue when sales have occurred because the Company applies the sales- or usage-based royalties recognition exception provided for under ASC 606. The Company determined the application of this exception is appropriate because at the time the royalties are generated, the technology license granted in the agreement is the predominant item to which the royalties relate.

As the Company receives upfront payments in its collaboration and licensing agreements, it evaluates whether any significant financing components exist in its collaboration and licensing agreements. Based on the nature of its collaboration and licensing agreements, there are no significant financing components as the purpose of the upfront payment is not to provide financing. The purpose is to provide the collaborator with assurance that the Company will complete its obligations under the contract or to secure the right to a specific product or service at the collaborator's discretion. In addition, the variable payments generally align with the timing of performance or the timing of the consideration varies on the basis of the occurrence or nonoccurrence of a future event that is not substantially within the control of the collaborator or the Company.

From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. Upon such cancellation or when the Company has determined no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue as revenue.

Product and service revenues

The Company's product and service revenues are generated primarily through Trans Ova and include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. As each promised product or service is distinct, the Company recognizes the transaction price as revenue at a point in time when control of the promised product is transferred to the customer or when the promised service is rendered. Payment terms are typically due within 30 days of invoicing, which occurs prior to or when revenue is recognized.

Revenue Recognition (For the Year Ended December 31, 2017)

Collaboration and licensing revenues

The Company historically generated collaboration and licensing revenue through agreements with collaborators and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development, and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement; (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement; (iii) milestone payments upon the achievement of specified development, regulatory, and commercial activities; and (iv) royalties on sales of products arising from the collaboration or licensing agreement.

The Company's collaboration and licensing agreements typically contain multiple elements, or deliverables, including technology licenses, research and development services, and in certain cases manufacturing services. The Company identifies the deliverables within the agreements and evaluates which deliverables represent separate units of accounting. Analyzing the agreements to identify deliverables requires the use of judgment. A deliverable is considered a separate unit of accounting when the deliverable has value to the collaborator or licensee on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement.

Consideration received is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. When available, the relative selling price for each deliverable is determined using vendor specific objective evidence ("VSOE") of the selling price or third-party evidence of the selling price, if VSOE does not exist. If neither VSOE nor third-party evidence of the selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. The Company recognizes the revenue allocated to each unit of accounting as the Company delivers the related goods or services. If the Company determines that certain deliverables should be treated as a single unit of accounting, then the revenue is recognized using either a proportional performance or straight-line method, depending on whether the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and whether such performance obligations are provided on a best-efforts basis. As the Company cannot reasonably estimate its performance

obligations related to its collaborators or licensees, the Company recognizes revenue on a straight-line basis over the period it expects to complete its performance obligations, which is reevaluated each reporting period.

The terms of the Company's agreements may provide for milestone payments upon achievement of certain defined events. The Company applies the Milestone Method for recognizing milestone payments. Under the Milestone Method, the Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:


(1)	The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity's performance to achieve the milestone;


(2)	The consideration relates solely to past performance; and


(3)	The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.

In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments.

Research and development services are a deliverable satisfied by the Company in accordance with the terms of the collaboration and licensing agreements and the Company considers these services to be inseparable from the license to the core technology; therefore, reimbursements of services performed are recognized as revenue. Because reimbursement (i) is contingent upon performance of the services by the Company, (ii) does not include a profit component, and (iii) does not relate to any future deliverable, the revenue is recognized during the period in which the related services are performed and collection of such amounts is reasonably assured. Payments received for manufacturing services will be recognized when the earnings process related to the manufactured materials has been completed. Royalties to be received under the agreements will be recognized as earned.

From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes the remaining balance of deferred revenue.

Product and service revenues

The Company's product and service revenues are generated primarily through Trans Ova and include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered or delivery has occurred such that risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collection from the customer is reasonably assured.

Research and Development

The Company considers that regulatory requirements inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, costs to acquire or reacquire technology rights, consultants, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Costs incurred in conjunction with collaboration and licensing arrangements are included in research and development. Indirect research and development costs include depreciation, amortization, and other indirect overhead expenses.

The Company has research and development arrangements with third parties that include upfront and milestone payments. As of December 31, 2019 and 2018, the Company had research and development commitments from continuing operations with third parties that had not yet been incurred totaling $15,369 and $11,801, respectively. The commitments are generally cancellable by the Company at any time upon written notice.

Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions. Recoverability of investments is dependent upon the performance of the issuer. As of December 31, 2019 and 2018, the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of $47,238 and $40,155, respectively.

Restricted Cash

Restricted cash represented funds deposited with the United States Treasury, as required by a court decision resulting from litigation against Trans Ova (Note 17).

Short-term and Long-term Investments

As of December 31, 2019, short-term investments include United States government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of Standard & Poor's, Moody's or Fitch and to have a minimum rating of A1, P1 or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.

Equity Securities

The Company has historically held equity securities of private and publicly traded companies, including investments received and/or purchased from certain collaborators. The Company evaluated whether to elect the fair value option on an individual investment basis. The Company elected the fair value option to account for its equity securities held in publicly traded companies. These equity securities were recorded at fair value at each reporting date and were subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments were reported in the consolidated statements of operations. The Company accounts for its investments in private companies using either the equity method, as discussed below, or the measurement alternative method for equity securities without readily determinable fair values, which represented cost and any adjustments for impairment or observable price changes in certain transactions. In June 2019, in connection with its collaboration agreement with Surterra Holdings, Inc. ("Surterra"), the Company received common shares of Surterra's parent company, SH Parent, Inc. ("SH Parent") and accounted for these common shares using the measurement alternative method. As of December 31, 2019, there have been no adjustments for impairment or observable price changes for the SH Parent common shares and these shares have been reclassified to current assets held for sale as of December 31, 2019, and were subsequently sold in January 2020 (Note 3). Equity securities that the Company did not intend to sell within one year were classified as noncurrent in the consolidated balance sheets. See Notes 3 and 18 for additional discussion of certain equity securities.

For equity securities received pursuant to a collaboration agreement, the Company recorded the fair value of securities received on the date the collaboration was consummated or the milestone was achieved using the fair value of the collaborator's security on that date, assuming the transfer of consideration was considered perfunctory. If the transfer of the consideration was not considered perfunctory, the Company considered the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluated whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concluded that a discount should be applied to securities accounted for under the fair value option, the fair value of the securities was adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.

Fair Value of Financial Instruments

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:



Level 1:	Quoted prices in active markets for identical assets and liabilities;

Level 2:	Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and

Level 3:	Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.

Concentrations of Risk

Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December 31, 2019, there were no gross unrealized losses on the Company's short-term investments. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions, or distribute its equity securities to shareholders as a stock dividend. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade and related party receivables. The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable.

Equity Method Investments

The Company accounts for its investments in each of its JVs and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), all of which are related parties, using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets. See additional discussion related to certain of the Harvest start-up entities in Note 4 and to certain of the Company's JVs in Note 5.

Effective in April 2019, the Company accounted for its investment in AquaBounty, using the fair value option until the Company sold the investment in October 2019. See Note 1 for additional discussion regarding AquaBounty.

Variable Interest Entities

The Company identifies entities that (i) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.

As of December 31, 2019 and 2018, the Company determined that certain of its collaborators and JVs as well as Harvest were VIEs. The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of December 31, 2019 and 2018, were $1,461 and $3,341, respectively, which represents the Company's maximum risk

of loss related to the identified VIEs. See Note 5 for discussion of the Company's future funding commitments for the significant JVs.

Accounts Receivables

Accounts receivables consist of credit extended to the Company's customers in the normal course of business and are reported net of an allowance for doubtful accounts. The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry, or specific customer conditions that may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts.

The following table shows the activity in the allowance for doubtful receivable accounts from continuing operations for the years ended December 31, 2019, 2018, and 2017:



	2019			2018			2017
Beginning balance	$	4,991		$	4,631		$	3,703
Charged to operating expenses	3,384			1,627			1,217
Write offs of accounts receivable, net of recoveries	(862		)	(1,267		)	(289		)
Ending balance	$	7,513		$	4,991		$	4,631

Inventory

The Company's inventory primarily includes adult female cows that are used in Trans Ova's production processes and are recorded at acquisition cost using the first-in, first-out method or net realizable value, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or net realizable value. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are generally expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets from continuing operations are as follows:



	Years
Land improvements	4-15
Buildings and building improvements	3-23
Furniture and fixtures	1–10
Equipment	1–9
Breeding stock	1–4
Computer hardware and software	1–7

Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to fourteen years.

Operating Leases

The Company adopted ASC Topic 842, Leases ("ASC 842"), effective January 1, 2019. Under ASC 842, the Company determines if an arrangement is a lease at inception. Operating leases are included as right-of-use assets ("ROU Assets") and lease liabilities on the consolidated balance sheets. The Company has elected not to recognize ROU Assets or lease liabilities for leases with lease terms of one year or less.

Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The initial measurement of the ROU Asset also includes any lease payments made, adjusted for lease incentives. For leases that contain non-lease payments, the Company accounts for the lease and non-lease components as a single lease component. Variable lease payments, which primarily include payments for non-lease components such as maintenance costs, are excluded from the ROU Assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. As the Company's operating leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate at the lease commencement date, which is the estimated rate the Company would be required to pay for a collateralized borrowing equal to the total lease payments over the term of the lease, in determining the present value of future payments. The lease term for all of the Company's leases includes the noncancelable period of the lease plus any additional periods covered by options that the Company is reasonably certain to exercise, either to extend or to not terminate the lease. Lease expense is recognized on a straight-line basis over the lease term.

Goodwill

Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is reviewed for impairment at least annually. The Company performs a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the quantitative goodwill impairment test is not required.

If the quantitative goodwill impairment test is required or elected to be performed, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, an indication of goodwill impairment exists for the reporting unit and the entity must record the impairment charge for the excess carrying amount, which is limited to the amount of goodwill allocated to the reporting unit. If the fair value of the reporting unit exceeds its carrying amount, no goodwill impairment charge is necessary.

The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review. In April 2019, as a result of the Company's change in segments (Notes 2 and 20), one of the Company's prior reporting units was separated into various reporting units. Accordingly, the Company performed a relative fair value allocation of certain of its goodwill to the applicable reporting units and reviewed the reallocated goodwill for impairment.

The fair value of the reporting units are primarily determined based on the income approach. The income approach is a valuation technique in which fair value is based from forecasted future cash flows, discounted at the appropriate rate of return commensurate with the risk as well as current rates of return for equity and debt capital as of the valuation date. The forecast used in the Company's estimation of fair value was developed by management based on historical operating results, incorporating adjustments to reflect management's planned changes in operations and market considerations. The discount rate utilizes a risk adjusted weighted average cost of capital. To assess the reasonableness of the calculated reporting unit fair values, the Company compares the sum of the reporting units' fair values to its market capitalization (per share stock price times the number of shares outstanding) and calculates an implied control premium (the excess of the sum of the reporting units' fair values over the market capitalization) and then assesses the reasonableness of its implied control premium.

See Notes 3 and 11 for additional discussion regarding goodwill impairment charges recorded in the year ended December 31, 2019.

Intangible Assets

Intangible assets subject to amortization consist of patents, developed technologies and know-how; customer relationships; and trademarks acquired as a result of mergers and acquisitions. These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition, and are stated net of accumulated amortization. Indefinite-lived intangible assets consist of in-process research and development technologies acquired in mergers or acquisitions and were recorded at fair value at the dates of the respective acquisitions.

The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their estimated useful lives, ranging from three to eighteen years for the patents, developed technologies, and know-how; customer relationships; and trademarks.

Impairment of Long-Lived Assets

Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.

Indefinite-lived intangible assets, including in-process research and development, are tested for impairment annually, or more frequently if events or circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. The Company monitors the progression of its in-process research and development, as the likelihood of success is contingent upon commercial development or regulatory approval.

See Notes 3 and 10 for additional discussion of impairment of long-lived assets for the three years ended December 31, 2019.

Convertible Notes

The Company allocated the proceeds received in July 2018 from the issuance of Precigen's 3.50% convertible senior notes due 2023 (the "Convertible Notes") between long-term debt (liability component) and additional paid-in capital (equity component) within the consolidated balance sheet. The original value assigned to long-term debt is the estimated fair value as of the issuance date of a similar debt instrument without a conversion option. The original value assigned to additional paid-in capital represents the value of the conversion option and is calculated by deducting the fair value of the long-term debt from the principal amount of the Convertible Notes and is not remeasured as long as it continues to meet the requirements for equity classification. The original value of the conversion option will accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method.

Debt issuance costs related to the Convertible Notes are also allocated between long-term debt and additional paid-in capital based on the original value assigned to each. Debt issuance costs allocated to long-term debt reduced the original carrying value and will accrete to the carrying value of the long-term debt and result in additional noncash interest expense over the expected life of the Convertible Notes using the effective interest method. Debt issuance costs allocated to additional paid-in capital are recorded as reduction of the original value assigned to the conversion option.

See Note 12 for the further discussion of the Convertible Notes.

Foreign Currency Translation

The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the "Tax Act") was signed into law and significantly revised United States corporate income tax law by, among other things, reducing the corporate income tax rate to 21% effective January 1, 2018, eliminating the corporate alternative minimum tax and implementing a modified territorial tax system that includes a one-time transition tax on deemed repatriated earnings from foreign subsidiaries. The United States Securities and Exchange Commission ("SEC") Staff issued Staff Accounting Bulletin No. 118 to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed, including computations, in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company recognized provisional tax impacts related to revaluation of most of the Company's domestic deferred tax assets, the impact of revaluation of those deferred tax assets on the Company's valuation allowance and elimination of the corporate alternative minimum tax, and included those amounts in the consolidated financial statements for the year ended December 31, 2017. The Company completed its accounting for the Tax Act in the fourth quarter of 2018, and there were no significant adjustments to the previously recorded provisional amounts.

In addition, the Tax Act implemented a new minimum tax on global intangible low-taxed income ("GILTI"). A company can elect an accounting policy to account for GILTI in either of the following ways:


•	As a period charge in the future period in which the tax arises; or


•	As part of deferred taxes related to the investment or subsidiary.

The Company elected to account for GILTI as a period charge in the period in which the tax arises. There was no impact to the accompanying consolidated financial statements as of and for the years ended December 31, 2019 and 2018.

See Note 13 for additional discussion of the Tax Act.

Share-Based Payments

Precigen uses the Black-Scholes option pricing model to estimate the grant-date fair value of all stock options. The Black-Scholes option pricing model requires the use of assumptions for estimated expected volatility, estimated expected term of stock options, risk-free rate, estimated expected dividend yield, and the fair value of the underlying common stock at the date of grant. Since Precigen does not have sufficient history to estimate the expected volatility of its common stock price, expected volatility is based on a blended approach that utilizes the volatility of Precigen's common stock and the volatility of peer public entities that are similar in size and industry. Precigen estimates the expected term of all options based on previous history of exercises. The risk-free rate is based on the United States Treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield is 0% as Precigen does not expect to declare cash dividends in the near future. The fair value of the underlying common stock is determined based on the quoted market price on the Nasdaq Global Select Market ("Nasdaq"). Forfeitures are recorded when incurred. The assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2019, 2018 and 2017 are set forth in the table below:



	2019	2018	2017
Valuation assumptions
Expected dividend yield	0%	0%	0%
Expected volatility	58%—64%	55%—59%	57%—60%
Expected term (years)	6.25	6.25	6.25
Risk-free interest rate	1.53%—2.58%	2.33%—3.06%	1.89%—2.27%

Grant date fair value for the Company's restricted stock units ("RSUs") is based on the fair value of the underlying common stock as determined based on the quoted market price on the Nasdaq on the date of grant.

Net Loss per Share

Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, shares to be issued pursuant to convertible debt, stock options, RSUs, and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.

Segment Information

The Company realigned its business in April 2019, and as a result, its chief operating decision maker ("CODM") now regularly reviews disaggregated financial information for various operating segments. As of December 31, 2019, the Company's reportable segments were (i) PGEN Therapeutics; (ii) ActoBio; (iii) MBP Titan; and (iv) Trans Ova. All of Precigen's consolidated subsidiaries and operating divisions that did not meet the quantitative thresholds to report separately are combined and reported in a single category, All Other. See Note 1 for a description of each of these reportable segments. Corporate expenses, which are not allocated to the segments and are managed at a consolidated level, include costs associated with general and administrative functions, including the Company's finance, accounting, legal, human resources, information technology, corporate communication, and investor relations functions. Corporate expenses exclude interest expense, depreciation and amortization, stock-based compensation expense, and equity in net loss of affiliates and include unrealized and realized gains and losses on the Company's securities portfolio as well as dividend income. The Company's segment presentation has been recast to retrospectively reflect the change from one reportable segment to multiple reportable segments. See Note 20 for further discussion of the Company's segments.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Recently Adopted Accounting Pronouncements

The Company adopted ASC 842 on January 1, 2019 using the modified retrospective method as of the adoption date without restating prior periods. In addition, the Company elected to use the package of practical expedients which allowed the Company to not have to reassess whether expired or existing contracts contain leases under the new definition of a lease or the lease classification for expired or existing leases under ASC Topic 840. As a result of the adoption of ASC 842, the Company recorded ROU Assets and lease liabilities of $30,000 and $32,300, respectively, as of January 1, 2019 for continuing operations. The difference between the ROU Assets and lease liabilities primarily represents the balance of deferred rent as of December 31, 2018 that resulted from historical straight-lining of operating leases expense, which was reclassified upon adoption to reduce the measurement of the ROU Assets. There was no impact to accumulated deficit.

In June 2018, the FASB issued Accounting Standards Update ("ASU") 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ("ASU 2018-07"). The provisions of ASU 2018-07 expand the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted this standard effective January 1, 2019, and there was no material impact to the accompanying consolidated financial statements.

Recently Issued Accounting Pronouncements

In October 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 ("ASU 2018-18"). The provisions of ASU 2018-18 clarify when certain transactions between collaborative arrangement participants should be accounted for under ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), and incorporates unit-of-account guidance consistent with ASC 606 to aid in this determination. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities ("ASU 2018-17"). The provisions of ASU 2018-17 modify the guidance under ASC Topic 810 related to the evaluation of indirect interests held through related parties under common control when determining whether fees paid to decision makers and service providers are variable interests. Indirect interests held through related parties that are under common control are no longer considered to be the equivalent of direct interests in their entirety and instead should be considered on a proportional basis. This guidance more closely aligns with accounting of how indirect interests held through related parties under common control are considered for determining whether a reporting entity must consolidate a VIE. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, Intangibles - Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract ("ASU 2018-15"). The provisions of ASU 2018-15 clarify the accounting for implementation costs of a hosting arrangement that is a service contract. The new standard requires an entity (customer) in a hosting arrangement that is a service contract to follow existing internal-use software guidance to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Capitalized implementation costs of a hosting arrangement that is a service contract should be amortized over the term of the hosting arrangement, which might extend beyond the noncancelable period if there are options to extend or terminate. ASU 2018-15 also specifies the financial statement presentation of capitalized implementation costs and related amortization, in addition to required disclosures for material capitalized implementation costs related to hosting arrangements that are service contracts. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurements (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements ("ASU 2018-13"). The provisions of ASU 2018-13 modify the disclosures related to recurring and nonrecurring fair value measurements. Disclosures related to the transfer of assets between Level 1 and Level 2 hierarchies have been eliminated and various additional disclosures related to Level 3 fair value measurements have been added, modified, or removed. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). The provisions of ASU 2016-13 modify the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, and requires a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2019, and is effective for the Company for the year ending December 31, 2020. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

Discontinued Operations

12 Months Ended

Dec. 31, 2019

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

On January 1, 2020, the Company and TS Biotechnology Holdings, LLC ("TS Biotechnology"), a related party and an entity managed by Third Security, entered into a Stock and Asset Purchase Agreement pursuant to which the Company agreed to sell a majority of the Company's bioengineering assets and operations to TS Biotechnology for $53,000 and certain contingent payment rights (the "TS Biotechnology Sale"). The TS Biotechnology Sale closed on January 31, 2020. The assets and operations sold in the TS Biotechnology Sale included the following wholly owned subsidiaries, as well as certain equity securities held in Oragenics, Inc. ("Oragenics") and SH Parent that were directly related to the subsidiaries sold:


•	Intrexon Produce Holdings, Inc. is the parent company of the Company's non-browning apple subsidiaries, Okanagan Specialty Fruits, Inc. and Fruit Orchard Holdings, Inc. (collectively referred herein as "Okanagan");


•	Intrexon UK Holdings, Inc. is the parent company of Oxitec Limited and subsidiaries, which is a pioneering company in biological insect solutions (referred to herein as "Oxitec");


•	ILH Holdings, Inc. includes the Company's fine chemicals operations that were focused primarily on microbial production of therapeutic compounds ("Fine Chemicals"); and


•	Blue Marble AgBio LLC which was formed in January 2020 and includes the Company's agriculture biotechnology assets and operations which were previously a division within Precigen ("AgBio").

Additionally, on January 2, 2020, the Company sold its equity interest in EnviroFlight, LLC ("EnviroFlight"), a JV with Darling Ingredients, Inc. ("Darling"), and related intellectual property rights to Darling for $12,200 (the "EnviroFlight Sale"). Unless referenced separately, the TS Biotechnology Sale and the EnviroFlight Sale are collectively referred to as the "Transactions".

The Transactions were approved by the Company's independent members of the board of directors in December 2019. The Transactions represent a strategic shift of the Company towards the Company becoming a primarily healthcare company

advancing technologies and products that address complex healthcare challenges. The assets, liabilities, and operations related to the Transactions are reclassified and presented as discontinued operations in the accompanying consolidated financial statements for all periods. Immediately prior to the reclassification, the Company evaluated goodwill, long-lived assets, and the equity method investment included in the Transactions for impairment. The Company recorded an impairment charge of $79,396, including $58,042 and $21,354 related to goodwill and other long-lived assets, respectively, at the Okanagan, Oxitec, Fine Chemicals, and AgBio reporting units. Additionally, the Company recorded a $10,283 impairment charge for the write down of the equity method investment and related intangible assets included in the EnviroFlight Sale. These impairment charges are included in loss from discontinued operations in the accompanying consolidated statement of operations for the year ended December, 31, 2019. As of December 31, 2019, the Company has estimated $942 of selling costs related to the Transactions.

The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale for the Transactions are as follows:



	December 31, 2019
	TS Biotechnology Sale		EnviroFlight Sale		Total
Assets
Cash and cash equivalents	$	2,223	$	—	$	2,223
Other current assets	9,698		—		9,698
Property, plant and equipment, net	51,975		—		51,975
Intangible assets, net	20,891		4,383		25,274
Investments in affiliates	—		7,817		7,817
Right-of-use assets	13,622		—		13,622
Other noncurrent assets	212		—		212
Total assets held for sale	$	98,621	$	12,200	$	110,821
Liabilities
Deferred revenue, current (1)	$	8,723	$	—	$	8,723
Operating lease liabilities, current	2,459		—		2,459
Other current liabilities	3,058		41		3,099
Deferred revenue, net of current portion (2)	19,410		—		19,410
Operating lease liabilities, net of current portion	12,623		—		12,623
Other long-term liabilities	1,019		—		1,019
Total liabilities held for sale	$	47,292	$	41	$	47,333


(1)	Includes deferred revenue, current, from related parties of $1,243.


(2)	Includes deferred revenue, net of current portion, from related parties of $6,836.



	December 31, 2018
	TS Biotechnology Sale		EnviroFlight Sale		Total
Assets
Cash and cash equivalents	$	5,892	$	—	$	5,892
Other current assets	3,263		—		3,263
Property, plant and equipment, net	41,978		—		41,978
Intangible assets, net	31,782		8,547		40,329
Investments in affiliates	—		16,720		16,720
Goodwill	55,958		—		55,958
Other noncurrent assets	1,376		—		1,376
Total assets held for sale	$	140,249	$	25,267	$	165,516
Liabilities
Deferred revenue, current (1)	$	4,466	$	—	$	4,466
Other current liabilities	3,874		—		3,874
Deferred revenue, net of current portion (2)	7,482		—		7,482
Other long-term liabilities	3,476		—		3,476
Total liabilities held for sale	$	19,298	$	—	$	19,298


(1)	Includes deferred revenue, current, from related parties of $443.


(2)	Includes deferred revenue, net of current portion, from related parties of $7,455.

The following tables present the financial results of discontinued operations:



	Year Ended December 31, 2019
	TS Biotechnology Sale			EnviroFlight Sale			Total
Revenue (1)	$	12,307		$	—		$	12,307
Operating expenses (2)	116,091			10,794			126,885
Operating loss	(103,784		)	(10,794		)	(114,578		)
Other expense, net	(272		)	—			(272		)
Equity in net loss of affiliates	—			(4,314		)	(4,314		)
Loss before income taxes	(104,056		)	(15,108		)	(119,164		)
Income tax benefit	3,005			—			3,005
Loss from discontinued operations	$	(101,051	)	$	(15,108	)	$	(116,159	)


(1)	Includes revenue recognized from related parties of $3,042.


(2)	Includes the impairment charge of $89,679 related to the Transactions discussed above.



	Year Ended December 31, 2018
	TS Biotechnology Sale			EnviroFlight Sale			Total
Revenue (1)	$	9,396		$	—		$	9,396
Operating expenses (2)	111,039			470			111,509
Operating loss	(101,643		)	(470		)	(102,113		)
Other expense, net	(1,757		)	—			(1,757		)
Equity in net loss of affiliates	—			(2,622		)	(2,622		)
Loss before income taxes	(103,400		)	(3,092		)	(106,492		)
Income tax benefit	6,103			—			6,103
Loss from discontinued operations	$	(97,297	)	$	(3,092	)	$	(100,389	)


(1)	Includes revenue recognized from related parties of $4,665.


(2)	Includes an impairment charge of $60,504 recorded in 2018 related to Oxitec's developed technology targeting the Aedes Aegypti mosquito and a $5,057 loss on disposal of certain leasehold improvements, equipment and other fixed assets in conjunction with the closing of one of Oxitec's research and development facilities in Brazil.



	Year Ended December 31, 2017
	TS Biotechnology Sale			EnviroFlight Sale			Total
Revenue (1)	$	11,518		$	—		$	11,518
Operating expenses (2)	53,028			470			53,498
Operating loss	(41,510		)	(470		)	(41,980		)
Other expense, net	(7,506		)	—			(7,506		)
Equity in net loss of affiliates	—			(1,847		)	(1,847		)
Loss before income taxes	(49,016		)	(2,317		)	(51,333		)
Income tax benefit	4,952			—			4,952
Loss from discontinued operations	$	(44,064	)	$	(2,317	)	$	(46,381	)


(1)	Includes revenue recognized from related parties of $8,185.


(2)	Includes an impairment charge of $2,950 recorded as part of its annual impairment assessment of indefinite-lived intangible assets.

The following table presents the significant non-cash items, investments in EnviroFlight and purchases of property, plant and equipment for the discontinued operations that are included in the accompanying consolidated statements of cash flows.



	Year Ended December 31,
	2019			2018			2017
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	$	5,107		$	9,007		$	9,536
Impairment loss	89,679			60,504			2,950
Unrealized and realized depreciation on equity securities and preferred stock, net	458			1,927			7,544
Equity in net loss of EnviroFlight	4,314			2,622			1,847
Stock-based compensation expense	2,507			3,872			4,683
Deferred income taxes	(2,710		)	(5,703		)	(4,575		)
Cash flows from investing activities
Investments in EnviroFlight	(2,000		)	(12,250		)	(4,750		)
Purchases of property, plant and equipment	(23,326		)	(21,191		)	(13,455		)

Also see Note 23 below.

Equity Method Investments

The Company accounted for its investment in EnviroFlight using the equity method of accounting.

The Company accounted for its equity securities held in Oragenics, one of its collaborators and a related party, using the fair value option. Oragenics was considered an equity method investment through September 30, 2018.

Summarized financial data for equity method investments included in discontinued operations during the periods below are shown in the following tables.



	December 31,
	2019		2018
Current assets	$	703	$	5,119
Noncurrent assets	30,549		29,326
Total assets	31,252		34,445
Current liabilities	2,352		1,005
Non-current liabilities	88		—
Total liabilities	2,440		1,005
Net assets	$	28,812	$	33,440



	Year Ended December 31,
	2019			2018			2017
Revenues	$	510		$	268		$	254
Operating expenses	9,159			12,709			10,671
Operating loss	(8,649		)	(12,441		)	(10,417		)
Other, net	21			39			(8		)
Net loss	$	(8,628	)	$	(12,402	)	$	(10,425	)

Where applicable, the notes to the consolidated financial statements have been updated to reflect information pertaining to the Company's continuing operations.

Mergers and Acquisitions

12 Months Ended

Dec. 31, 2019

Mergers and Acquisitions [Abstract]

Mergers and Acquisitions

Asset Acquisition of Certain Harvest Entities

In September 2018, the Company, through its wholly owned subsidiary ActoBio, issued $30,000 of convertible promissory notes to Harvest, a related party, to acquire Harvest's ownership in CRS Bio, Inc. ("CRS Bio"); Genten Therapeutics, Inc. ("Genten Therapeutics"); and Relieve Genetics, Inc. ("Relieve Genetics") (collectively the "Harvest entities"). The Company also received $15,500 cash in the transaction from the acquisition of the Harvest entities. Prior to the transaction, the Company held a noncontrolling interest in the Harvest entities, with a combined carrying value for all entities of $4,303, and accounted for its ownership using the equity method of accounting. Following the transaction, the Company owns 100% of the equity interests of the Harvest entities including the rights that had been previously licensed to the Harvest entities by the Company. The Harvest entities did not meet the definition of a business and accordingly, the transaction was accounted for as an asset acquisition.

By reacquiring the rights previously licensed to the Harvest entities, the Company was relieved from its obligations under the original ECCs and therefore wrote off deferred revenue of $10,078 in September 2018 as part of the transaction. The remaining value acquired of $8,721 was considered in-process research and development related to the reacquired rights under the ECCs and expensed immediately.

See Note 12 for additional discussion of the convertible promissory notes.

GenVec Acquisition

In June 2017, pursuant to an Agreement and Plan of Merger (the "GenVec Merger Agreement"), the Company acquired 100% of the outstanding shares of GenVec, Inc. ("GenVec"), a clinical-stage company and pioneer in the development of AdenoVerse gene delivery technology. Pursuant to the GenVec Merger Agreement, the former shareholders of GenVec received an aggregate of 684,240 shares of the Company's common stock and have the right to receive contingent consideration equal to 50% of any milestone or royalty payments received under one of GenVec's collaboration agreements, provided such payments are received within three years after the closing of the transaction. The Company also assumed warrants held by certain former shareholders of GenVec. The results of GenVec's operations subsequent to the acquisition date have been included in the consolidated financial statements.

The fair value of the total consideration transferred was $17,582. The acquisition date fair value of each class of consideration transferred is presented below:



Common shares	$	15,616
Warrants	1,381
Contingent consideration	585
	$	17,582

The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock immediately prior to the closing of the acquisition. The fair value of the warrants assumed was estimated using the Black-Scholes option-pricing model. The fair value of the contingent consideration was determined using a probability weighted discounted cash flows model and is considered a freestanding financial instrument and recorded at fair value each reporting period. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash and cash equivalents	$	2,054
Short-term investments	542
Trade receivables	75
Other receivables	97
Prepaid expenses and other	227
Property and equipment	250
Intangible assets	14,000
Other noncurrent assets	58
Total assets acquired	17,303
Accounts payable	2,158
Accrued compensation and benefits	1,226
Other accrued expenses	856
Other long-term liabilities	92
Deferred tax liabilities	239
Total liabilities assumed	4,571
Net assets acquired	12,732
Goodwill	4,850
Total consideration	$	17,582

The acquired intangible assets include developed technology, the fair value of which was determined using the multi-period excess earning method, which is a variation of the income approach that converts future cash flows to single discounted present value amounts. The intangible assets are being amortized over a useful life of eleven years. Goodwill, which is not deductible for tax purposes, represents the assembled workforce and the anticipated buyer-specific synergies arising from the combination of the Company's and GenVec's technology.

Acquisition-related costs totaling $507 are included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2017.

Unaudited Condensed Pro Forma Financial Information

GenVec's results of operations subsequent to the acquisition are included in the consolidated statements of operations. The following unaudited condensed pro forma financial information for the year ended December 31, 2017, is presented as if the acquisition had been consummated on January 1, 2016:



	Year Ended December 31,
	2017
	Pro Forma
Revenues	$	219,695
Loss from continuing operations before income taxes	(85,633		)
Net loss	(134,275		)
Net loss attributable to the noncontrolling interests	9,802
Net loss attributable to Precigen	(124,473		)

Investments in Joint Ventures	12 Months Ended
Investments in Joint Ventures	Dec. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Investments in Joint Ventures	Investments in Joint Ventures Intrexon Energy Partners In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, a related party, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a JV formed to optimize and scale-up the Company's methane bioconversion platform technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion for the production of certain fuels and lubricants, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Precigen has committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of December 31, 2019, the Company's remaining commitment was $4,225. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board, which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board. The Company's investment in Intrexon Energy Partners was $(423) and $(656) as of December 31, 2019 and 2018, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners. Intrexon Energy Partners II In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a JV formed to utilize the Company's methane bioconversion platform technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II that provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Precigen has committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. As of December 31, 2019, the Company's remaining commitment was $10,000. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board, which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board. The Company's investment in Intrexon Energy Partners II was $(435) and $(50) as of December 31, 2019 and 2018, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, which represents the Company's equity in losses for contractually committed contributions to Intrexon Energy Partners II. Intrexon T1D Partners In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, entered into a Limited Liability Company Agreement that governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a JV formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners that provided the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $10,000 while retaining a 50% membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling $10,000 in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling 50%. Precigen committed to make capital contributions of up to $5,000, and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, committed to make additional capital contributions of up to $5,000, at the request of Intrexon T1D Partners' board of managers, which consisted of two members appointed by the Company and three members appointed by a majority of the T1D Investors. The Company satisfied its commitment in 2018. In November 2018, the Company, together with its wholly owned subsidiary ActoBio, issued 1,933,737 shares of Precigen common stock valued at $18,970 to the T1D Investors to acquire their ownership interest in Intrexon T1D Partners. Following the transaction, the Company owns 100% of the membership interests in Intrexon T1D Partners, including the rights that had been previously licensed to Intrexon T1D Partners by the Company in the ECC. Intrexon T1D Partners did not meet the definition of a business, and accordingly, the transaction was accounted for as an asset acquisition. By reacquiring the rights previously licensed to Intrexon T1D Partners, the Company was relieved from its obligations under the original ECC and therefore wrote off $8,517 of deferred revenue in November 2018 as part of the transaction. The remaining value of $10,453 was considered in-process research and development related to the reacquired rights under the ECC and expensed immediately.

Collaboration and Licensing Revenue

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaboration and Licensing Revenue

The Company's collaborations and licensing agreements provide for multiple promises to be satisfied by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, and performance of certain research and development services. Based on the nature of the promises in the Company's collaboration and licensing agreements, the Company typically combines most of its promises into a single performance obligation because the promises are highly interrelated and not individually distinct. Options to acquire additional services are considered to determine if they constitute material rights. At contract inception, the transaction price is typically the upfront payment received and is allocated to the performance obligations. The Company has determined the transaction price should be recognized as revenue based on its measure of progress under the agreement primarily based on inputs necessary to fulfill the performance obligation.

See Note 2 for additional discussion of the Company's revenue recognition policy related to collaboration and licensing payments.

The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with either majority-owned subsidiaries or equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. Amounts for periods subsequent to January 1, 2018 reflect revenue recognition under ASC 606.

The following table summarizes the amounts recorded as revenue from continuing operations in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December 31, 2019, 2018 and 2017.



	Year Ended December 31,
	2019			2018		2017
ZIOPHARM Oncology, Inc.	$	2,171		$	16,298	$	69,812
Ares Trading S.A.	—			11,175		10,738
Oragenics, Inc.	(564		)	1,353		1,469
Intrexon T1D Partners, LLC	—			2,502		5,968
Intrexon Energy Partners, LLC	2,596			6,929		10,665
Intrexon Energy Partners II, LLC	1,217			2,998		3,672
Fibrocell Science, Inc.	3,713			1,394		7,344
OvaXon, LLC	—			—		1,966
S & I Ophthalmic, LLC	—			—		755
Harvest start-up entities (1)	4,862			14,447		15,232
Other	64			12,444		7,003
Total	$	14,059		$	69,540	$	134,624


(1)	For the years ended December 31, 2019, 2018, and 2017, revenue recognized from collaborations with Harvest start-up entities include Exotech Bio, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. For the years ended December 31, 2018 and 2017, revenue recognized from collaborations with Harvest start-up entities also include Genten Therapeutics

and CRS Bio. For the year ended December 31, 2017, revenue recognized from collaborations with Harvest start-up entities also include Relieve Genetics.

The following is a summary of the terms of the Company's significant collaborations and licensing agreements from continuing operations.

ZIOPHARM Collaborations

In January 2011, the Company entered into an ECC with ZIOPHARM Oncology, Inc. ("ZIOPHARM"), a related party at the time. Pursuant to the ECC, ZIOPHARM received a license to the Company's technology platform within the field of oncology as defined more specifically in the agreement. Upon execution of the ECC, the Company received 3,636,926 shares of ZIOPHARM's common stock valued at $17,457 as upfront consideration. In addition to the promises discussed above, the Company transferred two clinical product candidates to ZIOPHARM for which $1,115 of the upfront consideration was allocated and recognized as collaboration revenue in 2011. The remaining $16,342 of upfront consideration was allocated to a single performance obligation as discussed above. The Company was entitled to additional shares of common stock at the date of the dosing of the first patient in a Phase II clinical trial of a product candidate created, produced or developed by ZIOPHARM using the Company's technology ("ZIOPHARM Milestone"). In October 2012, the ZIOPHARM Milestone was achieved and the Company received 3,636,926 shares of ZIOPHARM's common stock valued at $18,330 as milestone consideration. Upon adoption of ASC 606, the Company recorded a cumulative catch-up adjustment of $873 related to milestone consideration. The Company allocated the ZIOPHARM Milestone to the two performance obligations and recognized those in a manner similar to the discussion above. The Company received reimbursement payments for research and development services provided and manufacturing services for Company materials provided to ZIOPHARM during the ECC. In March 2015, in conjunction with the worldwide License and Collaboration Agreement ("Merck Agreement") with Ares Trading S.A. ("Ares Trading"), a wholly owned subsidiary of Merck KGaA, and ZIOPHARM discussed below, the Company and ZIOPHARM amended their existing ECC. The amendment modified the scope of the ECC in connection with the Merck Agreement and provided that the Company would pay to ZIOPHARM 50% of all payments received for upfront fees, milestones and royalties under the Merck Agreement. See discussion of the Merck Agreement below.

In September 2015, the Company entered into its second ECC with ZIOPHARM ("ZIOPHARM ECC 2"). Pursuant to the ECC, ZIOPHARM received a license to the Company's technology platform to develop and commercialize novel biotherapeutics for the treatment of patients with graft-versus-host disease. Upon execution of ZIOPHARM ECC 2, the Company received a technology access fee of $10,000. The Company received reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to ZIOPHARM during the ECC. In December 2017, the Company and ZIOPHARM mutually agreed to terminate ZIOPHARM ECC2 and accordingly, the Company recognized the remaining balance of the deferred revenue associated with ZIOPHARM ECC2 totaling $28,943.

In June 2016, the Company amended each of its two existing collaboration agreements with ZIOPHARM and as a result the rate of the royalty that the Company is entitled to receive on certain products commercialized pursuant to the agreements was reduced from 50% to 20%. As consideration for execution of the amendments, ZIOPHARM issued the Company 100,000 shares of ZIOPHARM's Series 1 Preferred Stock valued at $120,000. The Company allocated the consideration received to each ECC based on the cumulative value of upfront and milestone payments previously received pursuant to that ECC. Upon adoption of ASC 606, the Company recognized a cumulative catch-up adjustment of $32,422 as a result of the contract modification requiring a cumulative catch-up under ASC 606 versus prospective recognition under previous revenue recognition accounting standards. See Note 18 for additional discussion of the terms of the preferred stock and the accounting treatment.

In October 2018, the Company, through its wholly owned subsidiary PGEN Therapeutics, entered into a license agreement (the "ZIOPHARM License Agreement") with ZIOPHARM, which terminated and replaced the terms of the original ZIOPHARM ECC, including the amendments thereto. Pursuant to the terms of the ZIOPHARM License Agreement, the Company granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize (i) products utilizing the Company's RheoSwitch gene switch ("RTS") to express IL-12 (the "IL-12 Products") for the treatment of cancer, (ii) chimeric antigen receptor ("CAR") products directed to (a) CD19 for the treatment of cancer (the "CD19 Products"), and (b) a second target, subject to the rights of the Company to pursue such target under the Merck Agreement, and (iii) T-cell receptor ("TCR") products (the "TCR Products") designed for neoantigens for the treatment of cancer or the treatment and prevention of human papilloma virus ("HPV") to the extent that the primary reason for such treatment or prevention is to prevent cancer, which is referred to as the HPV Field. The Company has also granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license for certain patents relating to the Company's Sleeping Beauty technology to research, develop and commercialize TCR Products for both neoantigens and shared antigens for the treatment of

cancer and in the HPV Field. ZIOPHARM will be solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. ZIOPHARM is required to use commercially reasonable efforts to develop and commercialize IL-12 Products and CD19 Products, and after a two-year period, the TCR Products. The Company also granted ZIOPHARM an exclusive, worldwide, royalty-bearing, sub-licensable license to research, develop and commercialize products utilizing an additional construct that expresses RTS IL-12 (the "Gorilla IL-12 Products") for the treatment of cancer and in the HPV Field. ZIOPHARM is responsible for all development costs associated with each of the licensed products, other than Gorilla IL-12 Products. ZIOPHARM and the Company will share the development costs and operating profits for Gorilla IL-12 Products, with ZIOPHARM responsible for 80% of the development costs and receiving 80% of the operating profits, as defined in the ZIOPHARM License Agreement, and the Company responsible for the remaining 20% of the development costs and receiving 20% of the operating profits, except that ZIOPHARM will bear all development costs and the Company will share equally in operating profits for Gorilla IL-12 Products in the HPV Field (the "Gorilla Program").

In consideration of the licenses and other rights granted by the Company, ZIOPHARM will pay the Company an annual license fee of $100 and agreed to reimburse the Company $1,000, paid in four quarterly installments, with respect to historical Gorilla IL-12 Products (the "historical Gorilla reimbursements"). ZIOPHARM will make milestone payments, payable upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions, totaling up to an additional $52,500 for each of four exclusively licensed products, up to an aggregate of $210,000. In addition, ZIOPHARM will pay the Company tiered royalties ranging from low-single digits to high-single digits on the net sales derived from the sales of any approved IL-12 Products and CAR products. ZIOPHARM will also pay the Company royalties ranging from low-single digits to mid-single digits on the net sales derived from the sales of any approved TCR Products, up to maximum royalty amount of $100,000 in the aggregate. ZIOPHARM will also pay the Company 20% of any sublicensing income received by ZIOPHARM relating to the licensed products.

The Company reacquired rights to research, develop and commercialize CAR products for all other targets. In addition, the Company may research, develop and commercialize products for the treatment of cancer, outside of the products exclusively licensed to ZIOPHARM. The Company will pay ZIOPHARM royalties ranging from low-single digits to mid-single digits on the net sales derived from the sale of the Company's CAR products, up to $50,000. The Company also received from ZIOPHARM reimbursement of costs incurred to transition the necessary knowledge and materials for ZIOPHARM programs for a period of one year from the effective date (the "Transition Services").

As between the parties, the Company agreed to perform all of the obligations of ZIOPHARM under the Merck Agreement, other than an obligation of exclusivity thereunder and ZIOPHARM will remain responsible for all payments owed under the Merck Agreement with respect to CD19 and the other target under the Merck Agreement as a result of ZIOPHARM's, its affiliates' or its sublicensees' exploitation of CAR products. Further, the Company is entitled to receive all rights and financial considerations with respect to all other CAR products, subject to the CAR royalties due to ZIOPHARM for such products. The ZIOPHARM License Agreement will terminate on a product-by-product and/or country-by-country basis upon the expiration of the later to occur of (i) the expiration of the last to expire patent claim for a licensed product, or (ii) 12 years after the first commercial sale of a licensed product in such country. In addition, ZIOPHARM may terminate the ZIOPHARM License Agreement on a country-by-country or program-by-program basis following written notice to the Company, and either party may terminate the ZIOPHARM License Agreement following notice of a material breach.

Pursuant to the ZIOPHARM License Agreement, the 2016 Securities Issuance Agreement between the Company and ZIOPHARM was terminated as of the effective date of the ZIOPHARM License Agreement, all of the benefits, rights, obligations and liabilities thereunder immediately ceased and terminated and the Company returned to ZIOPHARM all of the preferred stock owned by the Company as of the Effective Date, which was valued at $158,376. See Note 18 for additional discussion of the preferred stock.

Prior to the execution of the ZIOPHARM License Agreement, the Company had $51,084 of deferred revenue remaining from the original ECC, which was related to the Company's obligations to perform under that agreement. Replacement of the original ECC with the ZIOPHARM License Agreement is a contract modification under ASC 606 that represents the termination of the original agreement and the creation of a new agreement as the remaining rights, obligations, and services to be exchanged, which are limited to the Transition Services, are distinct from those under the ECC. Therefore, the Company reviewed the various forms of consideration in the ZIOPHARM License Agreement to determine the transaction price. As the Company's obligations under the ZIOPHARM License Agreement are only related to the Transition Services and no other obligations under the ECC remain, a portion of the previously deferred revenue from the ECC should be relieved, which the Company determined to be $49,329, and the remaining $1,755 was included in the transaction price. The initial annual license payment of $100 was also included in the transaction price. The remaining annual license payments and potential milestone payments were constrained at the modification date and will only be recognized when the payments become probable of being

received. Royalty payments from sales of ZIOPHARM products developed pursuant to the ZIOPHARM License Agreement will be recognized when the sales occur. The Company recognized payments from Transition Services as those services were performed and recognized the transaction price of $1,855 as it performed the Transition Services required under the ZIOPHARM License Agreement.

The Company also reviewed the consideration paid and potential consideration to be paid to ZIOPHARM as part of the ZIOPHARM License Agreement, which includes the $158,376 of ZIOPHARM preferred stock returned by the Company and potential royalty payments to ZIOPHARM from sales of the Company's CAR products. The Company determined the exchange of its investment in ZIOPHARM preferred stock for certain CAR rights previously licensed under the ECC (i.e., in-process research and development) and the relief of performance obligations to ZIOPHARM under the ECC constituted an exchange for distinct goods and services. Therefore, the Company wrote off the $49,329 of relieved deferred revenue and recorded an expense of $109,047 for the reacquired in-process research and development. Potential royalty payments to ZIOPHARM will be expensed as incurred as they relate to distinct goods or services.

The Company determined that the Gorilla Program represents a separate collaboration agreement under the scope of ASC 808, Collaborative Arrangements, ("ASC 808") and will not be included in the accounting for the ZIOPHARM License Agreement under ASC 606. The Company recognized $500 of the historical Gorilla reimbursements on the contract modification date and recognized the remaining amounts when receipt became probable. The development costs and operating profits from the Gorilla Program will be recognized in accordance with ASC 808.

Merck Licensing Agreement

In March 2015, the Company signed the Merck Agreement with Ares Trading and ZIOPHARM through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Pursuant to the Merck Agreement, the Company received a technology access fee of $115,000 as upfront consideration, of which $57,500 was paid to ZIOPHARM in accordance with the terms of the agreement. Upon the selection of the first two targets by Ares Trading, the Company received $10,000 in equal quarterly installments over two years.

In December 2018, the Company entered into a Securities Purchase, Assignment and Assumption Agreement (the "Merck Purchase Agreement") with Ares Trading pursuant to which the Company reacquired Ares Trading's development and commercialization rights under the Merck Agreement. As consideration for the reacquisition of the Merck Agreement, the Company issued Ares Trading 20,640,119 shares of Precigen common stock valued at $140,353 and agreed to pay Ares Trading a royalty of 10% of the net sales derived from two CAR products specified in the Merck Purchase Agreement. By reacquiring the rights previously licensed to Ares Trading, the Company is relieved of its obligations under the Merck Agreement and therefore wrote off deferred revenue of $31,826. The remaining value acquired of $108,527 was considered in-process research and development related to the reacquired rights under the Merck Agreement and expensed immediately. The potential future royalty payments to Ares Trading do not represent consideration paid to a customer and will be recorded when the payments are probable. See Note 12 for additional discussion of this transaction.

Oragenics Collaborations

In June 2015, the Company entered into an ECC with Oragenics. Pursuant to the ECC, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of biotherapeutics for use in certain treatments of oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. Upon execution of the ECC, the Company received a technology access fee of a $5,000 convertible promissory note maturing on or before December 31, 2015 as upfront consideration. Prior to the maturity date, Oragenics had the right to convert the promissory note into shares of Oragenics' common stock, subject to its shareholders' approval. In December 2015, Oragenics converted the promissory note into 338,100 shares of Oragenics' common stock. These shares were sold in the TS Biotechnology Sale (Note 3). Following an amendment in November 2017, the Company is entitled to up to $37,500 of potential one-time payments for development and commercial milestones under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during the ECC. Oragenics will pay the Company royalties as a percentage in the low-teens of net sales derived from the sale of products developed from the ECC, as defined in the agreement.

Oragenics is responsible for funding the further development of products under the ECC towards the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of the ECC commenced in June 2015 and may be

terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Oragenics upon 90 days written notice to the Company.

Intrexon T1D Partners Collaboration

In March 2016, the Company entered into an ECC with Intrexon T1D Partners, a JV between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon T1D Partners received an exclusive license to the Company's technology platform to develop and commercialize products to treat type 1 diabetes. Upon execution of the ECC, the Company received a technology access fee of $10,000. The Company received reimbursement of research and development services provided pursuant to the ECC agreement. In November 2018, the Company completed an asset acquisition with the T1D Investors, resulting in the Company owning 100% of the membership interest of Intrexon T1D Partners including all rights under the ECC (Note 5).

Genten Therapeutics Collaboration

In September 2016, the Company entered into an ECC with Genten Therapeutics, an affiliate of Harvest and a related party. Genten Therapeutics was formed for the purpose of entering into the ECC and developing and commercializing products using the Company's technology for expression of gluten peptides, alone or in combination with immunomodulatory cytokines, to reestablish immune tolerance for patients with celiac disease. Upon execution of the ECC, the Company received a technology access fee in the form of a $1,500 cash payment and equity in Genten Therapeutics valued at $3,000 as upfront consideration. The Company received reimbursement payments for research and development services provided pursuant to the ECC. In September 2018, the Company completed an asset acquisition with Harvest, resulting in the Company owning 100% of the equity interests of Genten Therapeutics including all rights under the ECC (Note 4).

CRS Bio Collaboration

In September 2016, the Company entered into an ECC with CRS Bio, an affiliate of Harvest and a related party. CRS Bio was formed for the purpose of entering into the ECC and developing and commercializing products through targeted delivery of antibodies for treatment of chronic rhinosinusitis with and without nasal polyps, by utilizing the Company's technology to block inflammatory mediators in the nasal passage, leading to improved breathing and, importantly, patients' quality of life. Upon execution of the ECC, the Company received a technology access fee in the form of equity in CRS Bio valued at $2,100. The Company received reimbursement payments for research and development services provided pursuant to the ECC. In September 2018, the Company completed an asset acquisition with Harvest, resulting in the Company owning 100% of the equity interests of CRS Bio including all rights under the ECC (Note 4).

Relieve Genetics Collaboration

In March 2016, the Company entered into an ECC with Relieve Genetics, an affiliate of Harvest and a related party. Relieve Genetics was formed for the purpose of entering into the ECC and developing and commercializing products using a viral vector expressing interleukin-10 for the treatment of chronic neuropathic pain resultant from cancer in humans. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Relieve Genetics valued at $4,333 as upfront consideration. The Company received reimbursement payments for research and development services provided pursuant to the ECC. In September 2018, the Company completed an asset acquisition with Harvest, resulting in the Company owning 100% of the equity interests of Relieve Genetics including all rights under the ECC (Note 4).

Intrexon Energy Partners Collaboration

In March 2014, the Company entered into an ECC with Intrexon Energy Partners, a JV between the Company and certain investors and a related party. The ECC grants Intrexon Energy Partners an exclusive license to the Company's technology platform to optimize and scale-up the Company's methane bioconversion platform for the production of certain fuels and lubricants. Upon execution of the ECC, the Company received a technology access fee of $25,000 as upfront consideration. The Company receives reimbursement payments for research and development services as provided for in the ECC agreement. The term of the ECC commenced in March 2014 and continues until March 2034 unless terminated prior to that date by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Intrexon Energy Partners upon 90 days written notice to the Company.

Intrexon Energy Partners II Collaboration

In December 2015, the Company entered into an ECC with Intrexon Energy Partners II, a JV between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon Energy Partners II received an exclusive license to the Company's technology platform to optimize and scale-up the Company's methane bioconversion platform for the production of 1,4-butanediol (BDO), a key chemical intermediate that is used to manufacture spandex, polyurethane, plastics, and polyester. Upon execution of the ECC, the Company received a technology access fee of $18,000 and is entitled to reimbursement of research and development services as provided for in the ECC agreement. The term of the ECC commenced in December 2015 and continues until December 2035; termination prior to that date may be initiated (i) by either party in the event of certain material breaches defined in the agreement or (ii) may be terminated voluntarily by Intrexon Energy Partners II upon 90 days written notice to the Company.

Exotech Bio Collaboration

In March 2016, the Company entered into an ECC with Exotech Bio, Inc. ("Exotech Bio"), an affiliate of Harvest and a related party. Exotech Bio was formed for the purpose of entering into the ECC and developing and commercializing products using exosomes carrying a RNA payload designed to kill, suppress, or render immune-visible a cancer cell. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Exotech Bio valued at $5,000 as upfront consideration. In June 2018, the Company and Exotech Bio amended the ECC, which resulted in the expansion of the defined field of use and the Company's ownership in Exotech Bio increasing to 49%. The amendment also eliminated potential future milestone payments and royalties for which the Company was previously entitled. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Exotech Bio upon 90 days written notice to the Company.

AD Skincare Collaboration

In June 2016, the Company entered into an ECC with AD Skincare, Inc. ("AD Skincare"), an affiliate of Harvest and a related party. AD Skincare was formed for the purpose of entering into the ECC and developing an advanced topical delivery system to improve the efficacy of biologically active ingredients aimed at improving signs of aging human skin. Upon execution of the ECC, the Company received a technology access fee in the form of equity in AD Skincare valued at $4,333 as upfront consideration. The Company is also entitled to up to $2,000 of potential payments for substantive and non-substantive development milestones for each product developed under the ECC, as well as up to $17,000 in one-time commercial milestones. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. AD Skincare will pay the Company royalties as a percentage in the low double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. AD Skincare is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in June 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by AD Skincare upon 90 days written notice to the Company.

Fibrocell Science Collaborations

In October 2012, the Company entered into an ECC ("Fibrocell ECC 1") with Fibrocell Science, Inc. ("Fibrocell"), a then publicly traded cell and gene therapy company focused on diseases affecting the skin and connective tissue and a related party until the acquisition of Fibrocell by a third party as discussed below. Pursuant to Fibrocell ECC 1, at the transaction effective date, Fibrocell received a license to the Company's technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. Upon execution of Fibrocell ECC 1, the Company received a technology access fee of 87,835 shares of Fibrocell's common stock valued at $7,576 as upfront consideration. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during Fibrocell ECC 1 and manufacturing services for Company materials provided to Fibrocell during Fibrocell ECC 1. On a quarterly basis, Fibrocell will pay the Company royalties of 7% of net sales up to $25,000 and 14% of net sales above $25,000 on each product developed from Fibrocell ECC 1, as defined in the agreement. If Fibrocell uses the Company's technology platform to improve the production of a current or new Fibrocell product not developed from Fibrocell ECC 1, Fibrocell will pay the Company quarterly royalties equal to 33% of the cost of goods sold savings generated by the improvement, as defined in the agreement.

Fibrocell is responsible for conducting preclinical and clinical development of product candidates associated with Fibrocell ECC 1, as well as for other aspects of commercialization and manufacturing of the product candidates. The term of the ECC commenced in October 2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by

either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Fibrocell upon 90 days written notice to the Company.

In June 2013, the Company and Fibrocell entered into an amendment to the Fibrocell ECC 1. The amendment expanded the field of use defined in the ECC agreement. Under the terms of the amendment to the Fibrocell ECC 1, the Company received 82,919 shares of Fibrocell's common stock valued at $7,612 as a supplemental technology access fee.

In April 2019, Fibrocell entered into a collaboration agreement with a Castle Creek Pharmaceuticals, LLC to develop and commercialize a product in the field of the Fibrocell ECC 1. Pursuant to the terms of the Fibrocell ECC 1, the Company is entitled to 50% of sublicensing fees and accordingly, received $3,750 during the year ended December 31, 2019.

In December 2015, the Company entered into a second ECC with Fibrocell ("Fibrocell ECC 2"). Pursuant to the ECC, at the transaction effective date, Fibrocell received a license to the Company's technology platform to develop and commercialize genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions. Upon execution of the ECC, the Company received a technology access fee of $10,000. The Company is also entitled to (i) up to $30,000 of potential one-time payments for certain development and regulatory milestones for the first product developed under Fibrocell ECC 2, (ii) up to $30,000 of potential payments for certain regulatory milestones for each additional product developed under Fibrocell ECC 2, and (iii) up to $22,500 of potential payments for certain sales milestones for each product developed under Fibrocell ECC 2. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Fibrocell during the ECC. Fibrocell will pay the Company royalties as a percentage in the low double-digits of net sales derived from the sale of products developed from Fibrocell ECC 2, as defined in the agreement.

Fibrocell is responsible for conducting preclinical and clinical development of product candidates associated with Fibrocell ECC 2, as well as for other aspects of commercialization and manufacturing of the product candidates. The term of the ECC commenced in December 2015 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Fibrocell upon 90 days written notice to the Company.

In December 2019, Fibrocell was acquired by Castle Creek Pharmaceutical Holdings, Inc. ("Castle Creek"), a privately held company focused on developing medicine for rare genetic disorders. See Note 18 for further discussion of the impact of the Castle Creek acquisition on the Company's investments in Fibrocell.

Thrive Agrobiotics Collaboration

In September 2015, the Company entered into an ECC with Thrive Agrobiotics, Inc. ("Thrive Agrobiotics"), an affiliate of Harvest and a related party. Thrive Agrobiotics was formed for the purpose of entering into the ECC and developing and commercializing products to improve the overall growth and feed efficiency in piglets. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Thrive Agrobiotics valued at $1,667 as upfront consideration. The Company is also entitled to up to $5,500 of potential payments for development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Thrive Agrobiotics will pay the Company royalties as a percentage in the lower-double digits on the quarterly gross profits of product sales from products developed under the ECC, as defined in the agreement. Thrive Agrobiotics is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in September 2015 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Thrive Agrobiotics upon 90 days written notice to the Company.

Deferred Revenue

Deferred revenue primarily consists of consideration received for the Company's collaboration and licensing agreements. Deferred revenue from continuing operations consists of the following:



	December 31,
	2019		2018
Collaboration and licensing agreements	$	50,593	$	54,323
Prepaid product and service revenues	2,805		2,933
Other	435		560
Total	$	53,833	$	57,816
Current portion of deferred revenue	$	5,697	$	11,088
Long-term portion of deferred revenue	48,136		46,728
Total	$	53,833	$	57,816

The following table summarizes the remaining balance of deferred revenue from continuing operations associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of December 31, 2019 and 2018, including the estimated remaining performance period as of December 31, 2019.



	Average Remaining Performance Period (Years)	December 31,
	Average Remaining Performance Period (Years)	2019		2018
ZIOPHARM Oncology, Inc.	0.0	$	—	$	1,214
Oragenics, Inc.	4.4	2,864		1,785
Intrexon Energy Partners, LLC	4.2	8,362		10,267
Intrexon Energy Partners II, LLC	4.9	12,843		14,060
Fibrocell Science, Inc.	4.9	17,697		17,519
Harvest start-up entities (1)	5.2	6,993		7,644
Other	2.8	1,834		1,834
Total		$	50,593	$	54,323

(1)

As of December 31, 2019 and 2018, the balance of deferred revenue for collaborations with Harvest start-up entities includes Exotech Bio, AD Skincare, and Thrive Agrobiotics.

Short-term Investments

12 Months Ended

Dec. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Short-term Investments

The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2019:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Aggregate Fair Value
United States government debt securities	$	8,989	$	7	$	—	$	8,996
Certificates of deposit	264		—		—		264
Total	$	9,253	$	7	$	—	$	9,260

The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2018:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Fair Value
United States government debt securities	$	119,401	$	—	$	(61	)	$	119,340
Certificates of deposit	274		—		—			274
Total	$	119,675	$	—	$	(61	)	$	119,614

See Notes 2 and 8 for further discussion on the Company's method for determining the fair value of its assets.

As of December 31, 2019, all of the available-for-sale investments were due within one year based on their contractual maturities.

Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments as of December 31, 2018 were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments, and there were none as of December 31, 2019.

As of December 31, 2018, the Company did not consider any of its debt security investments to be other-than-temporarily impaired. When evaluating its debt security investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company's ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis.

Fair Value Measurements

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

The carrying amount of cash and cash equivalents, restricted cash, receivables, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.

Assets

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December 31, 2019:



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2019
Assets
United States government debt securities	$	—	$	8,996	$	—	$	8,996
Other	—		264		—		264
Total	$	—	$	9,260	$	—	$	9,260



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2018
Assets
United States government debt securities	$	—	$	119,340	$	—	$	119,340
Equity securities	950		74		—		1,024
Other	—		394		191		585
Total	$	950	$	119,808	$	191	$	120,949

The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term debt investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The methods used to estimate the fair value of the Level 2 equity securities in the tables above are based on the quoted market price of the publicly-traded security, adjusted for adjusted for a discount for lack of marketability. The Company owned preferred stock in certain of its collaborators, and these investments were classified as Level 3 within the fair value hierarchy. See Note 18 for additional discussion of these investments in preferred stock.

The following table summarizes the changes in the Level 3 investments during the years ended December 31, 2019 and 2018.



	2019			2018
Beginning balance	$	191		$	161,225
Retained interest in deconsolidated subsidiary	14,239			—
Dividend income from investments in preferred stock	48			14,841
Net unrealized appreciation (depreciation) in the fair value of the investments in equity securities and preferred stock	7,446			(17,499		)
Return of preferred stock	—			(158,376		)
Proceeds from sale of equity securities	(21,587		)	—
Proceeds to be received from preferred stock	(337		)	—
Ending balance	$	—		$	191

There were no transfers of assets between levels of the fair value hierarchy during the year ended December 31, 2019.

Liabilities

The carrying values of the Company's long-term debt, excluding the Convertible Notes, approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates.

The calculated fair value of the Convertible Notes (Note 12) was approximately $126,000 and $141,000 as of December 31, 2019 and 2018, respectively, and is based on the recent third-party trades of the instrument as of the balance sheet dates. The fair value of the Convertible Notes is classified as Level 2 within the fair value hierarchy as there is not an active market for the Convertible Notes, however, third-party trades of the instrument are considered observable inputs. The Convertible Notes are reflected on the accompanying consolidated balance sheets at amortized cost, which was $157,560 and $148,101 as of December 31, 2019 and 2018, respectively.

The Company's contingent consideration liabilities (Note 4) are measured on a recurring basis and were $585 as of December 31, 2019 and 2018. These fair value measurements were based on significant inputs not observable in the market and thus represented a Level 3 measurement. A significant change in unobservable inputs could result in a significant impact on the fair value of the Company's contingent consideration liabilities. The contingent consideration liabilities are remeasured to fair

value at each reporting date until the contingencies are resolved, and those changes in fair value are recognized in earnings. There were no changes in the fair value of the Level 3 liabilities during the years ended December 31, 2019 and 2018.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Inventory

12 Months Ended

Dec. 31, 2019

Inventory Disclosure [Abstract]

Inventory

Inventory from continuing operations consists of the following:



	December 31,
	2019		2018
Supplies, embryos and other production materials	$	2,282	$	3,857
Work in process	3,702		4,391
Livestock	7,553		10,167
Feed	2,560		2,160
Total inventory	$	16,097	$	20,575

Property, Plant and Equipment, Net

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment, Net

Property, plant and equipment consist of the following:



	December 31,
	2019			2018
Land and land improvements	$	9,814		$	10,001
Buildings and building improvements	11,765			20,099
Furniture and fixtures	1,315			1,812
Equipment	54,448			63,947
Leasehold improvements	12,821			14,219
Breeding stock	5,191			4,582
Computer hardware and software	9,434			10,789
Construction and other assets in progress	5,313			10,497
	110,101			135,946
Less: Accumulated depreciation and amortization	(49,132		)	(49,050		)
Property, plant and equipment, net	$	60,969		$	86,896

The deconsolidation of AquaBounty (Note 1) in April 2019 resulted in the reduction of $24,186 of property, plant and equipment, net on the accompanying consolidated balance sheet during the year ended December 31, 2019.

During the year ended December 31, 2019, the Company recorded $448 of property, plant and equipment impairment losses in conjunction with the closing of two of its operating units during the third quarter of 2019.

Depreciation expense was $11,869, $12,439 and $10,137 for the years ended December 31, 2019, 2018 and 2017, respectively.

Goodwill and Intangible Assets, Net

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets, Net

The changes in the carrying amount of goodwill for the years ended December 31, 2019 and 2018, are as follows:



	2019			2018
Beginning of year	$	93,627		$	93,751
Impairment	(29,820		)	—
Foreign currency translation adjustments	(53		)	(124		)
End of year	$	63,754		$	93,627

The Company had $43,643 and $13,823 of cumulative impairment losses as of December 31, 2019 and 2018, respectively.

For the year ended December 31, 2019, the Company recorded $29,820 of goodwill impairment charges. During the Company's annual goodwill impairment test, the Company determined it was more-likely-than-not that the fair value of the Trans Ova reporting unit was less than its carrying amount. As a result, the Company compared the carrying amount of the Trans Ova reporting unit to the fair value and determined the carrying amount exceeded the fair value resulting in a $29,642 goodwill impairment charge for the excess carrying value. Additionally, the Company recorded $178 of goodwill impairment charges in conjunction with the closing of two of its reporting units in the third quarter of 2019.

See Note 20 for information regarding goodwill by reportable segment.

Intangible assets consist of the following as of December 31, 2019:



	Weighted Average Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Patents, developed technologies and know-how	15.8	$	90,659	$	(26,619	)	$	64,040
Customer relationships	6.5	10,700		(8,440		)	2,260
Trademarks	8.4	5,900		(3,854		)	2,046
Total		$	107,259	$	(38,913	)	$	68,346

Intangible assets consist of the following as of December 31, 2018:



	Gross Carrying Amount		Accumulated Amortization			Net
Patents, developed technologies and know-how	$	106,042	$	(23,674	)	$	82,368
Customer relationships	10,700		(7,565		)	3,135
Trademarks	6,800		(3,341		)	3,459
Total	$	123,542	$	(34,580	)	$	88,962

In the fourth quarter of 2018, the Company recorded a $16,027 loss related to the abandonment of certain developed technologies that the Company ceased using in the fourth quarter of 2018. The Company does not expect to use these technologies as a defensive asset or market them for sale in the future. Because these technologies were used in combination with other technologies, the identifiable cash flows did not result in an impairment; however, because the Company made a decision to abandon the assets, it recorded the charge to research and development expense.

The deconsolidation of AquaBounty (Note 1) in April 2019 resulted in the reduction of $11,567 of net intangible assets, primarily related to patents, developed technologies, and know-how, on the accompanying consolidated balance sheet during the year ended December 31, 2019.

Amortization expense was $7,920, $11,666 and $11,472 for the years ended December 31, 2019, 2018 and 2017, respectively. Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows:



2020	$	7,501
2021	7,313
2022	6,518
2023	5,350
2024	5,066
Thereafter	36,598
Total	$	68,346

Lines of Credit and Long-Term Debt

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Lines of Credit and Long-Term Debt

Lines of Credit

Trans Ova has a $5,000 revolving line of credit with First National Bank of Omaha that matures on April 1, 2020. The line of credit bears interest at the greater of 2.95% above the London Interbank Offered Rate or 3.00%, and the actual rate was 4.76% as of December 31, 2019. As of December 31, 2019, there was an outstanding balance of $1,695. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount, and was $3,235 as of December 31, 2019. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures. Trans Ova was in compliance with these covenants as of December 31, 2019.

Exemplar has a $700 revolving line of credit with American State Bank that matures on October 31, 2020. The line of credit bears interest at 5.50% per annum. As of December 31, 2019, there was an outstanding balance of $227.

Long-Term Debt

Long-term debt consists of the following:



	December 31,
	2019		2018
Convertible debt	$	213,771	$	203,391
Notes payable	4,089		4,551
Other	131		3,753
Long-term debt	217,991		211,695
Less current portion	31,670		479
Long-term debt, less current portion	$	186,321	$	211,216

The deconsolidation of AquaBounty (Note 1) in April 2019 resulted in the reduction of $4,030 of long-term debt on the accompanying consolidated balance sheet during the year ended December 31, 2019.

Convertible Debt

Precigen Convertible Notes

In July 2018, Precigen completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes and issued the Convertible Notes under an indenture (the "Base Indenture") between Precigen and The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented by the First Supplemental Indenture (together with the Base Indenture, the "Indenture"). Precigen received net proceeds of $193,958 after deducting underwriting discounts and offering expenses of $6,042.

The Convertible Notes are senior unsecured obligations of Precigen and bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year beginning on January 1, 2019. The Convertible Notes mature on July 1, 2023, unless earlier repurchased or converted. The Convertible Notes are convertible into cash, shares of Precigen's common stock or a combination of cash and shares, at Precigen's election. The initial conversion rate of the Convertible Notes is 58.6622 shares of Precigen common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $17.05 per share of common stock). The conversion rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date as defined in the Indenture, Precigen will increase the conversion rate for a holder who elects to convert its Convertible Notes in connection with such a corporate event in certain circumstances. Prior to April 1, 2023, the holders may convert the Convertible Notes at their option only upon the satisfaction of the following circumstances:


•	During any calendar quarter commencing after the calendar quarter ended on September 30, 2018, if the last reported sales price of Precigen's common stock for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;


•	During the five business day period after any five consecutive trading day period in which the trading price, as defined in the Indenture, for the Convertible Notes is less than 98% of the product of the last reported sales price of Precigen's common stock and the conversion rate for the Convertible Notes on each such trading day; or


•	Upon the occurrence of specified corporate events as defined in the Indenture.

None of the above events allowing for conversion prior to April 1, 2023 occurred during the year ended December 31, 2019. On or after April 1, 2023 until June 30, 2023, holders may convert their Convertible Notes at any time. Precigen may not redeem the Convertible Notes prior to the maturity date.

If Precigen undergoes a fundamental change, as defined in the Indenture, holders of the Convertible Notes may require Precigen to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture contains customary events of default, as defined in the agreement, and, if any of the events occur, could require repayment of a portion or all of the Convertible Notes, including accrued and unpaid interest. Additionally, the Indenture provides that Precigen shall not consolidate with or merge with or into, or sell, convey, transfer or lease all or substantially all of its properties and assets to, another entity, unless (i) the surviving entity is organized under the laws of the United States and such entity expressly assumes all of Precigen's obligations under the Convertible Notes and the Indenture; and (ii) immediately after such transaction, no default or event of default has occurred and is continuing under the Indenture.

The net proceeds received from the issuance of the Convertible Notes were initially allocated between long-term debt, the liability component, in the amount of $143,723, and additional paid-in capital, the equity component, in the amount of $50,235. Additional paid-in capital was further reduced by $13,367 of deferred taxes resulting from the difference between the carrying amount and the tax basis of the Convertible Notes that is created by the equity component, which also resulted in deferred tax benefit recognized from the reversal of valuation allowances on the then current year domestic operating losses in the same amount (Note 13). As of December 31, 2019, the outstanding principal balance on the Convertible Notes was $200,000 and the carrying value of long-term debt was $157,560. The effective interest rate on the Convertible Notes, including amortization of the long-term debt discount and debt issuance costs, is 11.02%. As of December 31, 2019, the unamortized long-term debt discount and debt issuance costs totaled $42,440.

The components of interest expense related to the Convertible Notes were as follows:



	Year Ended December 31,
	2019		2018
Cash interest expense	$	7,000	$	3,462
Non-cash interest expense	9,459		4,378
Total interest expense	$	16,459	$	7,840

Accrued interest of $3,500 is included in other accrued liabilities on the accompanying consolidated balance sheet as of December 31, 2019.

ActoBio Convertible Notes

In September 2018, ActoBio issued $30,000 of convertible promissory notes (the "ActoBio Notes") to a related party in conjunction with an asset acquisition with Harvest (Note 4). The ActoBio Notes have a maturity date of September 6, 2020, accrue interest at 3.0% compounded annually ("accrued PIK interest"), are convertible into shares of ActoBio common stock at any time by the holder, and are automatically convertible in shares of ActoBio common stock upon the closing of certain financing events as defined in the ActoBio Notes. If the ActoBio Notes have not been converted to ActoBio common stock by the maturity date, ActoBio can pay the principal and accrued PIK interest in cash or with shares of Precigen common stock at its election. There are no embedded features that are required to be separated from the debt host and accounted for separately, so the ActoBio Notes were recorded at $30,000. Interest expense was $921 and $290 for the years ended December 31, 2019 and 2018, respectively. As of December 31, 2019, the carrying value of the ActoBio Notes, including accrued interest, was $31,211.

Precigen and PGEN Therapeutics Convertible Note

In December 2018, in conjunction with the Merck Purchase Agreement (Note 6), Precigen and PGEN Therapeutics jointly and severally issued a $25,000 convertible note (the "Merck Note") to Ares Trading in exchange for cash. The Merck Note has a maturity date of June 28, 2021 and will be converted to Precigen common stock on the first trading day following maturity if not otherwise converted prior to that date. Prior to maturity, Ares Trading may convert the Merck Note, at their election, into (i) Precigen common stock at any time, (ii) Precigen common stock upon the Company's closing of qualified financing as defined in the agreement, (iii) PGEN Therapeutics equity upon PGEN Therapeutics closing a qualified financing as defined in the agreement, and (iv) PGEN Therapeutics common stock upon the closing of a qualified initial public offering ("IPO") of PGEN Therapeutics common stock. In the event of a conversion upon a qualified IPO, the conversion price will be 90% of the IPO price. There is no stated interest rate on the Merck Note. However, in the event Ares Trading elects to convert the Merck Note into PGEN Therapeutics equity, the Merck Note accrues interest at a rate of 5% per year ("PIK interest") and will be converted with the outstanding principal. The Company determined that the potential PIK interest and IPO conversion discount represented embedded derivatives requiring bifurcation from the debt host but had no significant value as of December 31, 2019.

Notes Payable

Trans Ova has a note payable to American State Bank that matures in April 2033 and had an outstanding principal balance of $4,077 as of December 31, 2019. Trans Ova pays monthly installments of $39, which includes interest at 3.95%. The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets.

Future Maturities

Future maturities of long-term debt are as follows:



2020	$	31,670
2021	25,328
2022	341
2023	200,355
2024	369
Thereafter	2,368
Total	$	260,431

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

The components of loss from continuing operations before income taxes are presented below:



	Year Ended December 31,
	2019			2018			2017
Domestic	$	(205,413	)	$	(428,410	)	$	(24,965	)
Foreign	(3,274		)	(1,332		)	(53,402		)
Loss from continuing operations before income taxes	$	(208,687	)	$	(429,742	)	$	(78,367	)

The components of income tax expense (benefit) from continuing operations are presented below:



	Year Ended December 31,
	2019			2018			2017
United States federal income taxes:
Current	$	—		$	(31	)	$	27
Deferred	(561		)	(11,855		)	(523		)
Foreign income taxes:
Current	34			68			(4		)
Deferred	(230		)	635			2,308
State income taxes:
Current	—			113			—
Deferred	(173		)	(4,355		)	264
Income tax expense (benefit) from continuing operations	$	(930	)	$	(15,425	)	$	2,072

Income tax expense (benefit) from continuing operations for the years ended December 31, 2019, 2018 and 2017 differed from amounts computed by applying the applicable United States federal corporate income tax rate of 21% for 2019 and 2018, and 34% for 2017, to loss before income taxes as a result of the following:



	2019			2018			2017
Computed statutory income tax benefit from continuing operations	$	(43,824	)	$	(90,246	)	$	(26,645	)
State and provincial income tax benefit, net of federal income taxes	(7,298		)	(23,347		)	(1,888		)
Nondeductible stock based compensation	10,303			4,696			3,391
Nondeductible officer compensation	595			294			476
Gain on dividend distribution of AquaBounty common stock	—			—			3,965
Impairment of goodwill	273			—			4,700
Research and development tax incentives	(1,772		)	(185		)	(359		)
Acquisition and internal restructuring transaction costs	260			52			354
Provisional impact of the Tax Act	—			—			85,288
Enacted changes in foreign tax rates and foreign tax reforms	—			—			2,021
Reacquired in-process research and development	—			2,696			—
Change in deferred state tax rate	—			8,666			—
United States-foreign rate differential	(76		)	215			410
Other, net	(72		)	(3,517		)	(189		)
	(41,611		)	(100,676		)	71,524
Change in valuation allowance for deferred tax assets	40,681			85,251			(69,452		)
Total income tax expense (benefit) from continuing operations	$	(930	)	$	(15,425	)	$	2,072

The tax effects of temporary differences that comprise the deferred tax assets and liabilities included in continuing operations as of December 31, 2019 and 2018, are as follows:



	2019			2018
Deferred tax assets
Allowance for doubtful accounts	$	2,140		$	1,490
Inventory	415			614
Equity securities and investments in affiliates	11,933			30,241
Property, plant and equipment	1,830			—
Intangible assets	85,308			78,858
Accrued liabilities	3,385			4,412
Lease liabilities	10,035			—
Stock-based compensation	19,389			28,885
Deferred revenue	14,876			16,297
Research and development tax credits	9,686			10,558
Investments in subsidiaries included in discontinued operations	8,592			—
Net operating and capital loss carryforwards	196,663			129,291
Total deferred tax assets	364,252			300,646
Less: Valuation allowance	349,008			292,217
Net deferred tax assets	15,244			8,429
Deferred tax liabilities
Property, plant and equipment	—			149
Right-of-use assets	8,091			—
Intangible assets	—			—
Long-term debt	9,987			12,136
Total deferred tax liabilities	18,078			12,285
Net deferred tax liabilities included in continuing operations	$	(2,834	)	$	(3,856	)

Activity within the valuation allowance for deferred tax assets included in continuing operations during the years ended December 31, 2019, 2018 and 2017 was as follows:



	2019			2018			2017
Valuation allowance at beginning of year	$	292,217		$	211,078		$	253,549
Increase (decrease) in valuation allowance as a result of
Mergers and acquisitions, net	—			418			—
Deconsolidation of AquaBounty	(3,504		)	—			—
Establishment of deferred taxes for subsidiaries included in discontinued operations	8,592			—			—
Current year continuing operations	40,681			107,284			17,735
Discontinued operations treated as asset sales	10,585			3,832			6,940
Adoption of ASC 842	512			—			—
Adoption of ASC 606	—			(7,477		)	—
Adoption of ASU 2016-09	—			—			17,843
Provisional impact of the Tax Act	—			—			(87,473		)
Equity component of long-term debt	—			(13,367		)	—
Change in deferred state tax rate	—			(8,666		)	—
Changes in foreign tax rates and foreign tax reforms	—			—			1,494
Foreign currency translation adjustment	(75		)	(885		)	990
Valuation allowance at end of year	$	349,008		$	292,217		$	211,078

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due to the Company and its subsidiaries' histories of net losses incurred from inception, any corresponding net domestic and certain foreign deferred tax assets have been fully reserved as the Company and its subsidiaries cannot sufficiently be assured that these deferred tax assets will be realized. The components of the deferred tax assets and liabilities as of the date of the mergers and acquisitions by the Company prior to consideration of the valuation allowance are substantially similar to the components of deferred tax assets presented herein.

The Company's past issuances of stock and mergers and acquisitions have resulted in ownership changes as defined in Section 382 of the Internal Revenue Code of 1986, as amended ("Section 382"). As a result, utilization of portions of the net operating losses may be subject to annual limitations, however as of December 31, 2019, all such limited losses applicable to Precigen, other than losses inherited via acquisition, have been fully utilized. As of December 31, 2019, approximately $42,100 of the Company's domestic net operating losses were inherited via acquisition, including $13,376 acquired via the acquisition of GenVec, and are limited based on the value of the target at the time of the transaction.

As of December 31, 2019, the Company has net operating loss carryforwards for United States federal income tax purposes of approximately $568,800 available to offset future taxable income, including approximately $316,100 generated after 2017, United States capital loss carryforwards of approximately $111,600, and federal and state research and development tax credits of approximately $9,600, prior to consideration of annual limitations that may be imposed under Section 382. Net operating loss carryforwards generated prior to 2018 will begin to expire in 2022, and capital loss carryforwards will expire if unutilized by 2024. The Company's foreign subsidiaries included in continuing operations have foreign loss carryforwards of approximately $72,800, most of which do not expire.

As of December 31, 2019, the Company's direct foreign subsidiaries included in continuing operations had accumulated deficits of approximately $14,900. Future distributions of accumulated earnings of the Company's direct foreign subsidiaries may be subject to United States income and foreign withholding taxes.

In the year ended December 31, 2017, the Company recorded a net provisional income tax benefit of $2,185 upon enactment of the Tax Act, which is comprised of several items. Amounts related to the remeasurement of most of the Company's domestic deferred tax assets as a result of the United States corporate rate change to 21% as part of the Tax Act are $87,473, which was fully offset by a reduction in the Company's valuation allowance. The Company's net United States deferred tax liability that is not offset by a valuation allowance was similarly written down, and the Company recorded a provisional deferred tax benefit of $1,730. The Company also recorded a provisional current tax benefit of $455 related to the expected refundability of accumulated corporate alternative minimum tax credits. The Company provisionally estimated its transition tax exposure to be zero, as any accumulated earnings in foreign subsidiaries are offset by accumulated deficits in other foreign subsidiaries. The Company completed its accounting for the Tax Act in the fourth quarter of 2018, and there were no significant adjustments to the previously recorded provisional amounts.

Additionally, in December 2017, Belgium enacted significant tax reform measures, the most significant of which to the Company is the limitation on the utilization of accumulated losses in years after 2017. After that date, loss carryforwards can only be used to offset 70% of taxable income that exceeds a certain threshold. As a result, the Company recorded adjustments to its net deferred tax assets and valuation allowances. These adjustments resulted in a net deferred tax liability of $2,307, which was recorded as a component of deferred tax expense for the year ended December 31, 2017.

The Company and its subsidiaries do not have material unrecognized tax benefits as of December 31, 2019. The Company does not anticipate significant changes in the amount of unrecognized tax benefits in the next 12 months. The Company's tax returns for years 2004 and forward are subject to examination by federal or state tax authorities due to the carryforward of unutilized net operating and capital losses and research and development tax credits.

Shareholders' Equity

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Shareholders' Equity

Issuances of Precigen Common Stock

In January 2018, Precigen closed a public offering of 6,900,000 shares of its common stock, including 1,000,000 shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were $82,374, after deducting underwriting discounts of $3,688 and offering expenses of $188, all of which were capitalized.

In December 2017, the Company entered into a securities purchase agreement with an affiliate of Third Security for the private placement of 1,207,980 shares of the Company's common stock for gross proceeds of $13,686.

Share Lending Agreement

Concurrently with the offering of the Convertible Notes (Note 12), Precigen entered into a share lending agreement (the "Share Lending Agreement") with J.P. Morgan Securities LLC (the "Share Borrower") pursuant to which Precigen loaned and delivered 7,479,431 shares of its common stock (the "Borrowed Shares") to the Share Borrower. The Share Lending Agreement will terminate, and the Borrowed Shares will be returned to Precigen within five business days of such termination, upon (i) termination by the Share Borrower or (ii) the earliest to occur of (a) October 1, 2023 and (b) the date, if any, on which the Share Lending Agreement is either mutually terminated or terminated by one party upon a default by the other party. The Share Borrower maintains collateral in the form of cash or certain permitted non-cash collateral with a market value at least equal to the market value of the Borrowed Shares as security for the obligation of the Share Borrower to return the Borrowed Shares when required by the terms above. The Borrowed Shares were offered and sold to the public at a price of $13.37 per share under a registered offering (the "Borrowed Shares Offering"). Precigen did not receive any proceeds from the sale of the Borrowed Shares to the public or any lending fees from the Share Lending Agreement. The Share Borrower or its affiliates received all the proceeds from the sale of the Borrowed Shares to the public. Affiliates of Third Security purchased all of the shares of common stock in the Borrowed Shares Offering.

The Share Lending Agreement was entered into at fair value and met the requirements for equity classification. Therefore, the value is netted against the issuance of the Borrowed Shares in additional paid-in capital. Additionally, the Borrowed Shares are not included in the denominator for loss per share attributable to Precigen shareholders unless the Share Borrower defaults on the Share Lending Agreement.

Issuances of AquaBounty Common Stock

In March 2019, AquaBounty completed an underwritten public offering that resulted in net proceeds of $6,611 after deducting discounts, fees, and expenses. See Note 1 for additional discussion of issuances of AquaBounty common stock in April 2019, which resulted in the deconsolidation of AquaBounty.

In January 2018, AquaBounty completed an underwritten public offering that resulted in net proceeds of $10,616 after deducting discounts, fees and expenses. As part of this offering, Precigen purchased $5,000 of additional AquaBounty common stock. In October 2018, certain investors exercised warrants acquired from the January 2018 offering, resulting in additional net proceeds of $4,316, including $3,077 from Precigen.

In January 2017, in conjunction with the listing by AquaBounty of their common stock on the Nasdaq Stock Market, Precigen purchased $25,000 of additional AquaBounty common stock and subsequently distributed shares of AquaBounty common stock as a dividend to Precigen shareholders.

Dividends to Shareholders

In January 2017, the Company distributed to its shareholders 1,776,557 shares of AquaBounty common stock valued at $22,385. The distribution constituted a dividend to shareholders of record as of January 9, 2017. In connection with the distribution and pursuant to the terms of the Company's equity incentive plans, the conversion terms of all outstanding options for shares of the Company's common stock as of January 9, 2017 were adjusted to reflect the value of the distribution with respect to shares of the Company's common stock by decreasing the exercise prices and increasing the number outstanding options. This adjustment resulted in 46,766 additional outstanding options at a weighted average exercise price of $31.11.

Components of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows:



	December 31,
	2019			2018
Unrealized gain (loss) on investments	$	7		$	(61	)
Loss on foreign currency translation adjustments	(27,475		)	(28,551		)
Total accumulated other comprehensive loss	$	(27,468	)	$	(28,612	)

Share-Based Payments

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Share-Based Payments

The Company measures the fair value of stock options and RSUs issued to employees and nonemployees as of the grant date for recognition of stock-based compensation expense. Stock-based compensation expense for employees and nonemployees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below:



	Year Ended December 31,
	2019		2018		2017
Cost of products	$	20	$	78	$	116
Cost of services	220		237		322
Research and development	4,784		6,850		7,654
Selling, general and administrative	11,419		25,259		28,801
Discontinued operations	2,507		3,872		4,683
Total	$	18,950	$	36,296	$	41,576

Precigen Stock Option Plans

In April 2008, Precigen adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Precigen's board of directors granted share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of December 31, 2019, there were 378,409 stock options outstanding under the 2008 Plan.

Precigen adopted the 2013 Plan for employees and nonemployees pursuant to which Precigen's board of directors may grant share-based awards, including stock options, and shares of common stock, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective in August 2013, and as of December 31, 2019, there were 25,000,000 shares authorized for issuance under the 2013 Plan, of which 8,643,873 stock options and 1,781,982 RSUs were outstanding and 8,991,369 shares were available for grant.

In April 2019, Precigen adopted the 2019 Incentive Plan for Non-Employee Service Providers (the "2019 Plan"), which became effective upon shareholder approval in June 2019. The 2019 Plan permits the grant of share-based awards, including stock options, restricted stock awards, and RSUs, to non-employee service providers, including board members. As of December 31, 2019, there were 5,000,000 shares authorized for issuance under the 2019 Plan, of which no awards were outstanding and 4,087,444 were available for grant.

Stock options may be granted with an exercise price equal to or greater than the stock's fair market value at the date of grant. Stock options may be granted with an exercise price less than the stock's fair market value at the date of grant if the stock options are replacement options in accordance with certain United States Treasury regulations. Virtually all stock options have ten-year terms and vest four years from the date of grant.

Stock option activity was as follows:



	Number of Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2016	11,640,383		$	31.25		8.21
Granted	3,920,950		21.47
Adjustment due to dividend (Note 14)	46,766		31.11
Exercised	(149,429	)	(6.37		)
Forfeited	(3,797,105	)	(28.37		)
Expired	(278,818	)	(33.18		)
Balances at December 31, 2017	11,382,747		28.99			7.32
Granted	1,470,339		14.26
Exercised	(45,159	)	(6.59		)
Forfeited	(929,596	)	(21.48		)
Expired	(785,268	)	(26.25		)
Balances at December 31, 2018	11,093,063		27.95			6.81
Granted	1,556,575		6.52
Exercised	(19,887	)	(3.17		)
Forfeited	(1,236,326	)	(24.92		)
Expired	(2,371,143	)	(38.53		)
Balances at December 31, 2019	9,022,282		21.94			6.10
Exercisable at December 31, 2019	6,264,194		24.89			5.20

Total unrecognized compensation costs related to unvested awards as of December 31, 2019 were $16,057, and are expected to be recognized over a weighted-average period of approximately two years.

The weighted average grant date fair value of options granted during 2019, 2018 and 2017 was $3.79, $7.94 and $12.19, respectively. The aggregate intrinsic value of options exercised during 2019, 2018 and 2017 was $66, $356 and $2,429, respectively. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair value of Precigen's common stock for those shares where the exercise price was lower than the fair value of Precigen's common stock on the date of exercise.

The following table summarizes additional information about stock options outstanding as of December 31, 2019:



					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value		Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value
$	3.17	—	$	8.60	1,612,219	$	6.40	8.08	$	473	585,144	$	5.61	5.95	$	194
$	8.77	—	$	20.68	1,278,121	15.55		6.53	—		753,064	15.89		5.20	—
$	20.94				1,646,500	20.94		6.51	—		892,000	20.94		6.02	—
$	21.00	—	$	29.47	1,976,645	23.71		6.06	—		1,585,940	23.71		5.79	—
$	29.56	—	$	65.08	2,508,797	34.46		4.38	—		2,448,046	34.47		4.33	—
					9,022,282	$	21.94	6.10	$	473	6,264,194	$	24.89	5.20	$	194

The following table summarizes additional information about stock options outstanding as of December 31, 2018:



					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value		Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value
$	3.17	—	$	19.52	1,973,818	$	13.70	7.54	$	169	833,007	$	12.80	4.85	$	169
$	19.85	—	$	20.94	1,914,763	20.93		7.99	—		500,263	20.92		7.67	—
$	21.00	—	$	27.08	2,057,126	23.29		7.26	—		1,248,370	23.01		6.69	—
$	27.10	—	$	29.56	2,666,109	29.19		5.28	—		2,593,151	29.20		5.23	—
$	29.58	—	$	65.08	2,481,247	47.24		6.59	—		1,827,728	47.65		6.54	—
					11,093,063	$	27.95	6.81	$	169	7,002,519	$	30.37	5.97	$	169

RSU activity was a follows:



	Number of Restricted Stock Units		Weighted Average Grant Date Fair Value			Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2017	—		$	—		0.00
Granted	1,069,126		13.84
Vested	(25,000	)	(15.82		)
Forfeited	(73,785	)	(13.47		)
Balances at December 31, 2018	970,341		13.82			1.43
Granted	2,278,460		6.59
Vested	(1,159,165	)	(8.74		)
Forfeited	(307,654	)	(8.99		)
Balances at December 31, 2019	1,781,982		8.71			1.24

Total unrecognized compensation costs related to unvested RSU awards as of December 31, 2019 were $10,795 and are expected to be recognized over a weighted-average period of approximately two years.

Precigen currently uses authorized and unissued shares to satisfy share award exercises.

The Company's Executive Chairman ("Executive Chairman"), who previously served as the Company's Chief Executive Officer ("CEO") until January 1, 2020, receives a base salary of $200 per month payable in fully-vested shares of Precigen common stock with such shares subject to a three-year lock-up on resale. The monthly number of shares of common stock was calculated based on the closing price on the last trading day of each month and the shares were issued pursuant to the terms of a Restricted Stock Unit Agreement ("RSU Agreement") between Precigen and the Executive Chairman pursuant to the terms of the 2013 Plan. The RSU Agreement, which is subject to renewal annually by the compensation committee of the board of directors of the Company, expired March 31, 2019. In April 2019, the Company entered into a new RSU agreement through March 31, 2020, pursuant to which the base salary and lock-up terms remained unchanged and the number of fully-vested shares of Precigen common stock paid monthly was subsequently calculated based on the volume weighted average of the price of Precigen common stock over the 30 day period ending on the last calendar day of each month. The fair value of the shares issued as compensation for services is included in selling, general, and administrative expenses in the Company's consolidated statements of operations and totaled $1,868, $1,956, and $1,908 for the years ended December 31, 2019, 2018 and 2017, respectively.

Operating Leases

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Operating Leases

The Company leases certain facilities and equipment under operating leases. Leases with a lease term of twelve months or less are considered short term leases and are not recorded on the balance sheet, and expense for these leases is recognized over the

term of the lease. The Company's leases have remaining terms of one to ten years, some of which may include options to extend the lease and some of which may include options to terminate the lease within one year. In these leases, the Company uses judgment to determine whether it is reasonably possible to extend the lease beyond the initial term or terminate before the initial term ends and the length of the possible extension or early termination. The leases are renewable at the option of the Company and do not contain residual value guarantees, covenants, or other restrictions. The Company's finance leases are not material.

The components of lease costs from continuing operations were as follows:



	Year Ended December 31,
	2019
Operating lease costs	$	7,260
Short-term lease costs	2,042
Variable lease costs	2,076
Lease costs	$	11,378

As of December 31, 2019, maturities of lease liabilities, excluding short-term leases, for continuing operations were as follows:



2020	$	7,071
2021	7,449
2022	6,996
2023	5,831
2024	5,734
Thereafter	4,280
Total	37,361
Present value adjustment	(9,330		)
Total	$	28,031
Current portion of operating lease liabilities	$	4,182
Long-term portion of operating lease liabilities	23,849
Total	$	28,031

Other information related to operating leases in continuing operations was as follows:



	December 31,
	2019
Weighted average remaining lease term (years)	5.24
Weighted average discount rate	10.96	%



	Year Ended December 31,
	2019
Supplemental Cash Flows Information
Cash paid for operating lease liabilities	$	7,294
Operating lease right-of-use assets added in exchange for new lease liabilities	1,137

At December 31, 2018, future minimum lease payments under operating leases for continuing operations having initial or remaining noncancelable lease terms in excess of one year were as follows:



2019	$	6,889
2020	7,384
2021	7,246
2022	6,815
2023	5,747
Thereafter	11,734
Total	$	45,815

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingencies In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, LLC ("XY") alleging that certain of Trans Ova's sale of semen-sorting products and services breached a 2004 licensing agreement and infringed on patents related to semen sorting that XY allegedly owned. Trans Ova filed a number of counterclaims in the case. The matter proceeded to a jury trial in the United States District Court for the District of Colorado in January 2016. The jury determined that XY and Trans Ova had each breached the licensing agreement and that Trans Ova had infringed XY's patents. In April 2016, the court issued its post-trial order, awarding $528 in damages to Trans Ova and $6,066 in damages to XY. The order also provided Trans Ova with the ability to continue to practice XY's technology, subject to an ongoing royalty obligation of 12.5% of gross proceeds on Trans Ova's standard sorted semen products, plus a 2% enhancement on those products utilizing "reverse-sorted semen", or semen that is frozen before being sorted. In addition, the court assigned a $5.00 minimum royalty for a straw of sexed semen. Both parties appealed the district court's order. In May 2018, the Court of Appeals for the Federal Circuit denied Trans Ova's appeal of its claims for antitrust, breach of contract and patent invalidity (except as to one patent, for which the Federal Circuit affirmed invalidity in a separate, same-day ruling in a third-party case). The Federal Circuit remanded the district court's calculation of the ongoing royalty and instructed the district court to re-calculate the ongoing royalty in light of post-verdict economic factors. In March 2019, the district court clarified the royalty base and reset the royalty rates consistent with the Federal Circuit's opinion. The district court increased the royalty rate on Trans Ova's standard sorted semen products to 18.75%. For the reverse-sort enhancement, however, it applied a weighted, blended royalty of 12.63% to Trans Ova's entire in vitro fertilization service cycle that utilizes reverse-sorted semen. The district court also changed the minimum royalty for a straw of sexed semen to $6.25 for a 2-million cell straw (prorated appropriately for straws of higher cell counts), and assigned a minimum royalty for a sexed embryo at $6.25 per embryo. The new royalty rates were made retroactive to February 2016 (the end date of the trial). Since the inception of the 2004 licensing agreement, Trans Ova has remitted payments to XY pursuant to the terms of that agreement, or pursuant to the terms of the district court's April 2016 post-trial order and its March 2019 post-remand order, and has recorded these payments in cost of services in the consolidated statements of operations for the respective periods. For the period from inception of the 2004 licensing agreement through the district court's April 2016 order, aggregate royalty and license payments were $3,170, of which $2,759 had not yet been deposited by XY. In 2016, the Company recorded the expense of $4,228, representing the excess of the net damages awarded to XY, including prejudgment interest, over the liability previously recorded by Trans Ova for uncashed checks previously remitted to XY. In August 2016, Trans Ova deposited the net damages amount, including prejudgment interest, into the district court's registry, to be held until the appeals process was complete and final judgment amounts were determined. These amounts were included in restricted cash and other accrued liabilities on the accompanying consolidated balance sheet as of December 31, 2018. After the appeal, the district court subsequently released the funds held in its registry to XY in January 2019. As for post-trial damages, Trans Ova continued to remit payment to XY every quarter based on the original ongoing royalty rates set by the district court, though XY refused to cash those checks. Under the district court's March 2019 post-remand order clarifying the royalty base and resetting the royalty rates, Trans Ova recalculated royalties owed from February 2016 through the first quarter of 2019, plus any applicable pre- and post-judgment interest, and remitted that payment, totaling $5,801, to XY in May 2019. In June 2019, XY deposited the $5,801 into the district court's registry while the parties resolve two separate disputes over the appropriate calculation of royalties. In the first dispute, XY filed a motion claiming over $1,000 in additional back royalties. Trans Ova contested XY's motion. On February 6, 2020, the district court denied XY's motion without prejudice, holding that XY failed to satisfy its obligation under the court's local rules to meaningfully confer with Trans Ova before filing its motion. The district court held that, if XY chooses to re-file its motion, it must include a substantial certificate of conferral demonstrating that it seriously and in good faith tried to resolve its disputes with Trans Ova. In the second dispute, Trans Ova moved for partial relief from judgment after XY's last patent covering standard sorting expired in December 2019. Trans Ova is seeking an appropriate reduction in its royalty obligation in light of the fact that XY's only non-expired patents are limited to reverse sorting. Trans Ova's motion is pending before the court. During the year ended December 31, 2019, the Company recorded additional royalty expense of $383 based on the recalculation of royalties owed XY from February 2016 through December 2018. This amount is included in selling, general and administrative expenses on the accompanying consolidated statement of operations. In December 2016, XY filed a complaint for patent infringement, trade secret misappropriation, and various state law claims against Trans Ova in the United States District Court for the Western District of Texas in Waco, Texas. Since the claims in the 2016 complaint directly relate to the parties' other litigation, Trans Ova filed and was granted a motion to transfer the case to Colorado district court. That court subsequently dismissed nine of the complaint's twelve counts, including all five non-patent counts and four patent counts. The court subsequently dismissed a fifth patent count after ruling that the patent was invalid, leaving only two patent counts left in the case. In February 2019, a Wisconsin district court invalidated one of the two remaining patents, which XY had asserted against another competitor. That ruling prompted the Colorado district court to stay the two remaining patent counts and enter final judgment against XY's ten other dismissed counts. The 2016 litigation is administratively closed, pending XY's appeal to the Federal Circuit, wherein XY is appealing the district court's dismissal of four of its patent causes of action. XY is not appealing one of the five dismissed patent counts or any of the dismissed non-patent causes of action. The Federal Circuit hearing is scheduled for March 5, 2020. Separately, after initially appealing the Wisconsin court's invalidation of the sixth patent, XY subsequently withdrew its appeal. Trans Ova shall continue to utilize the technology consistent with the determinations of the court proceedings. Nonetheless, these disputes remain subject to a number of uncertainties, including the outcome of appellate proceedings, the possibility of further claims by XY, and the impact of these matters on Trans Ova's ability to utilize the technology. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation. In October 2018, the Company received a subpoena from the Division of Enforcement of the SEC informing the Company of a non-public, fact-finding investigation concerning the Company's disclosures regarding its methane bioconversion platform. The Company has produced documents to, and met with, the staff of the SEC and is voluntarily cooperating with their investigation. In November 2019, the staff of the SEC informed the Company that its investigative work was largely completed. The Company and the staff of the SEC are currently in discussions, and there can be no assurance regarding the ultimate outcome of the investigation. The Company has previously entered into strategic collaborations, including ECCs and JVs, to fund and develop products enabled by its technologies. These relationships involve complex interests, and the Company's interests may diverge with those of its collaborators, which can occur as a result of operations under those collaborations, business or technological developments, or as the Company transitions away from, or terminates, strategic collaborations. The Company has had, and has, disagreements and disputes with certain collaborators and JV partners, including Harvest, the IEP Investors, and the IEPII Investors. While the Company believes it has the right to payment with respect to work performed for all of its collaborations and JVs, consistent with its policy for accounting for accounts receivable, the Company has fully reserved the amount of any disputed accounts receivable that remained outstanding as of December 31, 2019. These disagreements and disputes may result in litigation, unfavorable settlements or concessions by the Company, adverse regulatory action, or management distraction, any of which could harm the Company's business or results of operations. The Company may become subject to other claims, assessments and governmental investigations from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December 31, 2019, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Third Security and Affiliates The Company's Executive Chairman and Chairman of the board of directors is also the Senior Managing Director and CEO of Third Security and owns 100% of the equity interests of Third Security. In November 2015, the independent members of Precigen's board of directors, with the recommendation of the audit committee of the board of directors, approved the execution of a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provided the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its Executive Chairman. The Services Agreement provided for a term of one year, could be terminated by the Company at any time, and could be extended only by agreement of the parties, including approval of a majority of the independent members of Precigen's board of directors. The independent members of Precigen's board of directors, with the recommendation of the audit committee of the board of directors, subsequently approved extensions of the Services Agreement through January 1, 2020 at which point it was not further extended. Under the Services Agreement, as consideration for providing these services, Third Security was entitled to a fee paid in the form of fully-vested shares of Precigen common stock that approximates $800 per month. Through 2018, the number of shares of common stock was calculated based on the closing price of the Company's common stock on the 15th day of each month and issued to Third Security at the end of the month. In 2019, the number of shares of common stock was calculated based on the volume weighted average of the closing price of the Company's common stock over the 30-day period ending on the 15th day of the calendar month when the applicable services were provided. Through May 2019, the payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and are subject to the terms of the 2013 Plan. Following the effectiveness of the 2019 Plan in June 2019, subsequent payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2019 Plan and are subject to the terms of the 2019 Plan (Note 15). For the years ended December 31, 2019, 2018 and 2017, the Company issued 1,606,062 shares, 696,033 shares, and 500,650 shares, respectively, with values of $8,233, $8,324, and $8,704, respectively, to Third Security as payment for services pursuant to the Services Agreement. The Services Agreement was not extended and was allowed to expire on January 1, 2020. In addition to the foregoing Services Agreement, the Company reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf, and the total expenses incurred by the Company under this arrangement was $26, $47, and $409 for the years ended December 31, 2019, 2018 and 2017, respectively. See also Note 15 regarding compensation arrangements between the Company and its Executive Chairman. In October 2017, the Company entered into a Preferred Stock Equity Facility ("Preferred Stock Equity Facility") with an affiliate of Third Security ("Third Security Affiliate"). Under the Preferred Stock Equity Facility, the Company could, from time to time at its sole and exclusive option, issue and sell to the Third Security Affiliate, up to $100,000 of newly issued Series A Redeemable Preferred Stock ("Series A Preferred Stock"). In conjunction with the Company's July 2018 registered underwritten public offering of Convertible Notes (Note 12), the Preferred Stock Equity Facility was terminated. No shares of Series A Preferred Stock had been issued under the Preferred Stock Equity Facility. The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of $89, $89, and $43 for the years ended December 31, 2019, 2018 and 2017, respectively. See Notes 1, 3, and 23 regarding additional transactions with affiliates of Third Security. Transactions with ECC Parties Entities controlled by Third Security are considered related parties and are disclosed below. The Company also disclosed entity relationships below where it holds more than a de minimis equity interest, including equity securities received as upfront or milestone consideration, and that also are party to a collaboration with the Company. In June 2016, the Company received 100,000 shares of Series 1 Preferred Stock (the "Preferred Shares") of ZIOPHARM, with a per share stated value of $1,200, as consideration for amending their two previously existing ECC agreements (Note 6). The Company received a monthly dividend, paid in additional Preferred Shares, equal to $12.00 per Preferred Share held per month divided by the stated value of the Preferred Shares. The Company elected the fair value option to account for the Preferred Shares whereby the value of the Preferred Shares was adjusted to fair value as of each reporting date and unrealized gains and losses were reported in the consolidated statements of operations. In conjunction with the ZIOPHARM License Agreement in October 2018 (Note 6), the Company returned to ZIOPHARM all of the Preferred Shares owned or accrued by the Company as of the effective date of the agreement. During the years ended December 31, 2018 and 2017, the Company recognized $14,793 and $16,717 of dividend income in the accompanying consolidated statements of operations, respectively. Following the transaction in October 2018, ZIOPHARM is no longer considered a related party. In March 2017, Fibrocell sold Series A Convertible Preferred Stock (the "Convertible Preferred Shares") convertible into shares of Fibrocell common stock and warrants to purchase shares of Fibrocell common stock to certain institutional and accredited investors, including the Company and affiliates of Third Security. The Company paid $1,161 in exchange for 1,161 Convertible Preferred Shares and warrants to acquire 99,769 shares of Fibrocell common stock. The Convertible Preferred Shares accrued dividends at 4% per annum, compounded quarterly, increasing the stated value of the shares. The Company also holds a promissory note which was convertible into shares of Fibrocell common stock ("convertible note") and warrants to purchase shares of Fibrocell common stock. The Company elected the fair value option to account for these investments whereby the values of investments were adjusted to fair value as of each reporting date and unrealized gains and losses were reported in the consolidated statements of operations. As of December 31, 2018, the fair value of the Company's investment in Fibrocell preferred stock totaled $191, and the value of the convertible note and warrants totaled $120, all of which are included in other assets on the accompanying consolidated balance sheet. The Company also owned common shares of Fibrocell previously acquired through collaborations and other transactions, and the fair value of these common shares was $640 as of December 31, 2018. In December 2019, Fibrocell was acquired by Castle Creek, and as a result, the Company received $1,280 in December 2019 for its common shares and received a total of $3,311 in January 2020 for the Convertible Preferred Shares and the convertible note, including accrued interest thereon. The $3,311 is included in other receivables on the accompanying consolidated balance sheet as of December 31, 2019. The Company recognized a total gain of $3,222 on the change in fair value of these instruments, which is included in total other income (expense), net, in the accompanying consolidated statement of operations for the year ended December 31, 2019. Subsequent to the acquisition by Castle Creek, Fibrocell is no longer a related party. During 2018, the Company mutually terminated each of its ECC agreements with Histogenics Corporation ("Histogenics"), OvaScience, Inc., and Synthetic Biologics, Inc. ("Synthetic Biologics"). Upon termination of these ECCs, the Company recognized the remaining deferred revenue totaling $11,877. In December 2017, the Company purchased certain property and equipment comprising the pilot plant production facility for its energy programs for $2,812 from Intrexon Energy Partners. The Company intends to use the pilot plant to support the collaborations with Intrexon Energy Partners and Intrexon Energy Partners II and its own research programs. Other Related Parties In June 2015, the Company entered into an agreement with Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third Security. Harvest was established to invest in life science research and development start-up opportunities that the Company offered to Harvest with exclusive rights of first-look and first negotiation. Based on this agreement, Harvest established six new collaboration entities, each of which entered into an ECC with the Company in a designated field. The terms of such ECCs were negotiated between the Company and Harvest. As consideration for providing exclusive rights of first-look and first negotiation for start-up opportunities, the Company received a portion of the management fee collected by the fund sponsor of Harvest. These fees are included in other income in the accompanying consolidated statement of operations and totaled $1,839 for the year ended December 31, 2017. In September 2017, the commitment period for Harvest was terminated and, as a result, the agreement with Harvest terminated. The termination of the agreement had no effect on the existing collaborations with Harvest-controlled entities. See Note 4 for further discussion of the asset acquisition of certain Harvest entities.

Net Loss per Share

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Net Loss per Share

The following table presents the computation of basic and diluted net loss per share:



	2019			2018			2017
Historical net loss per share:
Numerator:
Net loss from continuing operations attributable to Precigen	$	(206,165	)	$	(408,947	)	$	(70,637	)
Net loss from discontinued operations attributable to Precigen	(116,159		)	(100,389		)	(46,381		)
Net loss attributable to Precigen	$	(322,324	)	$	(509,336	)	$	(117,018	)
Denominator:
Weighted average shares outstanding, basic and diluted	154,138,774			129,521,731			119,998,826
Net loss per share:
Net loss from continuing operations attributable to Precigen per share, basic and diluted	$	(1.34	)	$	(3.16	)	$	(0.59	)
Net loss from discontinued operations attributable to Precigen per share, basic and diluted	(0.75		)	(0.77		)	(0.39		)
Net loss attributable to Precigen per share, basic and diluted	$	(2.09	)	$	(3.93	)	$	(0.98	)

The following potentially dilutive securities as of December 31, 2019, 2018, and 2017, have been excluded from the above computations of diluted weighted average shares outstanding for the years then ended as they would have been anti-dilutive:



	December 31,
	2019	2018	2017
Convertible debt	21,323,068	18,955,668	—
Options	9,022,282	11,093,063	11,382,747
Restricted stock units	1,781,982	970,341	—
Warrants	133,264	133,264	133,264
Total	32,260,596	31,152,336	11,516,011

Segments

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Segments

Through March 31, 2019, the Company was a single operating segment. In April 2019, the Company initiated efforts to better deploy resources, realize inherent synergies, and position the Company for growth with a core focus on healthcare and initiated plans to achieve this through various corporate activities, ultimately resulting in the closing of the Transactions in January 2020 (Note 3). Beginning in the second quarter of 2019, the Company's CODM assessed the operating performance of and allocated resources for several operating segments using Segment Adjusted EBITDA. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net loss before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on impairment of goodwill and other long-lived assets, (vi) equity in net loss of affiliates, and (vii) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates.

Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's CODM now regularly reviews disaggregated financial information for each of the Company's operating segments. The Company's segment presentation has been recast to retrospectively reflect the change from one reportable segment to the newly identified reportable segments, including goodwill and also excludes consideration of all of the businesses included in the Transactions (Note 3).

For the year ended December 31, 2019, the Company's reportable segments are (i) PGEN Therapeutics, (ii) ActoBio, (iii) MBP Titan, and (iv) Trans Ova. These identified reportable segments met the quantitative thresholds for the year ended December 31, 2019, to be reported separately. See Note 1 for a description of each of these reportable segments. The All Other category as reported below reflects Precigen's other operating segments that do not meet the quantitative thresholds to report separately. The Company has also recast 2018 and 2017 segment information on the same basis as the 2019 presentation.

Information by reportable segment was as follows:



	PGEN Therapeutics		ActoBio			MBP Titan		Trans Ova			All Other			Total
Goodwill
Balances at December 31, 2017	$	—	$	—		$	—	$	46,236		$	47,515		$	93,751
Reallocations from changes to reporting units	15,232		1,788			—		—			(17,020		)	—
Foreign currency translation adjustments	—		—			—		—			(124		)	(124		)
Balances at December 31, 2018	15,232		1,788			—		46,236			30,371			93,627
Reallocations from changes to reporting units	—		—			9,635		—			(9,635		)	—
Impairments	—		—			—		(29,642		)	(178		)	(29,820		)
Foreign currency translation adjustments	—		(53		)	—		—			—			(53		)
Balances at December 31, 2019	$	15,232	$	1,735		$	9,635	$	16,594		$	20,558		$	63,754



	Year Ended December 31, 2019
	PGEN Therapeutics			ActoBio			MBP Titan			Trans Ova			All Other			Total
Revenues from external customers	$	2,227		$	(364	)	$	3,813		$	68,672		$	16,227		$	90,575
Intersegment revenues	11,341			498			96			1,361			1,270			14,566
Total segment revenues	$	13,568		$	134		$	3,909		$	70,033		$	17,497		$	105,141

Segment Adjusted EBITDA	$	(30,166	)	$	(13,662	)	$	(36,718	)	$	(6,337	)	$	(5,952	)	$	(92,835	)



	Year Ended December 31, 2018
	PGEN Therapeutics			ActoBio			MBP Titan			Trans Ova			All Other			Total
Revenues from external customers	$	29,021		$	6,684		$	9,927		$	75,178		$	30,213		$	151,023
Intersegment revenues	617			840			9			558			255			2,279
Total segment revenues	$	29,638		$	7,524		$	9,936		$	75,736		$	30,468		$	153,302

Segment Adjusted EBITDA	$	(32,841	)	$	(12,797	)	$	(29,403	)	$	(5,730	)	$	(10,708	)	$	(91,479	)



	Year Ended December 31, 2017
	PGEN Therapeutics			ActoBio			MBP Titan			Trans Ova		All Other			Total
Revenues from external customers	$	53,184		$	12,929		$	14,336		$	79,783	$	59,174		$	219,406
Intersegment revenues	—			1,183			—			243		630			2,056
Total segment revenues	$	53,184		$	14,112		$	14,336		$	80,026	$	59,804		$	221,462

Segment Adjusted EBITDA	$	(5,655	)	$	(2,656	)	$	(32,251	)	$	1,020	$	(1,102	)	$	(40,644	)

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:



	Year Ended December 31,
	2019			2018			2017
Total segment revenues from reportable segments	$	87,644		$	122,834		$	161,658
Other revenues, including from other operating segments	18,602			30,914			59,861
Elimination of intersegment revenues	(15,524		)	(2,570		)	(2,056		)
Total consolidated revenues	$	90,722		$	151,178		$	219,463

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss before income taxes:



	Year Ended December 31,
	2019			2018			2017
Segment Adjusted EBITDA for reportable segments	$	(86,883	)	$	(80,771	)	$	(39,542	)
All Other Segment Adjusted EBITDA	(5,952		)	(10,708		)	(1,102		)
Remove cash paid for capital expenditures and investments in affiliates	15,339			19,906			31,701
Add recognition of previously deferred revenue associated with upfront and milestone payments	17,843			39,446			68,539
Other expenses:
Interest expense	(17,666		)	(8,473		)	(584		)
Depreciation and amortization	(19,789		)	(24,105		)	(21,609		)
Impairment loss	(30,810		)	—			(13,823		)
Reacquisition of in-process research and development	—			(236,748		)	—
Stock-based compensation expense	(16,443		)	(32,424		)	(36,893		)
Equity in net loss of affiliates	(2,416		)	(8,986		)	(12,436		)
Other	67			—			—
Unallocated corporate costs	(47,577		)	(84,536		)	(53,197		)
Eliminations	(14,400		)	(2,343		)	579
Consolidated net loss from continuing operations before income taxes	$	(208,687	)	$	(429,742	)	$	(78,367	)

As of December 31, 2019 and 2018, the Company had $6,724 and $10,011, respectively, of long-lived assets in foreign countries from continuing operations. The Company recognized revenues from continuing operations derived in foreign countries totaling $1,401, $6,255, and $13,771 for the years ended December 31, 2019, 2018 and 2017, respectively.

Quarterly Financial Information (Unaudited)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information (Unaudited)

The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information. The information in the tables below reflect the impact of discontinued operations further discussed in Note 3.



	Three Months Ended
	March 31, 2019			June 30, 2019			September 30, 2019			December 31, 2019 (1)
Total revenues	$	22,585		$	32,836		$	18,299		$	17,002
Operating loss	(50,216		)	(31,373		)	(44,637		)	(77,986		)
Loss from continuing operations	(52,900		)	(32,305		)	(49,054		)	(73,498		)
Net loss attributable to Precigen	(60,709		)	(38,766		)	(53,634		)	(169,215		)
Net loss from continuing operations attributable to Precigen per share, basic and diluted	$	(0.34	)	$	(0.21	)	$	(0.32	)	$	(0.47	)
Net loss attributable to Precigen per share, basic and diluted	$	(0.40	)	$	(0.25	)	$	(0.35	)	$	(1.09	)


(1)	During the fourth quarter of 2019, the Company recorded a goodwill impairment charge related to the Trans Ova reporting unit (Note 11) as well as impairment charges on certain assets held for sale (Note 3).



	Three Months Ended
	March 31, 2018			June 30, 2018			September 30, 2018			December 31, 2018 (1)
Total revenues	$	37,160		$	42,771		$	30,055		$	41,192
Operating loss	(42,241		)	(34,807		)	(58,330		)	(268,119		)
Loss from continuing operations	(37,103		)	(52,120		)	(50,507		)	(274,587		)
Net loss attributable to Precigen	(46,165		)	(65,382		)	(57,324		)	(340,465		)
Net loss from continuing operations attributable to Precigen per share, basic and diluted	$	(0.28	)	$	(0.39	)	$	(0.38	)	$	(2.08	)
Net loss attributable to Precigen per share, basic and diluted	$	(0.36	)	$	(0.51	)	$	(0.44	)	$	(2.59	)

(1)

During the fourth quarter of 2018, the Company reacquired certain in-process research and development from ZIOPHARM, Ares Trading, and Intrexon T1D Partners, all of which were immediately expensed (Notes 5 and 6). The Company also recorded a loss on abandonment of certain of its intangible assets (Note 11). The Company also recognized the remaining balance of deferred revenue associated with Histogenics and Synthetic Biologics upon the mutual termination of the ECCs with these entities (Note 18).

Defined Contribution Plans	12 Months Ended
Defined Contribution Plans	Dec. 31, 2019
Retirement Benefits [Abstract]
Defined Contribution Plans	Defined Contribution Plans The Company sponsors defined contribution plans covering employees who meet certain eligibility requirements. The Company makes contributions to the plans in accordance with terms specified in the plan agreement. The Company's contributions to the plans for continuing operations were $1,427, $1,662 and $1,545 in 2019, 2018 and 2017, respectively.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In January 2020, the Company completed the Transactions discussed in Note 3. Concurrent with entering into the TS Biotechnology Sale on January 1, 2020, the Company also entered into a subscription agreement with TS Biotechnology pursuant to which TS Biotechnology purchased 5,972,696 shares of the Company's common stock for $35,000 on January 31, 2020. In February 2020, the Company and Fibrocell mutually agreed to terminate Fibrocell ECC 2. The Company is considering the impact of this termination on its 2020 financial results.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Principles of Consolidation

The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.

Revenue Recognition

Revenue Recognition (For the Years Ended December 31, 2019 and 2018)

transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligations.

Collaboration and licensing revenues

Product and service revenues

Revenue Recognition (For the Year Ended December 31, 2017)

Collaboration and licensing revenues


(1)	The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity's performance to achieve the milestone;


(2)	The consideration relates solely to past performance; and


(3)	The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.

In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments.

Product and service revenues

The Company's product and service revenues are generated primarily through Trans Ova and include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered or delivery has occurred such that risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collection from the customer is reasonably assured.

Research and Development

Cash and Cash Equivalents

Restricted Cash

Restricted cash represented funds deposited with the United States Treasury, as required by a court decision resulting from litigation against Trans Ova (Note 17).

Short-term and Long-term Investments

Equity Securities

Fair Value of Financial Instruments



Level 1:	Quoted prices in active markets for identical assets and liabilities;

Level 2:	Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and

Level 3:	Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.

Concentrations of Risk

Equity Method Investments

Variable Interest Entities

Trade Receivables

Accounts Receivables

Inventory

Property, Plant and Equipment



	Years
Land improvements	4-15
Buildings and building improvements	3-23
Furniture and fixtures	1–10
Equipment	1–9
Breeding stock	1–4
Computer hardware and software	1–7

Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to fourteen years

Operating Leases

Goodwill

Intangible Assets

Impairment of Long-Lived Assets

Convertible Notes

Foreign Currency Translation

Income Taxes

Share-Based Payments



	2019	2018	2017
Valuation assumptions
Expected dividend yield	0%	0%	0%
Expected volatility	58%—64%	55%—59%	57%—60%
Expected term (years)	6.25	6.25	6.25
Risk-free interest rate	1.53%—2.58%	2.33%—3.06%	1.89%—2.27%

Net Loss per Share

Segment Information

Use of Estimates

Recently Adopted and Issued Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Accounting Policies [Abstract]

Rollforward of Allowance for Doubtful Accounts

The following table shows the activity in the allowance for doubtful receivable accounts from continuing operations for the years ended December 31, 2019, 2018, and 2017:



	2019			2018			2017
Beginning balance	$	4,991		$	4,631		$	3,703
Charged to operating expenses	3,384			1,627			1,217
Write offs of accounts receivable, net of recoveries	(862		)	(1,267		)	(289		)
Ending balance	$	7,513		$	4,991		$	4,631

Estimated Useful Lives of Property, Plant and Equipment

The estimated useful lives of these assets from continuing operations are as follows:



	Years
Land improvements	4-15
Buildings and building improvements	3-23
Furniture and fixtures	1–10
Equipment	1–9
Breeding stock	1–4
Computer hardware and software	1–7

Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to fourteen years.

Summary of Assumptions Used in Option Pricing Model

The assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2019, 2018 and 2017 are set forth in the table below:



	2019	2018	2017
Valuation assumptions
Expected dividend yield	0%	0%	0%
Expected volatility	58%—64%	55%—59%	57%—60%
Expected term (years)	6.25	6.25	6.25
Risk-free interest rate	1.53%—2.58%	2.33%—3.06%	1.89%—2.27%

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2019

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations

The carrying values of the major classes of assets and liabilities included in assets and liabilities held for sale for the Transactions are as follows:



	December 31, 2019
	TS Biotechnology Sale		EnviroFlight Sale		Total
Assets
Cash and cash equivalents	$	2,223	$	—	$	2,223
Other current assets	9,698		—		9,698
Property, plant and equipment, net	51,975		—		51,975
Intangible assets, net	20,891		4,383		25,274
Investments in affiliates	—		7,817		7,817
Right-of-use assets	13,622		—		13,622
Other noncurrent assets	212		—		212
Total assets held for sale	$	98,621	$	12,200	$	110,821
Liabilities
Deferred revenue, current (1)	$	8,723	$	—	$	8,723
Operating lease liabilities, current	2,459		—		2,459
Other current liabilities	3,058		41		3,099
Deferred revenue, net of current portion (2)	19,410		—		19,410
Operating lease liabilities, net of current portion	12,623		—		12,623
Other long-term liabilities	1,019		—		1,019
Total liabilities held for sale	$	47,292	$	41	$	47,333


(1)	Includes deferred revenue, current, from related parties of $1,243.


(2)	Includes deferred revenue, net of current portion, from related parties of $6,836.



	December 31, 2018
	TS Biotechnology Sale		EnviroFlight Sale		Total
Assets
Cash and cash equivalents	$	5,892	$	—	$	5,892
Other current assets	3,263		—		3,263
Property, plant and equipment, net	41,978		—		41,978
Intangible assets, net	31,782		8,547		40,329
Investments in affiliates	—		16,720		16,720
Goodwill	55,958		—		55,958
Other noncurrent assets	1,376		—		1,376
Total assets held for sale	$	140,249	$	25,267	$	165,516
Liabilities
Deferred revenue, current (1)	$	4,466	$	—	$	4,466
Other current liabilities	3,874		—		3,874
Deferred revenue, net of current portion (2)	7,482		—		7,482
Other long-term liabilities	3,476		—		3,476
Total liabilities held for sale	$	19,298	$	—	$	19,298


(1)	Includes deferred revenue, current, from related parties of $443.


(2)	Includes deferred revenue, net of current portion, from related parties of $7,455.

The following tables present the financial results of discontinued operations:



	Year Ended December 31, 2019
	TS Biotechnology Sale			EnviroFlight Sale			Total
Revenue (1)	$	12,307		$	—		$	12,307
Operating expenses (2)	116,091			10,794			126,885
Operating loss	(103,784		)	(10,794		)	(114,578		)
Other expense, net	(272		)	—			(272		)
Equity in net loss of affiliates	—			(4,314		)	(4,314		)
Loss before income taxes	(104,056		)	(15,108		)	(119,164		)
Income tax benefit	3,005			—			3,005
Loss from discontinued operations	$	(101,051	)	$	(15,108	)	$	(116,159	)


(1)	Includes revenue recognized from related parties of $3,042.


(2)	Includes the impairment charge of $89,679 related to the Transactions discussed above.



	Year Ended December 31, 2018
	TS Biotechnology Sale			EnviroFlight Sale			Total
Revenue (1)	$	9,396		$	—		$	9,396
Operating expenses (2)	111,039			470			111,509
Operating loss	(101,643		)	(470		)	(102,113		)
Other expense, net	(1,757		)	—			(1,757		)
Equity in net loss of affiliates	—			(2,622		)	(2,622		)
Loss before income taxes	(103,400		)	(3,092		)	(106,492		)
Income tax benefit	6,103			—			6,103
Loss from discontinued operations	$	(97,297	)	$	(3,092	)	$	(100,389	)


(1)	Includes revenue recognized from related parties of $4,665.


(2)	Includes an impairment charge of $60,504 recorded in 2018 related to Oxitec's developed technology targeting the Aedes Aegypti mosquito and a $5,057 loss on disposal of certain leasehold improvements, equipment and other fixed assets in conjunction with the closing of one of Oxitec's research and development facilities in Brazil.



	Year Ended December 31, 2017
	TS Biotechnology Sale			EnviroFlight Sale			Total
Revenue (1)	$	11,518		$	—		$	11,518
Operating expenses (2)	53,028			470			53,498
Operating loss	(41,510		)	(470		)	(41,980		)
Other expense, net	(7,506		)	—			(7,506		)
Equity in net loss of affiliates	—			(1,847		)	(1,847		)
Loss before income taxes	(49,016		)	(2,317		)	(51,333		)
Income tax benefit	4,952			—			4,952
Loss from discontinued operations	$	(44,064	)	$	(2,317	)	$	(46,381	)


(1)	Includes revenue recognized from related parties of $8,185.


(2)	Includes an impairment charge of $2,950 recorded as part of its annual impairment assessment of indefinite-lived intangible assets.



	Year Ended December 31,
	2019			2018			2017
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	$	5,107		$	9,007		$	9,536
Impairment loss	89,679			60,504			2,950
Unrealized and realized depreciation on equity securities and preferred stock, net	458			1,927			7,544
Equity in net loss of EnviroFlight	4,314			2,622			1,847
Stock-based compensation expense	2,507			3,872			4,683
Deferred income taxes	(2,710		)	(5,703		)	(4,575		)
Cash flows from investing activities
Investments in EnviroFlight	(2,000		)	(12,250		)	(4,750		)
Purchases of property, plant and equipment	(23,326		)	(21,191		)	(13,455		)

Also see Note 23 below.

Equity Method Investments

The Company accounted for its investment in EnviroFlight using the equity method of accounting.

Summarized financial data for equity method investments included in discontinued operations during the periods below are shown in the following tables.



	December 31,
	2019		2018
Current assets	$	703	$	5,119
Noncurrent assets	30,549		29,326
Total assets	31,252		34,445
Current liabilities	2,352		1,005
Non-current liabilities	88		—
Total liabilities	2,440		1,005
Net assets	$	28,812	$	33,440



	Year Ended December 31,
	2019			2018			2017
Revenues	$	510		$	268		$	254
Operating expenses	9,159			12,709			10,671
Operating loss	(8,649		)	(12,441		)	(10,417		)
Other, net	21			39			(8		)
Net loss	$	(8,628	)	$	(12,402	)	$	(10,425	)

Where applicable, the notes to the consolidated financial statements have been updated to reflect information pertaining to the Company's continuing operations.

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Mergers and Acquisitions (Tables) - GenVec, Inc.

12 Months Ended

Dec. 31, 2019

Business Acquisition [Line Items]

Fair Value of Consideration Transferred

The fair value of the total consideration transferred was $17,582. The acquisition date fair value of each class of consideration transferred is presented below:



Common shares	$	15,616
Warrants	1,381
Contingent consideration	585
	$	17,582

Fair Value of Assets Acquired and Liabilities Assumed

The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash and cash equivalents	$	2,054
Short-term investments	542
Trade receivables	75
Other receivables	97
Prepaid expenses and other	227
Property and equipment	250
Intangible assets	14,000
Other noncurrent assets	58
Total assets acquired	17,303
Accounts payable	2,158
Accrued compensation and benefits	1,226
Other accrued expenses	856
Other long-term liabilities	92
Deferred tax liabilities	239
Total liabilities assumed	4,571
Net assets acquired	12,732
Goodwill	4,850
Total consideration	$	17,582

Condensed Pro forma Financial Information

The following unaudited condensed pro forma financial information for the year ended December 31, 2017, is presented as if the acquisition had been consummated on January 1, 2016:



	Year Ended December 31,
	2017
	Pro Forma
Revenues	$	219,695
Loss from continuing operations before income taxes	(85,633		)
Net loss	(134,275		)
Net loss attributable to the noncontrolling interests	9,802
Net loss attributable to Precigen	(124,473		)

Collaboration and Licensing Revenue (Tables)

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues



	Year Ended December 31,
	2019			2018		2017
ZIOPHARM Oncology, Inc.	$	2,171		$	16,298	$	69,812
Ares Trading S.A.	—			11,175		10,738
Oragenics, Inc.	(564		)	1,353		1,469
Intrexon T1D Partners, LLC	—			2,502		5,968
Intrexon Energy Partners, LLC	2,596			6,929		10,665
Intrexon Energy Partners II, LLC	1,217			2,998		3,672
Fibrocell Science, Inc.	3,713			1,394		7,344
OvaXon, LLC	—			—		1,966
S & I Ophthalmic, LLC	—			—		755
Harvest start-up entities (1)	4,862			14,447		15,232
Other	64			12,444		7,003
Total	$	14,059		$	69,540	$	134,624


(1)	For the years ended December 31, 2019, 2018, and 2017, revenue recognized from collaborations with Harvest start-up entities include Exotech Bio, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. For the years ended December 31, 2018 and 2017, revenue recognized from collaborations with Harvest start-up entities also include Genten Therapeutics

and CRS Bio. For the year ended December 31, 2017, revenue recognized from collaborations with Harvest start-up entities also include Relieve Genetics.

Summary of Deferred Revenue

Deferred revenue from continuing operations consists of the following:



	December 31,
	2019		2018
Collaboration and licensing agreements	$	50,593	$	54,323
Prepaid product and service revenues	2,805		2,933
Other	435		560
Total	$	53,833	$	57,816
Current portion of deferred revenue	$	5,697	$	11,088
Long-term portion of deferred revenue	48,136		46,728
Total	$	53,833	$	57,816

Summary of Deferred Revenue by Collaborator



	Average Remaining Performance Period (Years)	December 31,
	Average Remaining Performance Period (Years)	2019		2018
ZIOPHARM Oncology, Inc.	0.0	$	—	$	1,214
Oragenics, Inc.	4.4	2,864		1,785
Intrexon Energy Partners, LLC	4.2	8,362		10,267
Intrexon Energy Partners II, LLC	4.9	12,843		14,060
Fibrocell Science, Inc.	4.9	17,697		17,519
Harvest start-up entities (1)	5.2	6,993		7,644
Other	2.8	1,834		1,834
Total		$	50,593	$	54,323

(1)

As of December 31, 2019 and 2018, the balance of deferred revenue for collaborations with Harvest start-up entities includes Exotech Bio, AD Skincare, and Thrive Agrobiotics.

Short-term Investments (Tables)

12 Months Ended

Dec. 31, 2019

Investments, Debt and Equity Securities [Abstract]

Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments

The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2019:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Aggregate Fair Value
United States government debt securities	$	8,989	$	7	$	—	$	8,996
Certificates of deposit	264		—		—		264
Total	$	9,253	$	7	$	—	$	9,260

The following table summarizes the amortized cost, gross unrealized gains and losses, and fair value of available-for-sale investments as of December 31, 2018:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Fair Value
United States government debt securities	$	119,401	$	—	$	(61	)	$	119,340
Certificates of deposit	274		—		—			274
Total	$	119,675	$	—	$	(61	)	$	119,614

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2019
Assets
United States government debt securities	$	—	$	8,996	$	—	$	8,996
Other	—		264		—		264
Total	$	—	$	9,260	$	—	$	9,260



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2018
Assets
United States government debt securities	$	—	$	119,340	$	—	$	119,340
Equity securities	950		74		—		1,024
Other	—		394		191		585
Total	$	950	$	119,808	$	191	$	120,949

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

The following table summarizes the changes in the Level 3 investments during the years ended December 31, 2019 and 2018.



	2019			2018
Beginning balance	$	191		$	161,225
Retained interest in deconsolidated subsidiary	14,239			—
Dividend income from investments in preferred stock	48			14,841
Net unrealized appreciation (depreciation) in the fair value of the investments in equity securities and preferred stock	7,446			(17,499		)
Return of preferred stock	—			(158,376		)
Proceeds from sale of equity securities	(21,587		)	—
Proceeds to be received from preferred stock	(337		)	—
Ending balance	$	—		$	191

Inventory (Tables)

12 Months Ended

Dec. 31, 2019

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory from continuing operations consists of the following:



	December 31,
	2019		2018
Supplies, embryos and other production materials	$	2,282	$	3,857
Work in process	3,702		4,391
Livestock	7,553		10,167
Feed	2,560		2,160
Total inventory	$	16,097	$	20,575

Property, Plant and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2019

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment consist of the following:



	December 31,
	2019			2018
Land and land improvements	$	9,814		$	10,001
Buildings and building improvements	11,765			20,099
Furniture and fixtures	1,315			1,812
Equipment	54,448			63,947
Leasehold improvements	12,821			14,219
Breeding stock	5,191			4,582
Computer hardware and software	9,434			10,789
Construction and other assets in progress	5,313			10,497
	110,101			135,946
Less: Accumulated depreciation and amortization	(49,132		)	(49,050		)
Property, plant and equipment, net	$	60,969		$	86,896

Goodwill and Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2019 and 2018, are as follows:



	2019			2018
Beginning of year	$	93,627		$	93,751
Impairment	(29,820		)	—
Foreign currency translation adjustments	(53		)	(124		)
End of year	$	63,754		$	93,627

Schedule of Intangible Assets

Intangible assets consist of the following as of December 31, 2019:



	Weighted Average Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Patents, developed technologies and know-how	15.8	$	90,659	$	(26,619	)	$	64,040
Customer relationships	6.5	10,700		(8,440		)	2,260
Trademarks	8.4	5,900		(3,854		)	2,046
Total		$	107,259	$	(38,913	)	$	68,346

Intangible assets consist of the following as of December 31, 2018:



	Gross Carrying Amount		Accumulated Amortization			Net
Patents, developed technologies and know-how	$	106,042	$	(23,674	)	$	82,368
Customer relationships	10,700		(7,565		)	3,135
Trademarks	6,800		(3,341		)	3,459
Total	$	123,542	$	(34,580	)	$	88,962

Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense

Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows:



2020	$	7,501
2021	7,313
2022	6,518
2023	5,350
2024	5,066
Thereafter	36,598
Total	$	68,346

Lines of Credit and Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2019

Debt Disclosure [Abstract]

Schedule of Long-Term Debt Instruments

Long-term debt consists of the following:



	December 31,
	2019		2018
Convertible debt	$	213,771	$	203,391
Notes payable	4,089		4,551
Other	131		3,753
Long-term debt	217,991		211,695
Less current portion	31,670		479
Long-term debt, less current portion	$	186,321	$	211,216

Interest Income and Interest Expense Disclosure

The components of interest expense related to the Convertible Notes were as follows:



	Year Ended December 31,
	2019		2018
Cash interest expense	$	7,000	$	3,462
Non-cash interest expense	9,459		4,378
Total interest expense	$	16,459	$	7,840

Schedule of Maturities of Long-Term Debt

Future maturities of long-term debt are as follows:



2020	$	31,670
2021	25,328
2022	341
2023	200,355
2024	369
Thereafter	2,368
Total	$	260,431

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Tax Disclosure [Abstract]

Components of Loss Before Income Taxes

The components of loss from continuing operations before income taxes are presented below:



	Year Ended December 31,
	2019			2018			2017
Domestic	$	(205,413	)	$	(428,410	)	$	(24,965	)
Foreign	(3,274		)	(1,332		)	(53,402		)
Loss from continuing operations before income taxes	$	(208,687	)	$	(429,742	)	$	(78,367	)

Components of Income Tax Expense (Benefit)

The components of income tax expense (benefit) from continuing operations are presented below:



	Year Ended December 31,
	2019			2018			2017
United States federal income taxes:
Current	$	—		$	(31	)	$	27
Deferred	(561		)	(11,855		)	(523		)
Foreign income taxes:
Current	34			68			(4		)
Deferred	(230		)	635			2,308
State income taxes:
Current	—			113			—
Deferred	(173		)	(4,355		)	264
Income tax expense (benefit) from continuing operations	$	(930	)	$	(15,425	)	$	2,072

Schedule of Effective Income Tax Rate Reconciliation



	2019			2018			2017
Computed statutory income tax benefit from continuing operations	$	(43,824	)	$	(90,246	)	$	(26,645	)
State and provincial income tax benefit, net of federal income taxes	(7,298		)	(23,347		)	(1,888		)
Nondeductible stock based compensation	10,303			4,696			3,391
Nondeductible officer compensation	595			294			476
Gain on dividend distribution of AquaBounty common stock	—			—			3,965
Impairment of goodwill	273			—			4,700
Research and development tax incentives	(1,772		)	(185		)	(359		)
Acquisition and internal restructuring transaction costs	260			52			354
Provisional impact of the Tax Act	—			—			85,288
Enacted changes in foreign tax rates and foreign tax reforms	—			—			2,021
Reacquired in-process research and development	—			2,696			—
Change in deferred state tax rate	—			8,666			—
United States-foreign rate differential	(76		)	215			410
Other, net	(72		)	(3,517		)	(189		)
	(41,611		)	(100,676		)	71,524
Change in valuation allowance for deferred tax assets	40,681			85,251			(69,452		)
Total income tax expense (benefit) from continuing operations	$	(930	)	$	(15,425	)	$	2,072

Schedule of Deferred Tax Assets and Liabilities

The tax effects of temporary differences that comprise the deferred tax assets and liabilities included in continuing operations as of December 31, 2019 and 2018, are as follows:



	2019			2018
Deferred tax assets
Allowance for doubtful accounts	$	2,140		$	1,490
Inventory	415			614
Equity securities and investments in affiliates	11,933			30,241
Property, plant and equipment	1,830			—
Intangible assets	85,308			78,858
Accrued liabilities	3,385			4,412
Lease liabilities	10,035			—
Stock-based compensation	19,389			28,885
Deferred revenue	14,876			16,297
Research and development tax credits	9,686			10,558
Investments in subsidiaries included in discontinued operations	8,592			—
Net operating and capital loss carryforwards	196,663			129,291
Total deferred tax assets	364,252			300,646
Less: Valuation allowance	349,008			292,217
Net deferred tax assets	15,244			8,429
Deferred tax liabilities
Property, plant and equipment	—			149
Right-of-use assets	8,091			—
Intangible assets	—			—
Long-term debt	9,987			12,136
Total deferred tax liabilities	18,078			12,285
Net deferred tax liabilities included in continuing operations	$	(2,834	)	$	(3,856	)

Summary of Valuation Allowance

Activity within the valuation allowance for deferred tax assets included in continuing operations during the years ended December 31, 2019, 2018 and 2017 was as follows:



	2019			2018			2017
Valuation allowance at beginning of year	$	292,217		$	211,078		$	253,549
Increase (decrease) in valuation allowance as a result of
Mergers and acquisitions, net	—			418			—
Deconsolidation of AquaBounty	(3,504		)	—			—
Establishment of deferred taxes for subsidiaries included in discontinued operations	8,592			—			—
Current year continuing operations	40,681			107,284			17,735
Discontinued operations treated as asset sales	10,585			3,832			6,940
Adoption of ASC 842	512			—			—
Adoption of ASC 606	—			(7,477		)	—
Adoption of ASU 2016-09	—			—			17,843
Provisional impact of the Tax Act	—			—			(87,473		)
Equity component of long-term debt	—			(13,367		)	—
Change in deferred state tax rate	—			(8,666		)	—
Changes in foreign tax rates and foreign tax reforms	—			—			1,494
Foreign currency translation adjustment	(75		)	(885		)	990
Valuation allowance at end of year	$	349,008		$	292,217		$	211,078

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2019

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows:



	December 31,
	2019			2018
Unrealized gain (loss) on investments	$	7		$	(61	)
Loss on foreign currency translation adjustments	(27,475		)	(28,551		)
Total accumulated other comprehensive loss	$	(27,468	)	$	(28,612	)

Share-Based Payments (Tables)

12 Months Ended

Dec. 31, 2019

Share-based Payment Arrangement [Abstract]

Schedule of Stock-based Compensation Expense

Stock-based compensation costs included in the consolidated statements of operations are presented below:



	Year Ended December 31,
	2019		2018		2017
Cost of products	$	20	$	78	$	116
Cost of services	220		237		322
Research and development	4,784		6,850		7,654
Selling, general and administrative	11,419		25,259		28,801
Discontinued operations	2,507		3,872		4,683
Total	$	18,950	$	36,296	$	41,576

Schedule of Stock Option Activity

Stock option activity was as follows:



	Number of Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2016	11,640,383		$	31.25		8.21
Granted	3,920,950		21.47
Adjustment due to dividend (Note 14)	46,766		31.11
Exercised	(149,429	)	(6.37		)
Forfeited	(3,797,105	)	(28.37		)
Expired	(278,818	)	(33.18		)
Balances at December 31, 2017	11,382,747		28.99			7.32
Granted	1,470,339		14.26
Exercised	(45,159	)	(6.59		)
Forfeited	(929,596	)	(21.48		)
Expired	(785,268	)	(26.25		)
Balances at December 31, 2018	11,093,063		27.95			6.81
Granted	1,556,575		6.52
Exercised	(19,887	)	(3.17		)
Forfeited	(1,236,326	)	(24.92		)
Expired	(2,371,143	)	(38.53		)
Balances at December 31, 2019	9,022,282		21.94			6.10
Exercisable at December 31, 2019	6,264,194		24.89			5.20

Summary of Information About Stock Options Outstanding

The following table summarizes additional information about stock options outstanding as of December 31, 2019:



					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value		Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value
$	3.17	—	$	8.60	1,612,219	$	6.40	8.08	$	473	585,144	$	5.61	5.95	$	194
$	8.77	—	$	20.68	1,278,121	15.55		6.53	—		753,064	15.89		5.20	—
$	20.94				1,646,500	20.94		6.51	—		892,000	20.94		6.02	—
$	21.00	—	$	29.47	1,976,645	23.71		6.06	—		1,585,940	23.71		5.79	—
$	29.56	—	$	65.08	2,508,797	34.46		4.38	—		2,448,046	34.47		4.33	—
					9,022,282	$	21.94	6.10	$	473	6,264,194	$	24.89	5.20	$	194

The following table summarizes additional information about stock options outstanding as of December 31, 2018:



					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value		Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value
$	3.17	—	$	19.52	1,973,818	$	13.70	7.54	$	169	833,007	$	12.80	4.85	$	169
$	19.85	—	$	20.94	1,914,763	20.93		7.99	—		500,263	20.92		7.67	—
$	21.00	—	$	27.08	2,057,126	23.29		7.26	—		1,248,370	23.01		6.69	—
$	27.10	—	$	29.56	2,666,109	29.19		5.28	—		2,593,151	29.20		5.23	—
$	29.58	—	$	65.08	2,481,247	47.24		6.59	—		1,827,728	47.65		6.54	—
					11,093,063	$	27.95	6.81	$	169	7,002,519	$	30.37	5.97	$	169

Schedule of Restricted Stock Unit Activity

RSU activity was a follows:



	Number of Restricted Stock Units		Weighted Average Grant Date Fair Value			Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2017	—		$	—		0.00
Granted	1,069,126		13.84
Vested	(25,000	)	(15.82		)
Forfeited	(73,785	)	(13.47		)
Balances at December 31, 2018	970,341		13.82			1.43
Granted	2,278,460		6.59
Vested	(1,159,165	)	(8.74		)
Forfeited	(307,654	)	(8.99		)
Balances at December 31, 2019	1,781,982		8.71			1.24

Operating Leases (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Components of Lease Costs

The components of lease costs from continuing operations were as follows:



	Year Ended December 31,
	2019
Operating lease costs	$	7,260
Short-term lease costs	2,042
Variable lease costs	2,076
Lease costs	$	11,378

Other information related to operating leases in continuing operations was as follows:



	December 31,
	2019
Weighted average remaining lease term (years)	5.24
Weighted average discount rate	10.96	%



	Year Ended December 31,
	2019
Supplemental Cash Flows Information
Cash paid for operating lease liabilities	$	7,294
Operating lease right-of-use assets added in exchange for new lease liabilities	1,137

Maturities of Lease Liabilities

As of December 31, 2019, maturities of lease liabilities, excluding short-term leases, for continuing operations were as follows:



2020	$	7,071
2021	7,449
2022	6,996
2023	5,831
2024	5,734
Thereafter	4,280
Total	37,361
Present value adjustment	(9,330		)
Total	$	28,031
Current portion of operating lease liabilities	$	4,182
Long-term portion of operating lease liabilities	23,849
Total	$	28,031

Future Minimum Lease Payments

At December 31, 2018, future minimum lease payments under operating leases for continuing operations having initial or remaining noncancelable lease terms in excess of one year were as follows:



2019	$	6,889
2020	7,384
2021	7,246
2022	6,815
2023	5,747
Thereafter	11,734
Total	$	45,815

Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss per Share

The following table presents the computation of basic and diluted net loss per share:



	2019			2018			2017
Historical net loss per share:
Numerator:
Net loss from continuing operations attributable to Precigen	$	(206,165	)	$	(408,947	)	$	(70,637	)
Net loss from discontinued operations attributable to Precigen	(116,159		)	(100,389		)	(46,381		)
Net loss attributable to Precigen	$	(322,324	)	$	(509,336	)	$	(117,018	)
Denominator:
Weighted average shares outstanding, basic and diluted	154,138,774			129,521,731			119,998,826
Net loss per share:
Net loss from continuing operations attributable to Precigen per share, basic and diluted	$	(1.34	)	$	(3.16	)	$	(0.59	)
Net loss from discontinued operations attributable to Precigen per share, basic and diluted	(0.75		)	(0.77		)	(0.39		)
Net loss attributable to Precigen per share, basic and diluted	$	(2.09	)	$	(3.93	)	$	(0.98	)

Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share



	December 31,
	2019	2018	2017
Convertible debt	21,323,068	18,955,668	—
Options	9,022,282	11,093,063	11,382,747
Restricted stock units	1,781,982	970,341	—
Warrants	133,264	133,264	133,264
Total	32,260,596	31,152,336	11,516,011

Segments (Tables)

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Information by Reportable Segment

Information by reportable segment was as follows:



	PGEN Therapeutics		ActoBio			MBP Titan		Trans Ova			All Other			Total
Goodwill
Balances at December 31, 2017	$	—	$	—		$	—	$	46,236		$	47,515		$	93,751
Reallocations from changes to reporting units	15,232		1,788			—		—			(17,020		)	—
Foreign currency translation adjustments	—		—			—		—			(124		)	(124		)
Balances at December 31, 2018	15,232		1,788			—		46,236			30,371			93,627
Reallocations from changes to reporting units	—		—			9,635		—			(9,635		)	—
Impairments	—		—			—		(29,642		)	(178		)	(29,820		)
Foreign currency translation adjustments	—		(53		)	—		—			—			(53		)
Balances at December 31, 2019	$	15,232	$	1,735		$	9,635	$	16,594		$	20,558		$	63,754



	Year Ended December 31, 2019
	PGEN Therapeutics			ActoBio			MBP Titan			Trans Ova			All Other			Total
Revenues from external customers	$	2,227		$	(364	)	$	3,813		$	68,672		$	16,227		$	90,575
Intersegment revenues	11,341			498			96			1,361			1,270			14,566
Total segment revenues	$	13,568		$	134		$	3,909		$	70,033		$	17,497		$	105,141

Segment Adjusted EBITDA	$	(30,166	)	$	(13,662	)	$	(36,718	)	$	(6,337	)	$	(5,952	)	$	(92,835	)



	Year Ended December 31, 2018
	PGEN Therapeutics			ActoBio			MBP Titan			Trans Ova			All Other			Total
Revenues from external customers	$	29,021		$	6,684		$	9,927		$	75,178		$	30,213		$	151,023
Intersegment revenues	617			840			9			558			255			2,279
Total segment revenues	$	29,638		$	7,524		$	9,936		$	75,736		$	30,468		$	153,302

Segment Adjusted EBITDA	$	(32,841	)	$	(12,797	)	$	(29,403	)	$	(5,730	)	$	(10,708	)	$	(91,479	)



	Year Ended December 31, 2017
	PGEN Therapeutics			ActoBio			MBP Titan			Trans Ova		All Other			Total
Revenues from external customers	$	53,184		$	12,929		$	14,336		$	79,783	$	59,174		$	219,406
Intersegment revenues	—			1,183			—			243		630			2,056
Total segment revenues	$	53,184		$	14,112		$	14,336		$	80,026	$	59,804		$	221,462

Segment Adjusted EBITDA	$	(5,655	)	$	(2,656	)	$	(32,251	)	$	1,020	$	(1,102	)	$	(40,644	)

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:



	Year Ended December 31,
	2019			2018			2017
Total segment revenues from reportable segments	$	87,644		$	122,834		$	161,658
Other revenues, including from other operating segments	18,602			30,914			59,861
Elimination of intersegment revenues	(15,524		)	(2,570		)	(2,056		)
Total consolidated revenues	$	90,722		$	151,178		$	219,463

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss before income taxes:



	Year Ended December 31,
	2019			2018			2017
Segment Adjusted EBITDA for reportable segments	$	(86,883	)	$	(80,771	)	$	(39,542	)
All Other Segment Adjusted EBITDA	(5,952		)	(10,708		)	(1,102		)
Remove cash paid for capital expenditures and investments in affiliates	15,339			19,906			31,701
Add recognition of previously deferred revenue associated with upfront and milestone payments	17,843			39,446			68,539
Other expenses:
Interest expense	(17,666		)	(8,473		)	(584		)
Depreciation and amortization	(19,789		)	(24,105		)	(21,609		)
Impairment loss	(30,810		)	—			(13,823		)
Reacquisition of in-process research and development	—			(236,748		)	—
Stock-based compensation expense	(16,443		)	(32,424		)	(36,893		)
Equity in net loss of affiliates	(2,416		)	(8,986		)	(12,436		)
Other	67			—			—
Unallocated corporate costs	(47,577		)	(84,536		)	(53,197		)
Eliminations	(14,400		)	(2,343		)	579
Consolidated net loss from continuing operations before income taxes	$	(208,687	)	$	(429,742	)	$	(78,367	)

Quarterly Financial Information (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information (Unaudited)



	Three Months Ended
	March 31, 2019			June 30, 2019			September 30, 2019			December 31, 2019 (1)
Total revenues	$	22,585		$	32,836		$	18,299		$	17,002
Operating loss	(50,216		)	(31,373		)	(44,637		)	(77,986		)
Loss from continuing operations	(52,900		)	(32,305		)	(49,054		)	(73,498		)
Net loss attributable to Precigen	(60,709		)	(38,766		)	(53,634		)	(169,215		)
Net loss from continuing operations attributable to Precigen per share, basic and diluted	$	(0.34	)	$	(0.21	)	$	(0.32	)	$	(0.47	)
Net loss attributable to Precigen per share, basic and diluted	$	(0.40	)	$	(0.25	)	$	(0.35	)	$	(1.09	)


(1)	During the fourth quarter of 2019, the Company recorded a goodwill impairment charge related to the Trans Ova reporting unit (Note 11) as well as impairment charges on certain assets held for sale (Note 3).



	Three Months Ended
	March 31, 2018			June 30, 2018			September 30, 2018			December 31, 2018 (1)
Total revenues	$	37,160		$	42,771		$	30,055		$	41,192
Operating loss	(42,241		)	(34,807		)	(58,330		)	(268,119		)
Loss from continuing operations	(37,103		)	(52,120		)	(50,507		)	(274,587		)
Net loss attributable to Precigen	(46,165		)	(65,382		)	(57,324		)	(340,465		)
Net loss from continuing operations attributable to Precigen per share, basic and diluted	$	(0.28	)	$	(0.39	)	$	(0.38	)	$	(2.08	)
Net loss attributable to Precigen per share, basic and diluted	$	(0.36	)	$	(0.51	)	$	(0.44	)	$	(2.59	)

(1)

Organization and Basis of Presentation - Additional Information (Details) - USD ($)
$ in Thousands

1 Months Ended

3 Months Ended

12 Months Ended

Oct. 31, 2019

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Deconsolidation, loss, amount

$ 2,648

Net assets divested from deconsolidation

$ 38,682

38,682

Proceeds from sales of equity securities

$ 21,587

23,456

$ 217

$ 235

Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net

$ 7,348

7,833

(30,200)

2,586

Net loss attributable to Precigen

(169,215)

^[1]

$ (53,634)

$ (38,766)

$ (60,709)

$ (340,465)

^[2]

$ (57,324)

$ (65,382)

$ (46,165)

(322,324)

(509,336)

$ (117,018)

Accumulated deficit

$ (1,652,869)

$ (1,330,545)

$ (1,652,869)

$ (1,330,545)

[1]

During the fourth quarter of 2019, the Company recorded a goodwill impairment charge related to the Trans Ova reporting unit (Note 11) as well as impairment charges on certain assets held for sale (Note 3).

[2]

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019 segment	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017	Jan. 01, 2019 USD ($)	Jul. 31, 2018
Organization And Significant Accounting Policies [Line Items]
Research and development commitments with third parties not incurred		$ 15,369	$ 11,801
Maturity period of highly liquid investment		3 months
Cash equivalent investments in highly liquid money market accounts		$ 47,238	40,155
Maximum risk of loss related to the identified VIEs		1,461	$ 3,341
Number of segments \| segment	1
Right-of-use assets		25,228
Operating lease, liability		$ 28,031
Minimum
Organization And Significant Accounting Policies [Line Items]
Expected useful life of intangible asset		3 years
Maximum
Organization And Significant Accounting Policies [Line Items]
Expected useful life of intangible asset		18 years
Intrexon Equity Plans
Organization And Significant Accounting Policies [Line Items]
Expected dividend yield		0.00%	0.00%	0.00%
Accounting Standards Update 2016-02
Organization And Significant Accounting Policies [Line Items]
Right-of-use assets					$ 30,000
Operating lease, liability					$ 32,300
Collaboration and licensing agreements
Organization And Significant Accounting Policies [Line Items]
Required notice period for voluntary termination of collaborative agreement		90 days
Products and services revenues
Organization And Significant Accounting Policies [Line Items]
Product and service revenues, standard payment terms		30 days
3.5% Convertible Notes Due 2023
Organization And Significant Accounting Policies [Line Items]
Debt instrument, interest rate, stated percentage						3.50%

Summary of Significant Accounting Policies - Rollforward of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Allowance for Doubtful Accounts
Charged to operating expenses	$ 3,242	$ 1,779	$ 1,217
Continuing Operations
Allowance for Doubtful Accounts
Beginning balance	4,991	4,631	3,703
Charged to operating expenses	3,384	1,627	1,217
Write offs of accounts receivable, net of recoveries	(862)	(1,267)	(289)
Ending balance	$ 7,513	$ 4,991	$ 4,631

Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2019
Minimum \| Land improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	4 years
Minimum \| Buildings and building improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	3 years
Minimum \| Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum \| Equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum \| Breeding stock
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum \| Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum \| Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Maximum \| Land improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	15 years
Maximum \| Buildings and building improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	23 years
Maximum \| Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	10 years
Maximum \| Equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	9 years
Maximum \| Breeding stock
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	4 years
Maximum \| Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	7 years
Maximum \| Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	14 years

Summary of Significant Accounting Policies - Summary of Assumptions Used in Option Pricing Model (Details) - Intrexon Equity Plans	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility, minimum	58.00%	55.00%	57.00%
Expected volatility, maximum	64.00%	59.00%	60.00%
Expected term (years)	6 years 3 months	6 years 3 months	6 years 3 months
Risk-free interest rate, minimum	1.53%	2.33%	1.89%
Risk-free interest rate, maximum	2.58%	3.06%	2.27%

Discontinued Operations - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 31, 2020	Jan. 02, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment loss		$ 120,489	$ 60,504	$ 16,773
Goodwill impairment	$ 178	29,820	0
Impairment of long-lived assets to be disposed of		448
Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment loss		89,679	60,504	2,950
TS Biotechnology Holdings LLC and Enviro Flight LLC \| Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment loss		89,679	$ 60,504	$ 2,950
Estimated selling costs		942
EnviroFlight Sale \| Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charge on write down of investment in affiliate		10,283
Subsequent Event \| TS Biotechnology Sale \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration					$ 53,000
Subsequent Event \| EnviroFlight Sale \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration						$ 12,200
Okanagan, Oxitec, Fine Chemicals, And AgBio \| TS Biotechnology Holdings LLC and Enviro Flight LLC \| Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment loss		79,396
Goodwill impairment		58,042
Impairment of long-lived assets to be disposed of		$ 21,354

Discontinued Operations - Carrying Value of Major Classes of Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 2,223	$ 5,892
Discontinued Operations, Held-for-sale
Assets
Cash and cash equivalents	2,223	5,892
Other current assets	9,698	3,263
Property, plant and equipment, net	51,975	41,978
Intangible assets, net	25,274	40,329
Investments in affiliates	7,817	16,720
Right-of-use assets	13,622
Goodwill		55,958
Other noncurrent assets	212	1,376
Total assets held for sale	110,821	165,516
Liabilities
Deferred revenue, current	8,723	4,466
Operating lease liabilities, current	2,459
Other current liabilities	3,099	3,874
Deferred revenue, net of current portion	19,410	7,482
Operating lease liabilities, net of current portion	12,623
Other long-term liabilities	1,019	3,476
Total liabilities held for sale	47,333	19,298
TS Biotechnology Sale \| Discontinued Operations, Held-for-sale
Assets
Cash and cash equivalents	2,223	5,892
Other current assets	9,698	3,263
Property, plant and equipment, net	51,975	41,978
Intangible assets, net	20,891	31,782
Right-of-use assets	13,622
Goodwill		55,958
Other noncurrent assets	212	1,376
Total assets held for sale	98,621	140,249
Liabilities
Deferred revenue, current	8,723	4,466
Operating lease liabilities, current	2,459
Other current liabilities	3,058	3,874
Deferred revenue, net of current portion	19,410	7,482
Operating lease liabilities, net of current portion	12,623
Other long-term liabilities	1,019	3,476
Total liabilities held for sale	47,292	19,298
EnviroFlight Sale \| Discontinued Operations, Held-for-sale
Assets
Cash and cash equivalents	0	0
Other current assets	0	0
Property, plant and equipment, net	0	0
Intangible assets, net	4,383	8,547
Investments in affiliates	7,817	16,720
Right-of-use assets	0
Goodwill		0
Other noncurrent assets	0	0
Total assets held for sale	12,200	25,267
Liabilities
Deferred revenue, current	0	0
Operating lease liabilities, current	0
Other current liabilities	41	0
Deferred revenue, net of current portion	0	0
Operating lease liabilities, net of current portion	0
Other long-term liabilities	0	0
Total liabilities held for sale	$ 41	$ 0

Discontinued Operations - Summary of Financial Results (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment loss	$ 120,489	$ 60,504	$ 16,773
Loss from discontinued operations	(116,159)	(100,389)	(46,381)
Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deferred revenue, current	8,723	4,466
Deferred revenue, net of current portion	19,410	7,482
Revenue	12,307	9,396	11,518
Impairment loss	89,679	60,504	2,950
Loss on disposal		5,057
Operating expenses	126,885	111,509	53,498
Operating loss	(114,578)	(102,113)	(41,980)
Other expense, net	(272)	(1,757)	(7,506)
Equity in net loss of affiliates	(4,314)	(2,622)	(1,847)
Income tax benefit	(119,164)	(106,492)	(51,333)
Income tax benefit	3,005	6,103	4,952
Loss from discontinued operations	(116,159)	(100,389)	(46,381)
TS Biotechnology Sale \| Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deferred revenue, current	8,723	4,466
Deferred revenue, net of current portion	19,410	7,482
Revenue	12,307	9,396	11,518
Operating expenses	116,091	111,039	53,028
Operating loss	(103,784)	(101,643)	(41,510)
Other expense, net	(272)	(1,757)	(7,506)
Equity in net loss of affiliates			0
Income tax benefit	(104,056)	(103,400)	(49,016)
Income tax benefit	3,005	6,103	4,952
Loss from discontinued operations	(101,051)	(97,297)	(44,064)
EnviroFlight Sale \| Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deferred revenue, current	0	0
Deferred revenue, net of current portion	0	0
Revenue	0	0	0
Operating expenses	10,794	470	470
Operating loss	(10,794)	(470)	(470)
Other expense, net	0	0	0
Equity in net loss of affiliates	(4,314)	(2,622)	(1,847)
Income tax benefit	(15,108)	(3,092)	(2,317)
Income tax benefit	0	0	0
Loss from discontinued operations	(15,108)	(3,092)	(2,317)
TS Biotechnology Holdings LLC and Enviro Flight LLC \| Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment loss	89,679	60,504	2,950
Related Parties, Aggregated \| TS Biotechnology Sale \| Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deferred revenue, current	1,243	443
Deferred revenue, net of current portion	6,836	7,455
Revenue	$ 3,042	$ 4,665	$ 8,185

Discontinued Operations - Summary of Significant Non-Cash Items, Investments and Purchases of Property, Plant and Equipment on Cash Flows (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		$ 24,896	$ 33,112	$ 31,145
Impairment loss		120,489	60,504	16,773
Unrealized and realized depreciation on equity securities and preferred stock, net	$ (7,348)	(7,833)	30,200	(2,586)
Equity in net loss of EnviroFlight		6,730	11,608	14,283
Stock-based compensation expense		18,950	36,296	41,576
Deferred income taxes		(3,674)	(21,278)	(2,528)
Investments in EnviroFlight		(3,713)	(16,582)	(11,189)
Purchases of property, plant and equipment		(37,883)	(41,587)	(46,666)
Discontinued Operations, Held-for-sale
Adjustments to reconcile net loss to net cash used in operating activities
Impairment loss		89,679	60,504	2,950
TS Biotechnology Holdings LLC and Enviro Flight LLC \| Discontinued Operations, Held-for-sale
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		5,107	9,007	9,536
Impairment loss		89,679	60,504	2,950
Unrealized and realized depreciation on equity securities and preferred stock, net		458	1,927	7,544
Stock-based compensation expense		2,507	3,872	4,683
Deferred income taxes		(2,710)	(5,703)	(4,575)
Purchases of property, plant and equipment		(23,326)	(21,191)	(13,455)
EnviroFlight Sale \| Discontinued Operations, Held-for-sale
Adjustments to reconcile net loss to net cash used in operating activities
Equity in net loss of EnviroFlight		4,314	2,622	1,847
Investments in EnviroFlight		$ (2,000)	$ (12,250)	$ (4,750)

Discontinued Operations - Summary of Financial Data for Equity Method Investments Included in Discontinued Operations (Details) - TS Biotechnology Holdings LLC and Enviro Flight LLC - Discontinued Operations, Held-for-sale - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current assets	$ 703	$ 5,119
Noncurrent assets	30,549	29,326
Total assets	31,252	34,445
Current liabilities	2,352	1,005
Non-current liabilities	88	0
Total liabilities	2,440	1,005
Net assets	28,812	33,440
Revenues	510	268	$ 254
Operating expenses	9,159	12,709	10,671
Operating loss	(8,649)	(12,441)	(10,417)
Other, net	21	39	(8)
Net loss	$ (8,628)	$ (12,402)	$ (10,425)

Mergers and Acquisitions - Asset Acquisition of Certain Harvest Entities (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Aug. 31, 2018
Business Acquisition [Line Items]
Long-term debt issued to a related party in an asset acquisition		$ 0	$ 30,000,000	$ 0
Cash received in asset acquisition		0	15,500,000	(14,219,000)
Investments in affiliates		1,461,000	2,139,000
Deferred revenue		53,833,000	57,816,000
Reacquisition of in-process research and development		$ 0	$ 236,748,000	$ 0
Harvest Intrexon Enterprise Fund I, LP
Business Acquisition [Line Items]
Cash received in asset acquisition	$ 15,500,000
Precigen ActoBio, Inc. \| Harvest Intrexon Enterprise Fund I, LP
Business Acquisition [Line Items]
Long-term debt issued to a related party in an asset acquisition	30,000,000
CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc.
Business Acquisition [Line Items]
Investments in affiliates					$ 4,303,000
Ownership interest		100.00%
Deferred revenue	10,078,000
Reacquisition of in-process research and development	$ 8,721,000

Mergers and Acquisitions - GenVec - Fair Value of Consideration Transferred (Details) - GenVec, Inc. $ in Thousands	1 Months Ended
	Jun. 30, 2017 USD ($)
Business Acquisition [Line Items]
Common shares	$ 15,616
Warrants	1,381
Contingent consideration	585
Total consideration transferred	$ 17,582

Mergers and Acquisitions - GenVec - Additional Information (Details) - GenVec, Inc. - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2017
Business Acquisition [Line Items]
Percentage of outstanding common stock acquired	100.00%
Business combination, consideration paid, shares issued	684,240
Collaboration agreement, percent of collaboration payments	50.00%
Business combination, period subsequent to acquisition during which a portion of collaboration payments received will be paid to former stockholders of acquired entity	3 years
Expected useful life of intangible asset	11 years
Selling, general and administrative
Business Acquisition [Line Items]
Business combination, acquisition related cost		$ 507

Mergers and Acquisitions - GenVec - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2017
Business Acquisition [Line Items]
Goodwill	$ 63,754	$ 93,627	$ 93,751
GenVec, Inc.
Business Acquisition [Line Items]
Cash and cash equivalents				$ 2,054
Short-term investments				542
Trade receivables				75
Other receivables				97
Prepaid expenses and other				227
Property and equipment				250
Intangible assets				14,000
Other noncurrent assets				58
Total assets acquired				17,303
Accounts payable				2,158
Accrued compensation and benefits				1,226
Other accrued expenses				856
Other long-term liabilities				92
Deferred tax liabilities				239
Total liabilities assumed				4,571
Net assets acquired				12,732
Goodwill				4,850
Total consideration				$ 17,582

Mergers and Acquisitions - GenVec - Pro Forma Financial Information (Details) - GenVec, Inc. $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenues	$ 219,695
Loss from continuing operations before income taxes	(85,633)
Net loss	(134,275)
Net loss attributable to the noncontrolling interests	9,802
Net loss attributable to Precigen	$ (124,473)

Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)	1 Months Ended
	Dec. 31, 2015 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2019 USD ($) board_seat	Dec. 31, 2018 USD ($)
Schedule Of Investments In Joint Venture [Line Items]
Investment			$ 1,461,000	$ 2,139,000
Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest		50.00%
Maximum additional capital contributions committed		$ 25,000,000
Additional capital contributions committed, remaining commitment			$ 4,225,000
Total number of seats on the joint venture's governing board \| board_seat			5
Total number of seats on the joint venture's governing board, internally selected \| board_seat			2
Total number of seats on the joint venture's governing board, externally selected \| board_seat			3
Investor \| Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest		50.00%
Capital contribution		$ 25,000,000
Maximum additional capital contributions committed		25,000,000
Other accrued liabilities \| Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment			$ (423,000)	$ (656,000)
Intrexon Energy Partners II, LLC \| Collaboration and licensing agreements
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value	$ 18,000,000
Intrexon Energy Partners, LLC \| Collaboration and licensing agreements
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value		$ 25,000,000

Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)	1 Months Ended
	Dec. 31, 2015 USD ($) board_seat	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017
Schedule Of Investments In Joint Venture [Line Items]
Investment		$ 1,461,000	$ 2,139,000
Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest				50.00%
Maximum additional capital contributions committed	$ 10,000,000
Additional capital contributions committed, remaining commitment		10,000,000
Total number of seats on the joint venture's governing board \| board_seat	5
Total number of seats on the joint venture's governing board, internally selected \| board_seat	1
Total number of seats on the joint venture's governing board, externally selected \| board_seat	4
Investor \| Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%
Capital contribution	$ 18,000,000
Maximum additional capital contributions committed	10,000,000
All Investors \| Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution	4,000,000
Other accrued liabilities \| Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment		$ (435,000)	$ (50,000)
Intrexon Energy Partners II, LLC \| Collaboration and licensing agreements
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value	$ 18,000,000

Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details)	1 Months Ended		12 Months Ended
	Nov. 30, 2018 USD ($) shares	Mar. 31, 2016 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Oct. 31, 2018 board_seat
Schedule Of Investments In Joint Venture [Line Items]
Shares issued for reacquired in-process research and development				$ 159,323,000
Deferred revenue			$ 53,833,000	57,816,000
Reacquisition of in-process research and development			0	236,748,000	$ 0
Collaboration and licensing agreements
Schedule Of Investments In Joint Venture [Line Items]
Deferred revenue			$ 50,593,000	$ 54,323,000
Intrexon T1D Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	100.00%	50.00%
Maximum additional capital contributions committed		$ 5,000,000
Total number of seats on the joint venture's governing board, internally selected \| board_seat						2
Total number of seats on the joint venture's governing board, externally selected \| board_seat						3
Shares issued in asset acquisition or for reacquired in-process research and development, shares \| shares	1,933,737
Shares issued for reacquired in-process research and development	$ 18,970,000
Deferred revenue	8,517,000
Reacquisition of in-process research and development	$ 10,453,000
Investor \| Intrexon T1D Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest		50.00%
Capital contribution		$ 10,000,000
Maximum additional capital contributions committed		5,000,000
Intrexon T1D Partners, LLC \| Collaboration and licensing agreements
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value		$ 10,000,000

Collaboration and Licensing Revenue - Summarized Collaboration and Licensing Revenues (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

$ 90,722

$ 151,178

$ 219,463

Collaboration and licensing agreements

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

14,059

69,540

134,624

ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

2,171

16,298

69,812

Ares Trading S.A. | Collaboration and licensing agreements

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

11,175

10,738

Oragenics, Inc. | Collaboration and licensing agreements

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

(564)

1,353

1,469

Intrexon T1D Partners, LLC | Collaboration and licensing agreements

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

2,502

5,968

Intrexon Energy Partners, LLC | Collaboration and licensing agreements

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

2,596

6,929

10,665

Intrexon Energy Partners II, LLC | Collaboration and licensing agreements

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

1,217

2,998

3,672

Fibrocell Science, Inc. | Collaboration and licensing agreements

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

3,713

1,394

7,344

OvaXon, LLC | Collaboration and licensing agreements

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

1,966

S & I Ophthalmic, LLC | Collaboration and licensing agreements

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

755

Harvest Start-Up Entities | Collaboration and licensing agreements

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

^[1]

4,862

14,447

15,232

Other | Collaboration and licensing agreements

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Revenues

$ 64

$ 12,444

$ 7,003

[1]

For the years ended December 31, 2019, 2018, and 2017, revenue recognized from collaborations with Harvest start-up entities include Exotech Bio, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. For the years ended December 31, 2018 and 2017, revenue recognized from collaborations with Harvest start-up entities also include Genten Therapeutics

and CRS Bio. For the year ended December 31, 2017, revenue recognized from collaborations with Harvest start-up entities also include Relieve Genetics.

Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 53,833	$ 57,816
Current portion of deferred revenue	5,697	11,088
Long-term portion of deferred revenue	48,136	46,728
Collaboration and licensing agreements
Deferred Revenue Arrangement [Line Items]
Deferred revenue	50,593	54,323
Prepaid product and service revenues
Deferred Revenue Arrangement [Line Items]
Deferred revenue	2,805	2,933
Other
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 435	$ 560

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Prior Year (Details) - Upfront and Milestone Payments
$ in Thousands

Dec. 31, 2018

USD ($)

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred revenue

$ 54,323

ZIOPHARM Oncology, Inc.

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred revenue

1,214

Oragenics, Inc.

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred revenue

1,785

Intrexon Energy Partners, LLC

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred revenue

10,267

Intrexon Energy Partners II, LLC

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred revenue

14,060

Fibrocell Science, Inc.

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred revenue

17,519

Harvest Start-Up Entities, Aggregated [Member]

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred revenue

7,644

^[1]

Other

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]

Deferred revenue

$ 1,834

[1]	As of December 31, 2019 and 2018, the balance of deferred revenue for collaborations with Harvest start-up entities includes Exotech Bio, AD Skincare, and Thrive Agrobiotics.

Collaboration and Licensing Revenue - Additional Information (Details)	1 Months Ended																	5 Months Ended	12 Months Ended
	Apr. 30, 2019	Dec. 31, 2018 USD ($) shares	Nov. 30, 2018 USD ($) shares	Oct. 31, 2018 USD ($) quarterly_installment product	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($) shares	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) shares	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	May 31, 2015 USD ($) target	Mar. 31, 2014 USD ($)	Jun. 30, 2013 USD ($) shares	Oct. 31, 2012 USD ($) shares	Jan. 31, 2011 USD ($) shares	May 31, 2016	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018	Jan. 01, 2018 USD ($)	Jan. 01, 2017 USD ($)
Collaboration Agreements [Line Items]
Revenues																			$ 90,722,000	$ 151,178,000	$ 219,463,000
Cumulative effect of adoption of ASC 606																								$ 26,507,000	$ 0
Fair value of assets		$ 120,949,000																	9,260,000	120,949,000
Deferred revenue		57,816,000																	53,833,000	57,816,000
Reacquisition of in-process research and development																			0	236,748,000	0
Shares issued for reacquired in-process research and development																				159,323,000
Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues																			14,059,000	69,540,000	134,624,000
Deferred revenue		54,323,000																	$ 50,593,000	54,323,000
Required notice period for voluntary termination of collaborative agreement																			90 days
Licensing agreement between ZIOPHARM and Precigen 2018
Collaboration Agreements [Line Items]
License agreement, percentage of development costs for which responsible				20.00%
License agreement, percentage of operating profits to be received				20.00%
License agreement, annual fee				$ 100,000
License agreement, reimbursement of historical costs, number of quarterly installments \| quarterly_installment				4
Milestone payments required upon successful achievement, aggregated				$ 210,000,000
License agreement, royalty due, aggregated				$ 100,000,000
License agreement, percentage of sublicensing income				20.00%
Transition period during which costs will be reimbursed				1 year
License agreement, termination, period following triggering event				12 years
Maximum \| Licensing agreement between ZIOPHARM and Precigen 2018
Collaboration Agreements [Line Items]
License agreement, reimbursement of historical costs				$ 1,000,000
Milestone payments required upon successful achievement, per product				$ 52,500,000
License agreement, number of exclusively licensed products \| product				4
ZIOPHARM Oncology, Inc. \| Licensing agreement between ZIOPHARM and Precigen 2018
Collaboration Agreements [Line Items]
License agreement, percentage of development costs for which responsible				80.00%
License agreement, percentage of operating profits to be received				80.00%
License agreement, royalty due, aggregated				$ 50,000,000
ZIOPHARM Oncology, Inc.
Collaboration Agreements [Line Items]
Collaborative arrangement consideration received, number of preferred shares (in shares) \| shares								100,000
Reacquisition of in-process research and development				109,047,000
ZIOPHARM Oncology, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received (in shares) \| shares																3,636,926	3,636,926
Collaborative agreement, consideration received, value				100,000				$ 120,000,000			$ 10,000,000					$ 18,330,000	$ 17,457,000
Revenues																			$ 2,171,000	16,298,000	69,812,000
Royalty rate as a percentage of net profit								20.00%										50.00%
Collaborative arrangement consideration received, number of preferred shares (in shares) \| shares								100,000
Deferred revenue																						$ 51,084,000
ZIOPHARM Oncology, Inc. \| Transfer of clinical product candidate(s) \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues																	1,115,000
ZIOPHARM Oncology, Inc. \| Single performance obligation \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value																	$ 16,342,000
ZIOPHARM Oncology, Inc. \| Milestone consideration \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Cumulative effect of adoption of ASC 606																								873,000
ZIOPHARM Oncology, Inc. \| ZIOPHARM ECC 2 \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues					$ 28,943,000
ZIOPHARM Oncology, Inc. \| Contract modification consideration \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Cumulative effect of adoption of ASC 606																								$ 32,422,000
ZIOPHARM Oncology, Inc. \| Reacquired in-process research & development \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Deferred revenue																						49,329,000
ZIOPHARM Oncology, Inc. \| Transition services \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Deferred revenue				1,855,000																		$ 1,755,000
ZIOPHARM Oncology, Inc. \| Historical cost reimbursement \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues				$ 500,000
Ares Trading S.A.
Collaboration Agreements [Line Items]
Reacquisition of in-process research and development		$ 108,527,000
Shares issued in asset acquisition or for reacquired in-process research and development, shares \| shares		20,640,119
Shares issued for reacquired in-process research and development		$ 140,353,000
Royalty percentage to be paid to other party		0.10
Ares Trading S.A. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value													$ 115,000,000
Revenues																			$ 0	11,175,000	10,738,000
Collaborative agreement, consideration receivable, minimum targets required \| target													2
Ares Trading S.A. \| Reacquired in-process research & development \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Deferred revenue			$ 31,826,000
Ares Trading S.A. \| Research & development services \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Deferred revenue													$ 10,000,000
Collaborative agreement, consideration receivable, collection period													2 years
Ares Trading S.A. \| ZIOPHARM Oncology, Inc.
Collaboration Agreements [Line Items]
Collaboration agreement, percent of collaboration payments																			50.00%
Ares Trading S.A. \| ZIOPHARM Oncology, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Payments to related parties													$ 57,500,000
Oragenics, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues																			$ (564,000)	1,353,000	1,469,000
Collaborative agreement, consideration received, value of convertible promissory note												$ 5,000,000
Required notice period for voluntary termination of collaborative agreement												90 days
Oragenics, Inc. \| Maximum \| Oragenics ECC
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, one-time						$ 37,500,000
Intrexon T1D Partners, LLC \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value									$ 10,000,000
Revenues																			0	2,502,000	5,968,000
Genten Therapeutics, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value							$ 3,000,000
Collaborative agreement, consideration received, cash							1,500,000
CRS Bio, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value							$ 2,100,000
Relieve Genetics, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value									4,333,000
Intrexon Energy Partners, LLC \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value														$ 25,000,000
Revenues																			2,596,000	6,929,000	10,665,000
Required notice period for voluntary termination of collaborative agreement														90 days
Intrexon Energy Partners II, LLC \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value										$ 18,000,000
Revenues																			1,217,000	2,998,000	3,672,000
Required notice period for voluntary termination of collaborative agreement										90 days
Exotech Bio, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value									$ 5,000,000
Required notice period for voluntary termination of collaborative agreement									90 days
AD Skincare, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value								$ 4,333,000
Required notice period for voluntary termination of collaborative agreement								90 days
AD Skincare, Inc. \| Maximum \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product								$ 2,000,000
Milestone payments required upon successful achievement, one-time								$ 17,000,000
Fibrocell Science, Inc.
Collaboration Agreements [Line Items]
License agreement, percentage of sublicensing income	50.00%
Fibrocell Science, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received (in shares) \| shares															82,919	87,835
Collaborative agreement, consideration received, value										$ 10,000,000					$ 7,612,000	$ 7,576,000
Revenues																			3,713,000	$ 1,394,000	$ 7,344,000
Required notice period for voluntary termination of collaborative agreement										90 days						90 days
Collaborative agreement, consideration received, cash																			$ 3,750,000
Royalty rate as a percentage of net sales, tier 1																7.00%
Level of net sales at which royalty rate changes to tier 2																$ 25,000,000
Royalty rate as a percentage of net sales, tier 2																14.00%
Royalty rate of savings from improvement																33.00%
Maximum milestone payments required upon successful achievement, first product										$ 30,000,000
Maximum milestone payments required upon successful achievement, per each additional product										30,000,000
Maximum milestone payments required for certain sales milestones, per product										$ 22,500,000
Thrive Agrobiotics, Inc. \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value											$ 1,667,000
Required notice period for voluntary termination of collaborative agreement											90 days
Thrive Agrobiotics, Inc. \| Maximum \| Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product											$ 5,500,000
Intrexon T1D Partners, LLC
Collaboration Agreements [Line Items]
Deferred revenue			8,517,000
Reacquisition of in-process research and development			$ 10,453,000
Shares issued in asset acquisition or for reacquired in-process research and development, shares \| shares			1,933,737
Shares issued for reacquired in-process research and development			$ 18,970,000
Ownership interest			100.00%
Genten Therapeutics, Inc.
Collaboration Agreements [Line Items]
Ownership interest																						100.00%
CRS Bio, Inc.
Collaboration Agreements [Line Items]
Ownership interest																						100.00%
Relieve Genetics, Inc.
Collaboration Agreements [Line Items]
Ownership interest																						100.00%
Exotech Bio, Inc.
Collaboration Agreements [Line Items]
Ownership interest																							49.00%
ZIOPHARM Oncology, Inc. \| Preferred stock
Collaboration Agreements [Line Items]
Fair value of assets																						$ 158,376,000
Oragenics, Inc.
Collaboration Agreements [Line Items]
Conversion of promissory note into common stock (in shares) \| shares										338,100

Short-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 9,253	$ 119,675
Gross Unrealized Gains	7	0
Gross Unrealized Losses	0	(61)
Aggregate Fair Value	9,260	119,614
United States government debt securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	8,989	119,401
Gross Unrealized Gains	7	0
Gross Unrealized Losses	0	(61)
Aggregate Fair Value	8,996	119,340
Certificates of deposit
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	264	274
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	$ 264	$ 274

Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
United States government debt securities	$ 8,996	$ 119,340
Equity securities		1,024
Other	264	585
Fair value of assets	9,260	120,949
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
United States government debt securities	0	0
Equity securities		950
Other	0	0
Fair value of assets	0	950
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
United States government debt securities	8,996	119,340
Equity securities		74
Other	264	394
Fair value of assets	9,260	119,808
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
United States government debt securities	0	0
Equity securities		0
Other	0	191
Fair value of assets	$ 0	$ 191

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Jul. 31, 2018
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial liabilities measured at fair value on a recurring basis	$ 585	$ 585
3.5% Convertible Notes Due 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of convertible debt	126,000	141,000
Carrying value of convertible debt	$ 157,560	$ 148,101	$ 143,723

Fair Value Measurements - Schedule of Changes in Level 3 Liabilities (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Dividend income from investments in preferred stock		$ 48	$ 14,841	$ 16,756
Proceeds from sales of equity securities	$ (21,587)	(23,456)	(217)	(235)
Significant Unobservable Inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		191	161,225
Retained interest in deconsolidated subsidiary		14,239	0
Dividend income from investments in preferred stock		48	14,841
Net unrealized appreciation (depreciation) in the fair value of the investments in equity securities and preferred stock		7,446	(17,499)
Return of preferred stock		0	(158,376)
Proceeds from sales of equity securities		(21,587)	0
Proceeds to be received from preferred stock		(337)	0
Ending balance		$ 0	$ 191	$ 161,225

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Inventory [Line Items]
Inventory	$ 16,097	$ 20,575
Supplies, embryos and other production materials
Inventory [Line Items]
Inventory	2,282	3,857
Work in process
Inventory [Line Items]
Inventory	3,702	4,391
Livestock
Inventory [Line Items]
Inventory	7,553	10,167
Feed
Inventory [Line Items]
Inventory	$ 2,560	$ 2,160

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Land and land improvements	$ 9,814	$ 10,001
Buildings and building improvements	11,765	20,099
Furniture and fixtures	1,315	1,812
Equipment	54,448	63,947
Leasehold improvements	12,821	14,219
Breeding stock	5,191	4,582
Computer hardware and software	9,434	10,789
Construction and other assets in progress	5,313	10,497
Property, plant and equipment, gross	110,101	135,946
Less: Accumulated depreciation and amortization	(49,132)	(49,050)
Property, plant and equipment, net	$ 60,969	$ 86,896

Property, Plant and Equipment, Net - Additional Information (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2019 reporting_unit	Dec. 31, 2019 USD ($) reporting_unit	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Property, Plant and Equipment [Abstract]
Property, plant and equipment, net divested from deconsolidation		$ 24,186
Impairment of long-lived assets to be disposed of		$ 448
Number of reporting units closed \| reporting_unit	2	2
Depreciation expense		$ 11,869	$ 12,439	$ 10,137

Goodwill and Intangible Assets, Net - Additional Information (Details) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2019 USD ($) reporting_unit	Dec. 31, 2018 USD ($)	Dec. 31, 2019 USD ($) reporting_unit	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Goodwill [Line Items]
Accumulated goodwill impairment losses		$ 13,823	$ 43,643	$ 13,823
Impairments	$ 178		$ 29,820	0
Number of reporting units closed \| reporting_unit	2		2
Loss on abandonment of assets			$ 3,071	20,928	$ 3,124
Intangible assets divested from deconsolidation			11,567
Amortization expense			7,920	$ 11,666	$ 11,472
Patents, developed technologies and know-how
Goodwill [Line Items]
Loss on abandonment of assets		$ 16,027
Trans Ova
Goodwill [Line Items]
Impairments			$ 29,642

Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Goodwill
Beginning of year		$ 93,627	$ 93,751
Impairment	$ (178)	(29,820)	0
Foreign currency translation adjustments		(53)	(124)
End of year		$ 63,754	$ 93,627

Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	$ 107,259	$ 123,542
Accumulated Amortization	(38,913)	(34,580)
Net	68,346	88,962
Patents, developed technologies and know-how
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	90,659	106,042
Accumulated Amortization	(26,619)	(23,674)
Net	64,040	82,368
Customer relationships
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	10,700	10,700
Accumulated Amortization	(8,440)	(7,565)
Net	2,260	3,135
Trademarks
Finite-Lived Intangible Assets, Net [Abstract]
Gross Carrying Amount	5,900	6,800
Accumulated Amortization	(3,854)	(3,341)
Net	$ 2,046	$ 3,459
Weighted Average Useful Life (Years) \| Patents, developed technologies and know-how
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	15 years 9 months 18 days
Weighted Average Useful Life (Years) \| Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	6 years 6 months
Weighted Average Useful Life (Years) \| Trademarks
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	8 years 4 months 24 days

Goodwill and Intangible Assets, Net - Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
2020	$ 7,501
2021	7,313
2022	6,518
2023	5,350
2024	5,066
Thereafter	36,598
Net	$ 68,346	$ 88,962

Lines of Credit and Long-Term Debt - Lines of Credit - Additional Information (Details) - Revolving Credit Facility	12 Months Ended
	Dec. 31, 2019 USD ($)
Trans Ova Genetics, LC \| First National Bank of Omaha
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 5,000,000
Line of credit facility, interest rate at period end	4.76%
Line of credit outstanding	$ 1,695,000
Line of credit facility, current borrowing capacity	$ 3,235,000
Trans Ova Genetics, LC \| First National Bank of Omaha \| London Interbank Offered Rate (LIBOR)
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	2.95%
Exemplar Genetics, LLC \| American State Bank
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 700,000
Debt instrument, interest rate, stated percentage	5.50%
Line of credit outstanding	$ 227,000
Minimum \| Trans Ova Genetics, LC \| First National Bank of Omaha
Line of Credit Facility [Line Items]
Debt instrument, interest rate, stated percentage	3.00%

Lines of Credit and Long-Term Debt - Components of Long-Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Long-term debt	$ 217,991	$ 211,695
Less current portion	31,670	479
Long-term debt, less current portion	186,321	211,216
Convertible debt
Debt Instrument [Line Items]
Long-term debt	213,771	203,391
Notes payable
Debt Instrument [Line Items]
Long-term debt	4,089	4,551
Other
Debt Instrument [Line Items]
Long-term debt	$ 131	$ 3,753

Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)	1 Months Ended			12 Months Ended
	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jul. 31, 2018 USD ($) day $ / shares	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Debt Instrument [Line Items]
Long-term debt divested from deconsolidation				$ 4,030,000
Proceeds from long-term debt, net of issuance costs				376,000	$ 219,859,000	$ 325,000
Equity component of convertible debt, net of issuance costs and deferred taxes					36,868,000
Deferred income taxes				(3,674,000)	(21,278,000)	(2,528,000)
Interest payable				3,500,000
Long-term debt issued to a related party in an asset acquisition				0	30,000,000	$ 0
Long-term debt	$ 211,695,000			217,991,000	211,695,000
Convertible debt
Debt Instrument [Line Items]
Long-term debt	203,391,000			213,771,000	203,391,000
Convertible debt \| Precigen ActoBio, Inc. \| Harvest Intrexon Enterprise Fund I, LP
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		3.00%
Interest expense				921,000	290,000
Long-term debt				$ 31,211,000
Notes payable to banks \| Trans Ova Genetics, LC \| American State Bank
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage				3.95%
Long-term debt				$ 4,077,000
Debt instrument, periodic payment				39,000
3.5% Convertible Notes Due 2023
Debt Instrument [Line Items]
Aggregate principal amount			$ 200,000,000	200,000,000
Proceeds from long-term debt, net of issuance costs			193,958,000
Debt issuance costs			$ 6,042,000
Debt instrument, interest rate, stated percentage			3.50%
Conversion rate			58.6622
Principal amount used in conversion			$ 1,000
Conversion price (in usd per share) \| $ / shares			$ 17.05
Debt instrument redemption price, percentage			100.00%
Carrying value of convertible debt	148,101,000		$ 143,723,000	$ 157,560,000	148,101,000
Equity component of convertible debt, net of issuance costs and deferred taxes			50,235,000
Deferred income taxes			$ 13,367,000
Effective interest rate on convertible notes				11.02%
Convertible notes, unamortized discount and issuance costs				$ 42,440,000
3.5% Convertible Notes Due 2023 \| Minimum
Debt Instrument [Line Items]
Common stock price trading days \| day			20
Common stock price consecutive trading days \| day			30
Percentage of common share price over conversion price for conversion			130.00%
3.5% Convertible Notes Due 2023 \| Maximum
Debt Instrument [Line Items]
Common stock price trading days \| day			5
Common stock price consecutive trading days \| day			5
Debt instrument redemption price, percentage			98.00%
Merck Convertible Note
Debt Instrument [Line Items]
Aggregate principal amount	$ 25,000,000				$ 25,000,000
Percentage of IPO price used upon conversion	0.90
PIK interest rate if converted to subsidiary equity	0.05				0.05
Harvest Intrexon Enterprise Fund I, LP \| Precigen ActoBio, Inc.
Debt Instrument [Line Items]
Long-term debt issued to a related party in an asset acquisition		$ 30,000,000

Lines of Credit and Long-Term Debt - Components of Interest Expense (Details) - 3.5% Convertible Notes Due 2023 - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Cash interest expense	$ 7,000	$ 3,462
Non-cash interest expense	9,459	4,378
Total interest expense	$ 16,459	$ 7,840

Lines of Credit and Long-Term Debt - Schedule of Future Maturities of Long-Term Debt (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Debt Disclosure [Abstract]
2020	$ 31,670
2021	25,328
2022	341
2023	200,355
2024	369
Thereafter	2,368
Total	$ 260,431

Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax [Line Items]
Loss from continuing operations before income taxes	$ (208,687)	$ (429,742)	$ (78,367)
Domestic
Income Tax [Line Items]
Loss from continuing operations before income taxes	(205,413)	(428,410)	(24,965)
Foreign
Income Tax [Line Items]
Loss from continuing operations before income taxes	$ (3,274)	$ (1,332)	$ (53,402)

Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
United States federal income taxes:
Current	$ 0	$ (31)	$ 27
Deferred	(561)	(11,855)	(523)
Foreign income taxes:
Current	34	68	(4)
Deferred	(230)	635	2,308
State income taxes:
Current	0	113	0
Deferred	(173)	(4,355)	264
Total income tax expense (benefit) from continuing operations	$ (930)	$ (15,425)	$ 2,072

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Computed statutory income tax benefit from continuing operations	$ (43,824)	$ (90,246)	$ (26,645)
State and provincial income tax benefit, net of federal income taxes	(7,298)	(23,347)	(1,888)
Nondeductible stock based compensation	10,303	4,696	3,391
Nondeductible officer compensation	595	294	476
Gain on dividend distribution of AquaBounty common stock	0	0	3,965
Impairment of goodwill	273	0	4,700
Research and development tax incentives	(1,772)	(185)	(359)
Acquisition and internal restructuring transaction costs	260	52	354
Provisional impact of the Tax Act	0	0	85,288
Enacted changes in foreign tax rates and foreign tax reforms	0	0	2,021
Reacquired in-process research and development	0	2,696	0
Change in deferred state tax rate	0	8,666	0
United States-foreign rate differential	(76)	215	410
Other, net	(72)	(3,517)	(189)
Income tax reconciliation income tax benefit before valuation allowance, total	(41,611)	(100,676)	71,524
Change in valuation allowance for deferred tax assets	40,681	85,251	(69,452)
Total income tax expense (benefit) from continuing operations	$ (930)	$ (15,425)	$ 2,072

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets
Allowance for doubtful accounts	$ 2,140	$ 1,490
Inventory	415	614
Equity securities and investments in affiliates	11,933	30,241
Property, plant and equipment	1,830	0
Intangible assets	85,308	78,858
Accrued liabilities	3,385	4,412
Lease liabilities	10,035
Stock-based compensation	19,389	28,885
Deferred revenue	14,876	16,297
Research and development tax credits	9,686	10,558
Investments in subsidiaries included in discontinued operations	8,592	0
Net operating and capital loss carryforwards	196,663	129,291
Total deferred tax assets	364,252	300,646
Less: Valuation allowance	349,008	292,217	$ 211,078	$ 253,549
Net deferred tax assets	15,244	8,429
Deferred tax liabilities
Property, plant and equipment	0	149
Right-of-use assets	8,091
Intangible assets	0	0
Long-term debt	9,987	12,136
Total deferred tax liabilities	18,078	12,285
Net deferred tax liabilities included in continuing operations	$ (2,834)	$ (3,856)

Income Taxes - Summary of Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Valuation Allowance
Valuation allowance at beginning of year	$ 292,217	$ 211,078	$ 253,549
Mergers and acquisitions, net	0	418	0
Deconsolidation of AquaBounty	(3,504)	0	0
Establishment of deferred taxes for subsidiaries included in discontinued operations	8,592	0	0
Current year continuing operations	40,681	107,284	17,735
Discontinued operations treated as asset sales	10,585	3,832	6,940
Provisional impact of the Tax Act	0	0	(87,473)
Equity component of long-term debt	0	(13,367)	0
Change in deferred state tax rate	0	(8,666)	0
Changes in foreign tax rates and foreign tax reforms	0	0	1,494
Foreign currency translation adjustment	(75)	(885)	990
Valuation allowance at end of year	349,008	292,217	211,078
Adoption of ASC 842
Valuation Allowance
Adoption of new accounting pronouncements	512	0	0
Adoption of ASC 606
Valuation Allowance
Adoption of new accounting pronouncements	0	(7,477)	0
Adoption of ASU 2016-09
Valuation Allowance
Adoption of new accounting pronouncements	$ 0	$ 0	$ 17,843

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Federal and state research and development tax credits		$ 9,686	$ 10,558
Accumulated deficit		(1,652,869)	(1,330,545)
Estimated tax benefit upon enactment of Tax Act	$ 2,185
Change in deferred tax assets resulting from enactment of Tax Act	87,473
Estimated tax benefit due to changes in deferred tax liabilities upon enactment of Tax Act	1,730
Estimated current tax benefit upon enactment of Tax Act	455
Provisional transition tax amount	$ 0
Foreign Subsidiaries
Operating Loss Carryforwards [Line Items]
Accumulated deficit		14,900
Domestic
Operating Loss Carryforwards [Line Items]
Net operating losses inherited via acquisition		42,100
Operating loss carryforwards		568,800
Deferred tax assets, capital loss carryforwards		111,600
Federal and state research and development tax credits		9,600
Domestic \| GenVec, Inc.
Operating Loss Carryforwards [Line Items]
Net operating losses inherited via acquisition		13,376
Foreign
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		72,800
BELGIUM
Operating Loss Carryforwards [Line Items]
Additional deferred tax liabilities recorded due to enacted foreign tax changes			$ 2,307
Generated after 2017 \| Domestic
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		$ 316,100

Shareholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended					12 Months Ended
	Mar. 31, 2019	Oct. 31, 2018	Jan. 31, 2018	Dec. 31, 2017	Jan. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2018
Class of Stock [Line Items]
Shares issued in public or private offerings, net of issuance costs, shares			6,900,000	1,207,980
Value of shares issued in public or private offerings			$ 82,374	$ 13,686		$ 6,611	$ 87,990	$ 13,686
Underwriting discounts and commissions			3,688
Capitalized offering expenses			$ 188
Shares issued in share lending agreement, shares									7,479,431
Shares issued, price per share									$ 13.37
Shares issued for exercises of warrants						$ 313	$ 2,336
Noncash dividend to shareholders								$ 0
Affiliates of Third Security
Class of Stock [Line Items]
Shares issued in public or private offerings, net of issuance costs, shares			1,000,000
AquaBounty Technologies, Inc.
Class of Stock [Line Items]
Noncash dividend, shares					1,776,557
Noncash dividend to shareholders					$ 22,385
Intrexon Equity Plans
Class of Stock [Line Items]
Adjustment due to dividend (in shares)								46,766
Adjustment due to dividend (in usd per share)								$ 31.11
AquaBounty Technologies, Inc.
Class of Stock [Line Items]
Value of shares issued in public or private offerings	$ 6,611		$ 10,616
Shares issued for exercises of warrants		$ 4,316
AquaBounty Technologies, Inc.
Class of Stock [Line Items]
Additional investment in subsidiary		$ 3,077	$ 5,000		$ 25,000

Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	$ 71,711	$ 378,722	$ 546,545	$ 569,248
Unrealized gain (loss) on investments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	7	(61)
Loss on foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	(27,475)	(28,551)
Total accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	$ (27,468)	$ (28,612)	$ (15,554)	$ (36,202)

Share-Based Payments - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	$ 18,950	$ 36,296	$ 41,576
Cost of products
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	20	78	116
Cost of services
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	220	237	322
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	4,784	6,850	7,654
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	11,419	25,259	28,801
Discontinued operations
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation cost	$ 2,507	$ 3,872	$ 4,683

Share-Based Payments - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as payment for services	$ 10,446	$ 10,695	$ 11,118
Intrexon Equity Plan - 2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)	0
Options outstanding (in shares)	378,409
Intrexon Equity Plan - 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)	8,991,369
Options outstanding (in shares)	8,643,873
Number of authorized awards (in shares)	25,000,000
Restricted stock units outstanding (in shares)	1,781,982	970,341	0
Unrecognized compensation costs related to restricted stock unit awards	$ 10,795
Intrexon Stock Option Plan 2019 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)	4,087,444
Options outstanding (in shares)	0
Number of authorized awards (in shares)	5,000,000
Intrexon Equity Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	9,022,282	11,093,063	11,382,747	11,640,383
Term at issuance of option	10 years
Vesting period of equity grant	4 years
Unrecognized compensation costs related to unvested stock option awards	$ 16,057
Weighted average grant date fair value of options granted (in usd per share)	$ 3.79	$ 7.94	$ 12.19
Aggregate intrinsic value of options exercised	$ 66	$ 356	$ 2,429
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Monthly base salary	$ 200
Lock-up period	3 years
Selling, general and administrative \| Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as payment for services	$ 1,868	$ 1,956	$ 1,908
Options \| Intrexon Equity Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized over weighted-average period	2 years
Restricted stock units \| Intrexon Equity Plan - 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recognized over weighted-average period	2 years

Share-Based Payments - Intrexon Equity Plans - Schedule of Stock Option Activity (Details) - Intrexon Equity Plans - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Balances at beginning of period (in shares)	11,093,063	11,382,747	11,640,383
Granted (in shares)	1,556,575	1,470,339	3,920,950
Adjustment due to dividend (in shares)			46,766
Exercised (in shares)	(19,887)	(45,159)	(149,429)
Forfeited (in shares)	(1,236,326)	(929,596)	(3,797,105)
Expired (in shares)	(2,371,143)	(785,268)	(278,818)
Balances at period end (in shares)	9,022,282	11,093,063	11,382,747	11,640,383
Weighted Average Exercise Price (usd per share)
Balances at beginning of period (in usd per share)	$ 27.95	$ 28.99	$ 31.25
Granted (in usd per share)	6.52	14.26	21.47
Adjustment due to dividend (in usd per share)			31.11
Exercised (in usd per share)	(3.17)	(6.59)	(6.37)
Forfeited (in usd per share)	(24.92)	(21.48)	(28.37)
Expired (in usd per share)	(38.53)	(26.25)	(33.18)
Balances at period end (in usd per share)	$ 21.94	27.95	$ 28.99	$ 31.25
Additional Disclosures
Exercisable at period end (in shares)	6,264,194
Options exercisable, weighted average exercise price (in usd per share)	$ 24.89	$ 30.37
Balances at period end, weighted average remaining contractual period	6 years 1 month 6 days	6 years 9 months 21 days	7 years 3 months 25 days	8 years 2 months 15 days
Exercisable at period end, weighted average remaining contractual period	5 years 2 months 12 days

Share-Based Payments - Intrexon Equity Plans - Summary of Information About Stock Options Outstanding (Details) - Intrexon Equity Plans - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Vesting period of equity grant	4 years
Options outstanding, number of options (in shares)	9,022,282	11,093,063
Options outstanding, weighted average exercise price (in usd per share)	$ 21.94	$ 27.95	$ 28.99	$ 31.25
Options outstanding, weighted average remaining life (in years)	6 years 1 month 6 days	6 years 9 months 21 days
Options outstanding, aggregate intrinsic value	$ 473	$ 169
Options exercisable, number of options (in shares)	6,264,194	7,002,519
Options exercisable, weighted average exercise price (in usd per share)	$ 24.89	$ 30.37
Options exercisable, weighted average remaining life (in years)	5 years 2 months 12 days	5 years 11 months 19 days
Options exercisable, aggregate intrinsic value	$ 194	$ 169
Price range 1
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 3.17	$ 3.17
Stock options, exercise price range, upper limit (in usd per share)	$ 8.60	$ 19.52
Options outstanding, number of options (in shares)	1,612,219	1,973,818
Options outstanding, weighted average exercise price (in usd per share)	$ 6.40	$ 13.70
Options outstanding, weighted average remaining life (in years)	8 years 29 days	7 years 6 months 14 days
Options outstanding, aggregate intrinsic value	$ 473	$ 169
Options exercisable, number of options (in shares)	585,144	833,007
Options exercisable, weighted average exercise price (in usd per share)	$ 5.61	$ 12.80
Options exercisable, weighted average remaining life (in years)	5 years 11 months 12 days	4 years 10 months 6 days
Options exercisable, aggregate intrinsic value	$ 194	$ 169
Price range 2
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 8.77	$ 19.85
Stock options, exercise price range, upper limit (in usd per share)	$ 20.68	$ 20.94
Options outstanding, number of options (in shares)	1,278,121	1,914,763
Options outstanding, weighted average exercise price (in usd per share)	$ 15.55	$ 20.93
Options outstanding, weighted average remaining life (in years)	6 years 6 months 10 days	7 years 11 months 26 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	753,064	500,263
Options exercisable, weighted average exercise price (in usd per share)	$ 15.89	$ 20.92
Options exercisable, weighted average remaining life (in years)	5 years 2 months 12 days	7 years 8 months 1 day
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Price range 3
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 20.94	$ 21.00
Stock options, exercise price range, upper limit (in usd per share)		$ 27.08
Options outstanding, number of options (in shares)	1,646,500	2,057,126
Options outstanding, weighted average exercise price (in usd per share)	$ 20.94	$ 23.29
Options outstanding, weighted average remaining life (in years)	6 years 6 months 3 days	7 years 3 months 3 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	892,000	1,248,370
Options exercisable, weighted average exercise price (in usd per share)	$ 20.94	$ 23.01
Options exercisable, weighted average remaining life (in years)	6 years 7 days	6 years 8 months 8 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Price range 4
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 21.00	$ 27.10
Stock options, exercise price range, upper limit (in usd per share)	$ 29.47	$ 29.56
Options outstanding, number of options (in shares)	1,976,645	2,666,109
Options outstanding, weighted average exercise price (in usd per share)	$ 23.71	$ 29.19
Options outstanding, weighted average remaining life (in years)	6 years 21 days	5 years 3 months 10 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	1,585,940	2,593,151
Options exercisable, weighted average exercise price (in usd per share)	$ 23.71	$ 29.20
Options exercisable, weighted average remaining life (in years)	5 years 9 months 14 days	5 years 2 months 23 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Price range 5
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 29.56	$ 29.58
Stock options, exercise price range, upper limit (in usd per share)	$ 65.08	$ 65.08
Options outstanding, number of options (in shares)	2,508,797	2,481,247
Options outstanding, weighted average exercise price (in usd per share)	$ 34.46	$ 47.24
Options outstanding, weighted average remaining life (in years)	4 years 4 months 17 days	6 years 7 months 2 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	2,448,046	1,827,728
Options exercisable, weighted average exercise price (in usd per share)	$ 34.47	$ 47.65
Options exercisable, weighted average remaining life (in years)	4 years 3 months 29 days	6 years 6 months 14 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0

Share-Based Payments - Intrexon Equity Plans - Schedule of Restricted Stock Unit Activity (Details) - Intrexon Equity Plan - 2013 Plan - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of Restricted Stock Units
Balances at beginning of period (in shares)	970,341	0
Granted (in shares)	2,278,460	1,069,126
Vested (in shares)	(1,159,165)	(25,000)
Forfeited (in shares)	(307,654)	(73,785)
Balances at period end (in shares)	1,781,982	970,341	0
Weighted Average Grant Date Fair Value
Balances at beginning of period (in usd per share)	$ 13.82	$ 0
Granted (in usd per share)	6.59	13.84
Vested (in usd per share)	(8.74)	(15.82)
Forfeited (in usd per share)	(8.99)	(13.47)
Balances at period end (in usd per share)	$ 8.71	$ 13.82	$ 0
Additional Disclosures
Balances at period end, weighted average remaining contractual period	1 year 2 months 26 days	1 year 5 months 4 days	0 years

Operating Leases - Additional Information (Details)	12 Months Ended
Operating Leases - Additional Information (Details)	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Termination period	1 year
Minimum
Lessee, Lease, Description [Line Items]
Term of contract	1 year
Maximum
Lessee, Lease, Description [Line Items]
Term of contract	10 years

Operating Leases - Components of Lease Costs (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Leases [Abstract]
Operating lease costs	$ 7,260
Short-term lease costs	2,042
Variable lease costs	2,076
Lease costs	$ 11,378

Operating Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2020	$ 7,071
2021	7,449
2022	6,996
2023	5,831
2024	5,734
Thereafter	4,280
Total	37,361
Present value adjustment	(9,330)
Total	28,031
Current portion of lease liabilities	4,182
Long-term portion of operating lease liabilities	$ 23,849

Operating Leases - Lease Terms and Discount Rates (Details)	Dec. 31, 2019
Leases [Abstract]
Weighted average remaining lease term (years)	5 years 2 months 26 days
Weighted average discount rate	10.96%

Operating Leases - Other Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019 USD ($)
Supplemental Cash Flows Information
Cash paid for operating lease liabilities	$ 7,294
Operating lease right-of-use assets added in exchange for new lease liabilities	$ 1,137

Operating Leases - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2018 USD ($)
Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]
2019	$ 6,889
2020	7,384
2021	7,246
2022	6,815
2023	5,747
Thereafter	11,734
Total	$ 45,815

Commitments and Contingencies - Contingencies - Additional Information (Details) - Licensing and patent infringement suit	1 Months Ended		9 Months Ended	12 Months Ended		38 Months Ended	50 Months Ended
	Mar. 31, 2019	Apr. 30, 2016 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($) claim	Dec. 31, 2017 USD ($)	Mar. 31, 2019 USD ($)	Apr. 30, 2016 USD ($)	Feb. 28, 2019 claim
Loss Contingencies [Line Items]
Damages awarded to TransOva		$ 528,000
Cumulative payments for royalties							$ 3,170,000
Royalty payments not yet deposited		2,759,000					$ 2,759,000
Litigation settlement, minimum and license payment						$ 5,801,000
Loss contingency, damages sought, value				$ 1,000,000
Royalty expense				$ 383,000
XY, LLC
Loss Contingencies [Line Items]
Damages awarded against TransOva		$ 6,066,000
Litigation settlement, ongoing royalty percentage		12.50%	18.75%
Enhancement percentage		2.00%
Litigation settlement, minimum royalty price per unit		$ 5.00	$ 6.25
Litigation settlement, weighted blended royalty rate	12.63%
Claims dismissed \| claim				9
Total claims \| claim				12
Loss contingencies, non-patent counts, number \| claim				5
Claims pending resolution \| claim				2				1
Selling, general and administrative
Loss Contingencies [Line Items]
Litigation settlement expense					$ 4,228,000

Related Party Transactions - Additional Information (Details) - USD ($)	1 Months Ended							10 Months Ended	12 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	Jan. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Jun. 30, 2016	Nov. 30, 2015	Jul. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Oct. 31, 2017
Related Party Transaction [Line Items]
Shares issued as payment for services									$ 10,446,000	$ 10,695,000	$ 11,118,000
Shares issued during the period (in shares)			6,900,000	1,207,980
Dividend income from investments in preferred stock									48,000	14,841,000	16,756,000
Purchase of preferred stock									0	0	1,161,000
Equity securities										1,024,000
Revenues									90,722,000	151,178,000	219,463,000
Purchases of property and equipment									37,883,000	41,587,000	46,666,000
Third Security
Related Party Transaction [Line Items]
Services agreement, term							1 year
Expense for services									$ 26,000	$ 47,000	$ 409,000
Shares issued as payment for services, shares									1,606,062	696,033	500,650
Shares issued as payment for services									$ 8,233,000	$ 8,324,000	$ 8,704,000
Sublease rental income									89,000
Sublease rental income										89,000	43,000
Affiliates of Third Security
Related Party Transaction [Line Items]
Shares issued during the period (in shares)			1,000,000
Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Equity securities										640,000
Business acquisition, equity interest issued or issuable, value assigned		$ 1,280,000
Fair value, option, changes in fair value, gain (loss)									$ 3,222,000
Intrexon Energy Partners, LLC
Related Party Transaction [Line Items]
Purchases of property and equipment				$ 2,812,000
Harvest Intrexon Enterprise Fund I, LP
Related Party Transaction [Line Items]
Other nonoperating income											1,839,000
Common Stock \| Third Security
Related Party Transaction [Line Items]
Expense for services							$ 800,000
Series A Preferred Shares
Related Party Transaction [Line Items]
Shares issued during the period (in shares)								0
Series A Preferred Shares \| Affiliates of Third Security
Related Party Transaction [Line Items]
Convertible preferred stock, amount authorized												$ 100,000,000
ZIOPHARM Oncology, Inc.
Related Party Transaction [Line Items]
Dividend income from investments in preferred stock										14,793,000	16,717,000
Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Purchase of preferred stock					$ 1,161,000
Other assets \| Convertible note and warrants \| Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Equity securities										120,000
Third Security \| Chief Executive Officer
Related Party Transaction [Line Items]
Ownership interest		100.00%							100.00%
ZIOPHARM Oncology, Inc.
Related Party Transaction [Line Items]
Preferred shares, stated value (in usd per share)						$ 1,200
Preferred shares, dividend rate (in usd per share)						$ 12.00
Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Convertible preferred shares, shares issued					1,161
Number of common shares into which warrants are convertible (in shares)					99,769
Preferred stock, dividend rate, percentage					4.00%
Collaboration and licensing agreements
Related Party Transaction [Line Items]
Revenues									$ 14,059,000	69,540,000	134,624,000
Collaboration and licensing agreements \| Histogenics Corporation, OvaScience Inc., and Synthetic Biologics Inc.
Related Party Transaction [Line Items]
Revenues									11,877,000
Preferred stock \| Other assets \| Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Equity securities										191,000
ZIOPHARM Oncology, Inc.
Related Party Transaction [Line Items]
Collaborative arrangement consideration received, number of preferred shares (in shares)						100,000
ZIOPHARM Oncology, Inc. \| Collaboration and licensing agreements
Related Party Transaction [Line Items]
Collaborative arrangement consideration received, number of preferred shares (in shares)						100,000
Revenues									$ 2,171,000	$ 16,298,000	$ 69,812,000
Subsequent Event \| Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Business acquisition, equity interest issued or issuable, value assigned	$ 3,311,000

Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2019

^[1]

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

^[2]

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Numerator:

Net loss from continuing operations attributable to Precigen

$ (206,165)

$ (408,947)

$ (70,637)

Net loss from discontinued operations attributable to Precigen

(116,159)

(100,389)

(46,381)

Net loss attributable to Precigen

$ (169,215)

$ (53,634)

$ (38,766)

$ (60,709)

$ (340,465)

$ (57,324)

$ (65,382)

$ (46,165)

$ (322,324)

$ (509,336)

$ (117,018)

Denominator:

Weighted average shares outstanding, basic and diluted (in shares)

154,138,774

129,521,731

119,998,826

Net loss from continuing operations attributable to Precigen per share, basic and diluted (in usd per share)

$ (0.47)

$ (0.32)

$ (0.21)

$ (0.34)

$ (2.08)

$ (0.38)

$ (0.39)

$ (0.28)

$ (1.34)

$ (3.16)

$ (0.59)

Net loss from discontinued operations attributable to Precigen per share, basic and diluted (in usd per share)

(0.75)

(0.77)

(0.39)

Net loss attributable to Precigen per share, basic and diluted (in usd per share)

$ (1.09)

$ (0.35)

$ (0.25)

$ (0.40)

$ (2.59)

$ (0.44)

$ (0.51)

$ (0.36)

$ (2.09)

$ (3.93)

$ (0.98)

[1]

[2]

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	32,260,596	31,152,336	11,516,011
Convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	21,323,068	18,955,668	0
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	9,022,282	11,093,063	11,382,747
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,781,982	970,341	0
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	133,264	133,264	133,264

Segments - Information by Reportable Segment (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Goodwill

Goodwill

$ 63,754

$ 93,627

$ 63,754

$ 93,627

$ 93,751

Impairments

$ (178)

(29,820)

Foreign currency translation adjustments

(53)

(124)

Revenues from external customers

90,722

151,178

219,463

Revenues

17,002

^[1]

$ 18,299

$ 32,836

$ 22,585

41,192

^[2]

$ 30,055

$ 42,771

$ 37,160

Segment Adjusted EBITDA

(92,835)

(91,479)

(40,644)

PGEN Therapeutics

Goodwill

Segment Adjusted EBITDA

(30,166)

(32,841)

(5,655)

ActoBio

Goodwill

Segment Adjusted EBITDA

(13,662)

(12,797)

(2,656)

MBP Titan

Goodwill

Segment Adjusted EBITDA

(36,718)

(29,403)

(32,251)

Trans Ova

Goodwill

Impairments

(29,642)

Segment Adjusted EBITDA

(6,337)

(5,730)

1,020

All Other

Goodwill

Segment Adjusted EBITDA

(5,952)

(10,708)

(1,102)

Operating segments

Goodwill

Goodwill

63,754

93,627

63,754

93,627

93,751

Reallocations from changes to reporting units

Impairments

(29,820)

Foreign currency translation adjustments

(53)

(124)

Revenues from external customers

90,575

151,023

219,406

Revenues

105,141

153,302

221,462

Operating segments | PGEN Therapeutics

Goodwill

Goodwill

15,232

Reallocations from changes to reporting units

15,232

Impairments

Foreign currency translation adjustments

Revenues from external customers

2,227

29,021

53,184

Revenues

13,568

29,638

53,184

Operating segments | ActoBio

Goodwill

Goodwill

1,735

1,788

1,735

1,788

Reallocations from changes to reporting units

1,788

Impairments

Foreign currency translation adjustments

(53)

Revenues from external customers

(364)

6,684

12,929

Revenues

134

7,524

14,112

Operating segments | MBP Titan

Goodwill

Goodwill

9,635

Reallocations from changes to reporting units

9,635

Impairments

Foreign currency translation adjustments

Revenues from external customers

3,813

9,927

14,336

Revenues

3,909

9,936

14,336

Operating segments | Trans Ova

Goodwill

Goodwill

16,594

46,236

16,594

46,236

Reallocations from changes to reporting units

Impairments

(29,642)

Foreign currency translation adjustments

Revenues from external customers

68,672

75,178

79,783

Revenues

70,033

75,736

80,026

Operating segments | All Other

Goodwill

Goodwill

$ 20,558

$ 30,371

20,558

30,371

47,515

Reallocations from changes to reporting units

(9,635)

(17,020)

Impairments

(178)

Foreign currency translation adjustments

(124)

Revenues from external customers

16,227

30,213

59,174

Revenues

17,497

30,468

59,804

Intersegment revenues

Goodwill

Revenues

14,566

2,279

2,056

Intersegment revenues | PGEN Therapeutics

Goodwill

Revenues

11,341

617

Intersegment revenues | ActoBio

Goodwill

Revenues

498

840

1,183

Intersegment revenues | MBP Titan

Goodwill

Revenues

Intersegment revenues | Trans Ova

Goodwill

Revenues

1,361

558

243

Intersegment revenues | All Other

Goodwill

Revenues

$ 1,270

$ 255

$ 630

[1]

[2]

Segments - Reconciliation of Revenues from Reportable Segments to Consolidated Revenues (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2019

^[1]

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

^[2]

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Segment Reporting, Asset Reconciling Item [Line Items]

Revenues

$ 17,002

$ 18,299

$ 32,836

$ 22,585

$ 41,192

$ 30,055

$ 42,771

$ 37,160

Revenues

$ 90,722

$ 151,178

$ 219,463

Other revenues, including from other operating segments

Segment Reporting, Asset Reconciling Item [Line Items]

Revenues

18,602

30,914

59,861

Elimination of intersegment revenues

Segment Reporting, Asset Reconciling Item [Line Items]

Revenues

(15,524)

(2,570)

(2,056)

Total segment revenues from reportable segments

Segment Reporting, Asset Reconciling Item [Line Items]

Revenues

$ 87,644

$ 122,834

$ 161,658

[1]

[2]

Segments - Reconciliation of Net Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	$ (92,835)	$ (91,479)	$ (40,644)
Other expenses:
Depreciation and amortization	(24,896)	(33,112)	(31,145)
Impairment loss	(120,489)	(60,504)	(16,773)
Stock-based compensation expense	(18,950)	(36,296)	(41,576)
Equity in net loss of affiliates	(6,730)	(11,608)	(14,283)
Other	(837)	(1,093)	517
Loss from continuing operations before income taxes	(208,687)	(429,742)	(78,367)
Operating segments
Segment Reporting Information [Line Items]
Remove cash paid for capital expenditures and investments in affiliates	15,339	19,906	31,701
Corporate And Reconciling Items
Other expenses:
Interest expense	(17,666)	(8,473)	(584)
Depreciation and amortization	(19,789)	(24,105)	(21,609)
Impairment loss	(30,810)	0	(13,823)
Reacquisition of in-process research and development	0	(236,748)	0
Stock-based compensation expense	(16,443)	(32,424)	(36,893)
Equity in net loss of affiliates	(2,416)	(8,986)	(12,436)
Other	67	0	0
Unallocated corporate costs
Other expenses:
Loss from continuing operations before income taxes	(47,577)	(84,536)	(53,197)
Eliminations
Other expenses:
Loss from continuing operations before income taxes	(14,400)	(2,343)	579
Reportable segments
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(86,883)	(80,771)	(39,542)
All Other
Segment Reporting Information [Line Items]
Segment Adjusted EBITDA	(5,952)	(10,708)	(1,102)
Upfront and Milestone Payments \| Operating segments
Segment Reporting Information [Line Items]
Add recognition of previously deferred revenue associated with upfront and milestone payments	$ 17,843	$ 39,446	$ 68,539

Segments - Additional Information (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Segment Reporting Information [Line Items]

Revenues

$ 17,002

^[1]

$ 18,299

$ 32,836

$ 22,585

$ 41,192

^[2]

$ 30,055

$ 42,771

$ 37,160

Non-US

Segment Reporting Information [Line Items]

Long-lived assets

$ 6,724

$ 10,011

$ 6,724

$ 10,011

Revenues

$ 1,401

$ 6,255

$ 13,771

[1]

[2]

Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

^[2]

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Total revenues

$ 17,002

^[1]

$ 18,299

$ 32,836

$ 22,585

$ 41,192

$ 30,055

$ 42,771

$ 37,160

Operating loss

(77,986)

^[1]

(44,637)

(31,373)

(50,216)

(268,119)

(58,330)

(34,807)

(42,241)

Loss from continuing operations

(73,498)

^[2]

(49,054)

(32,305)

(52,900)

(274,587)

(50,507)

(52,120)

(37,103)

Net loss attributable to Precigen

$ (169,215)

^[1]

$ (53,634)

$ (38,766)

$ (60,709)

$ (340,465)

$ (57,324)

$ (65,382)

$ (46,165)

$ (322,324)

$ (509,336)

$ (117,018)

Net loss from continuing operations attributable to Precigen per share, basic and diluted (in usd per share)

$ (0.47)

^[1]

$ (0.32)

$ (0.21)

$ (0.34)

$ (2.08)

$ (0.38)

$ (0.39)

$ (0.28)

$ (1.34)

$ (3.16)

$ (0.59)

Net loss attributable to Precigen per share, basic and diluted (in usd per share)

$ (1.09)

^[1]

$ (0.35)

$ (0.25)

$ (0.40)

$ (2.59)

$ (0.44)

$ (0.51)

$ (0.36)

$ (2.09)

$ (3.93)

$ (0.98)

[1]

[2]

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Defined Contribution Plans - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Retirement Benefits [Abstract]
Defined contribution plans, cost recognized	$ 1,427	$ 1,662	$ 1,545

Subsequent Events (Details) - USD ($) $ in Thousands		1 Months Ended		12 Months Ended
Subsequent Events (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2018	Dec. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Subsequent Event [Line Items]
Shares issued during the period (in shares)		6,900,000	1,207,980
Value of shares issued in public or private offerings		$ 82,374	$ 13,686	$ 6,611	$ 87,990	$ 13,686
TS Biotechnology Holdings, LLC \| Subsequent Event
Subsequent Event [Line Items]
Shares issued during the period (in shares)	5,972,696
Value of shares issued in public or private offerings	$ 35,000

Label	Element	Value
AOCI Attributable to Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (104,000)
Additional Paid-in Capital [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	1,461,000
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Noncontrolling Interest [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	26,507,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	(1,461,000)
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 26,611,000